WO2007090617A2 - Thiadiazole derivatives for the treatment of neuro degenerative diseases - Google Patents
Thiadiazole derivatives for the treatment of neuro degenerative diseases Download PDFInfo
- Publication number
- WO2007090617A2 WO2007090617A2 PCT/EP2007/001022 EP2007001022W WO2007090617A2 WO 2007090617 A2 WO2007090617 A2 WO 2007090617A2 EP 2007001022 W EP2007001022 W EP 2007001022W WO 2007090617 A2 WO2007090617 A2 WO 2007090617A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thiadiazol
- piperazine
- fluorobenzyl
- methylpiperazine
- group
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 26
- 230000004770 neurodegeneration Effects 0.000 title description 12
- 208000015122 neurodegenerative disease Diseases 0.000 title description 7
- 150000004867 thiadiazoles Chemical class 0.000 title description 5
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical class C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 claims abstract description 25
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 9
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims abstract description 7
- 208000009829 Lewy Body Disease Diseases 0.000 claims abstract description 7
- 208000001089 Multiple system atrophy Diseases 0.000 claims abstract description 7
- 201000010374 Down Syndrome Diseases 0.000 claims abstract description 5
- 208000014060 Niemann-Pick disease Diseases 0.000 claims abstract description 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims abstract description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 5
- 208000033510 neuroaxonal dystrophy Diseases 0.000 claims abstract description 5
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims abstract description 5
- 230000009529 traumatic brain injury Effects 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 169
- -1 amino, hydroxy Chemical group 0.000 claims description 120
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 71
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 63
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 61
- 239000008194 pharmaceutical composition Substances 0.000 claims description 40
- 238000006243 chemical reaction Methods 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 30
- 229920006395 saturated elastomer Polymers 0.000 claims description 30
- 125000000623 heterocyclic group Chemical group 0.000 claims description 27
- 125000004432 carbon atom Chemical group C* 0.000 claims description 26
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 150000001409 amidines Chemical class 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 10
- 125000004429 atom Chemical group 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 229910021529 ammonia Inorganic materials 0.000 claims description 5
- 230000008021 deposition Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- VHKQYZZREFZIPO-UHFFFAOYSA-N 3-[(3-methoxyphenyl)methyl]-5-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-1,2,4-thiadiazole Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1CCN(C=2SN=C(CC=3C=C(OC)C=CC=3)N=2)CC1 VHKQYZZREFZIPO-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 229940077388 benzenesulfonate Drugs 0.000 claims description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 4
- 125000005647 linker group Chemical group 0.000 claims description 4
- 239000004090 neuroprotective agent Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- SPWROVREKKIDDP-UHFFFAOYSA-N 5-[4-(benzenesulfonyl)piperazin-1-yl]-3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazole Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CC2)S(=O)(=O)C=2C=CC=CC=2)=N1 SPWROVREKKIDDP-UHFFFAOYSA-N 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
- PDEPCDAFCRVIAB-UHFFFAOYSA-N 1-benzyl-3-[2-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl]urea Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CCNC(=O)NCC=3C=CC=CC=3)CC2)=N1 PDEPCDAFCRVIAB-UHFFFAOYSA-N 0.000 claims description 2
- RTXRREPUGGFNHC-UHFFFAOYSA-N 4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methyl-n-(2-methylphenyl)piperazine-1-carboxamide Chemical compound CC1CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CCN1C(=O)NC1=CC=CC=C1C RTXRREPUGGFNHC-UHFFFAOYSA-N 0.000 claims description 2
- OSRSMUBFMPCTRW-UHFFFAOYSA-N 5-[4-(4-bromophenyl)sulfonylpiperazin-1-yl]-3-[(4-methylphenyl)methyl]-1,2,4-thiadiazole Chemical compound C1=CC(C)=CC=C1CC1=NSC(N2CCN(CC2)S(=O)(=O)C=2C=CC(Br)=CC=2)=N1 OSRSMUBFMPCTRW-UHFFFAOYSA-N 0.000 claims description 2
- NGRZFFGUKGPERD-UHFFFAOYSA-N 5-[4-(4-chloro-3-nitrophenyl)sulfonyl-3-methylpiperazin-1-yl]-3-[(4-methylphenyl)methyl]-1,2,4-thiadiazole Chemical compound CC1CN(C=2SN=C(CC=3C=CC(C)=CC=3)N=2)CCN1S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 NGRZFFGUKGPERD-UHFFFAOYSA-N 0.000 claims description 2
- AWZJPHYNWYIXNL-UHFFFAOYSA-N 5-[4-(4-ethoxyphenyl)sulfonylpiperazin-1-yl]-3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazole Chemical compound C1=CC(OCC)=CC=C1S(=O)(=O)N1CCN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 AWZJPHYNWYIXNL-UHFFFAOYSA-N 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- VLXROHPROQZAGU-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide Chemical compound CC1CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CCN1C(=O)NC1=C(C)C=CC=C1C VLXROHPROQZAGU-UHFFFAOYSA-N 0.000 claims description 2
- LTZFLKPOJWGGGN-UHFFFAOYSA-N n-(4-ethylphenyl)-4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide Chemical compound C1=CC(CC)=CC=C1NC(=O)N1C(C)CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 LTZFLKPOJWGGGN-UHFFFAOYSA-N 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 8
- 239000011593 sulfur Substances 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 7
- 239000001301 oxygen Substances 0.000 claims 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 5
- 125000000464 thioxo group Chemical group S=* 0.000 claims 5
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 4
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 3
- 150000001420 substituted heterocyclic compounds Chemical class 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- KOTKCWAGVGYXMV-UHFFFAOYSA-N 3-[(3-fluorophenyl)methyl]-5-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-1,2,4-thiadiazole Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1CCN(C=2SN=C(CC=3C=C(F)C=CC=3)N=2)CC1 KOTKCWAGVGYXMV-UHFFFAOYSA-N 0.000 claims 2
- ARMDUGUDYUNAFO-UHFFFAOYSA-N 3-benzyl-5-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-1,2,4-thiadiazole Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1CCN(C=2SN=C(CC=3C=CC=CC=3)N=2)CC1 ARMDUGUDYUNAFO-UHFFFAOYSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- SKARBMDPODLSIA-UHFFFAOYSA-N (2-bromophenyl)-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]methanone Chemical compound CC1CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CCN1C(=O)C1=CC=CC=C1Br SKARBMDPODLSIA-UHFFFAOYSA-N 0.000 claims 1
- PHIGXUSUDBBDSR-UHFFFAOYSA-N (3-chlorophenyl)-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]methanone (4-fluorophenyl)-[4-[3-[(3-methoxyphenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]methanone Chemical compound FC1=CC=C(C(=O)N2C(CN(CC2)C2=NC(=NS2)CC2=CC(=CC=C2)OC)C)C=C1.ClC=1C=C(C(=O)N2C(CN(CC2)C2=NC(=NS2)CC2=CC=C(C=C2)F)C)C=CC1 PHIGXUSUDBBDSR-UHFFFAOYSA-N 0.000 claims 1
- UKFVFTFULAMWDV-UHFFFAOYSA-N (4-bromophenyl)-[4-[3-[(3-methoxyphenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]methanone;[2-methyl-4-[3-[(4-methylphenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]-phenylmethanone Chemical compound CC1CN(C=2SN=C(CC=3C=CC(C)=CC=3)N=2)CCN1C(=O)C1=CC=CC=C1.COC1=CC=CC(CC=2N=C(SN=2)N2CC(C)N(CC2)C(=O)C=2C=CC(Br)=CC=2)=C1 UKFVFTFULAMWDV-UHFFFAOYSA-N 0.000 claims 1
- VRONDQMIHPKMGA-UHFFFAOYSA-N (4-fluorophenyl)-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]methanone;[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]-phenylmethanone Chemical compound CC1CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CCN1C(=O)C1=CC=CC=C1.CC1CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CCN1C(=O)C1=CC=C(F)C=C1 VRONDQMIHPKMGA-UHFFFAOYSA-N 0.000 claims 1
- YRDYGYZGJHRYRG-UHFFFAOYSA-N (4-tert-butylphenyl)-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]methanone Chemical compound CC1CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CCN1C(=O)C1=CC=C(C(C)(C)C)C=C1 YRDYGYZGJHRYRG-UHFFFAOYSA-N 0.000 claims 1
- GFFYOCALKIOMPE-NBYYMMLRSA-N (e)-1-[4-[3-[(4-chlorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]-3-phenylprop-2-en-1-one;3-[(4-methylphenyl)methyl]-5-(4-propan-2-ylsulfonylpiperazin-1-yl)-1,2,4-thiadiazole Chemical compound C1CN(S(=O)(=O)C(C)C)CCN1C1=NC(CC=2C=CC(C)=CC=2)=NS1.CC1CN(C=2SN=C(CC=3C=CC(Cl)=CC=3)N=2)CCN1C(=O)\C=C\C1=CC=CC=C1 GFFYOCALKIOMPE-NBYYMMLRSA-N 0.000 claims 1
- ANABNUCXAOSOQD-IBMQDACXSA-N (e)-1-[4-[3-[(4-chlorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]-3-phenylprop-2-en-1-one;1-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]-3-phenylpropan-1-one Chemical compound C1=CC(Cl)=CC=C1CC1=NSC(N2CCN(CC2)C(=O)\C=C\C=2C=CC=CC=2)=N1.CC1CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CCN1C(=O)CCC1=CC=CC=C1 ANABNUCXAOSOQD-IBMQDACXSA-N 0.000 claims 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims 1
- AELHHLJGZJLDSP-UHFFFAOYSA-N 1,3-benzodioxol-5-yl-[2-methyl-4-[3-[(4-methylphenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]methanone;(4-fluorophenyl)-[4-[3-[(4-methylphenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]methanone Chemical compound C1=CC(C)=CC=C1CC1=NSC(N2CCN(CC2)C(=O)C=2C=CC(F)=CC=2)=N1.C1CN(C(=O)C=2C=C3OCOC3=CC=2)C(C)CN1C(SN=1)=NC=1CC1=CC=C(C)C=C1 AELHHLJGZJLDSP-UHFFFAOYSA-N 0.000 claims 1
- KEEZGOAGIOFTAV-UHFFFAOYSA-N 1,3-benzodioxol-5-yl-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-1,4-diazepan-1-yl]methanone Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CCC2)C(=O)C=2C=C3OCOC3=CC=2)=N1 KEEZGOAGIOFTAV-UHFFFAOYSA-N 0.000 claims 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims 1
- ZDODTEIXEDLORF-UHFFFAOYSA-N 1-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]-2-(4-methoxyphenyl)ethanone Chemical compound C1=CC(OC)=CC=C1CC(=O)N1C(C)CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 ZDODTEIXEDLORF-UHFFFAOYSA-N 0.000 claims 1
- BFQGCVLUTHPOBU-UHFFFAOYSA-N 1-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]-2-phenylethanone Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CC2)C(=O)CC=2C=CC=CC=2)=N1 BFQGCVLUTHPOBU-UHFFFAOYSA-N 0.000 claims 1
- SQDHWVVEMHBRTB-UHFFFAOYSA-N 3-[(3-methoxyphenyl)methyl]-5-[4-(4-methoxyphenyl)sulfonyl-3-methylpiperazin-1-yl]-1,2,4-thiadiazole Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C(C)CN(C=2SN=C(CC=3C=C(OC)C=CC=3)N=2)CC1 SQDHWVVEMHBRTB-UHFFFAOYSA-N 0.000 claims 1
- PHDPAAGTQJNKHL-UHFFFAOYSA-N 3-[(4-chlorophenyl)methyl]-5-[4-(3-phenylprop-2-enyl)piperazin-1-yl]-1,2,4-thiadiazole;3-[(4-fluorophenyl)methyl]-5-[4-(3-phenylprop-2-enyl)piperazin-1-yl]-1,2,4-thiadiazole Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CC=CC=3C=CC=CC=3)CC2)=N1.C1=CC(Cl)=CC=C1CC1=NSC(N2CCN(CC=CC=3C=CC=CC=3)CC2)=N1 PHDPAAGTQJNKHL-UHFFFAOYSA-N 0.000 claims 1
- HOWWEURPMSIEED-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-5-[4-(2-methoxyphenyl)sulfonylpiperazin-1-yl]-1,2,4-thiadiazole Chemical compound COC1=CC=CC=C1S(=O)(=O)N1CCN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 HOWWEURPMSIEED-UHFFFAOYSA-N 0.000 claims 1
- USGSEQDDRUBOHV-UHFFFAOYSA-N 3-[(4-methylphenyl)methyl]-5-[3-methyl-4-(3-phenylprop-2-enylsulfonyl)piperazin-1-yl]-1,2,4-thiadiazole 3-[(4-methylphenyl)methyl]-5-[4-(3-phenylprop-2-enylsulfonyl)piperazin-1-yl]-1,2,4-thiadiazole Chemical compound C1(=CC=CC=C1)C=CCS(=O)(=O)N1CCN(CC1)C1=NC(=NS1)CC1=CC=C(C=C1)C.C1(=CC=CC=C1)C=CCS(=O)(=O)N1C(CN(CC1)C1=NC(=NS1)CC1=CC=C(C=C1)C)C USGSEQDDRUBOHV-UHFFFAOYSA-N 0.000 claims 1
- JBVQWKJESIKVRR-UHFFFAOYSA-N 4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methyl-n-[2-(trifluoromethyl)phenyl]piperazine-1-carboxamide Chemical compound CC1CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CCN1C(=O)NC1=CC=CC=C1C(F)(F)F JBVQWKJESIKVRR-UHFFFAOYSA-N 0.000 claims 1
- VTAGBZXLTYZKQD-UHFFFAOYSA-N 5-(4-benzylpiperazin-1-yl)-3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazole;n-[2-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl]-3-phenylpropanamide Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CC=3C=CC=CC=3)CC2)=N1.C1=CC(F)=CC=C1CC1=NSC(N2CCN(CCNC(=O)CCC=3C=CC=CC=3)CC2)=N1 VTAGBZXLTYZKQD-UHFFFAOYSA-N 0.000 claims 1
- ILYPIKLXTSFLPU-UHFFFAOYSA-N 5-(4-benzylsulfonylpiperazin-1-yl)-3-[(4-chlorophenyl)methyl]-1,2,4-thiadiazole;5-[4-(4-chloro-3-nitrophenyl)sulfonylpiperazin-1-yl]-3-[(4-methylphenyl)methyl]-1,2,4-thiadiazole Chemical compound C1=CC(Cl)=CC=C1CC1=NSC(N2CCN(CC2)S(=O)(=O)CC=2C=CC=CC=2)=N1.C1=CC(C)=CC=C1CC1=NSC(N2CCN(CC2)S(=O)(=O)C=2C=C(C(Cl)=CC=2)[N+]([O-])=O)=N1 ILYPIKLXTSFLPU-UHFFFAOYSA-N 0.000 claims 1
- RCJRMQSLLXOVQB-UHFFFAOYSA-N 5-[3-methyl-4-(4-nitrophenyl)sulfonylpiperazin-1-yl]-3-[(4-methylphenyl)methyl]-1,2,4-thiadiazole;3-[(4-methylphenyl)methyl]-5-(4-quinolin-8-ylsulfonylpiperazin-1-yl)-1,2,4-thiadiazole Chemical compound CC1CN(C=2SN=C(CC=3C=CC(C)=CC=3)N=2)CCN1S(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1.C1=CC(C)=CC=C1CC1=NSC(N2CCN(CC2)S(=O)(=O)C=2C3=NC=CC=C3C=CC=2)=N1 RCJRMQSLLXOVQB-UHFFFAOYSA-N 0.000 claims 1
- HWGQNUUAEVONKI-UHFFFAOYSA-N 5-[4-(2,5-dichlorophenyl)sulfonyl-3-methylpiperazin-1-yl]-3-[(4-methylphenyl)methyl]-1,2,4-thiadiazole Chemical compound CC1CN(C=2SN=C(CC=3C=CC(C)=CC=3)N=2)CCN1S(=O)(=O)C1=CC(Cl)=CC=C1Cl HWGQNUUAEVONKI-UHFFFAOYSA-N 0.000 claims 1
- CMDACECZQDLONT-UHFFFAOYSA-N 5-[4-(4-bromophenyl)sulfonyl-2-methylpiperazin-1-yl]-3-[(4-methylphenyl)methyl]-1,2,4-thiadiazole Chemical compound CC1CN(S(=O)(=O)C=2C=CC(Br)=CC=2)CCN1C(SN=1)=NC=1CC1=CC=C(C)C=C1 CMDACECZQDLONT-UHFFFAOYSA-N 0.000 claims 1
- XXCMIZDMIUJNDY-UHFFFAOYSA-N 5-[4-(4-ethylphenyl)sulfonylpiperazin-1-yl]-3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazole Chemical compound C1=CC(CC)=CC=C1S(=O)(=O)N1CCN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 XXCMIZDMIUJNDY-UHFFFAOYSA-N 0.000 claims 1
- GKDVFOFRGUIEGE-UHFFFAOYSA-N 5-[4-(4-tert-butylphenyl)sulfonyl-3-methylpiperazin-1-yl]-3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazole Chemical compound CC1CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CCN1S(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GKDVFOFRGUIEGE-UHFFFAOYSA-N 0.000 claims 1
- BAEFVAKVQVCOQP-UHFFFAOYSA-N C(C)(C)(C)C1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C1=NC(=NS1)CC1=CC=C(C=C1)Cl.COC1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C1=NC(=NS1)CC1=CC=C(C=C1)C Chemical compound C(C)(C)(C)C1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C1=NC(=NS1)CC1=CC=C(C=C1)Cl.COC1=CC=C(C=C1)S(=O)(=O)N1CCN(CC1)C1=NC(=NS1)CC1=CC=C(C=C1)C BAEFVAKVQVCOQP-UHFFFAOYSA-N 0.000 claims 1
- PZAOBNQHXHTVKT-UHFFFAOYSA-N C(C)C1=CC=C(C(=O)N2C(CN(CC2)C2=NC(=NS2)CC2=CC(=CC=C2)OC)C)C=C1.BrC=1C=C(C(=O)N2C(CN(CC2)C2=NC(=NS2)CC2=CC=C(C=C2)F)C)C=CC1 Chemical compound C(C)C1=CC=C(C(=O)N2C(CN(CC2)C2=NC(=NS2)CC2=CC(=CC=C2)OC)C)C=C1.BrC=1C=C(C(=O)N2C(CN(CC2)C2=NC(=NS2)CC2=CC=C(C=C2)F)C)C=CC1 PZAOBNQHXHTVKT-UHFFFAOYSA-N 0.000 claims 1
- DQLAVUXBXUVFTO-UHFFFAOYSA-N C(C)S(=O)(=O)N1CCN(CC1)C1=NC(=NS1)CC1=CC=C(C=C1)Cl.C(CCC)S(=O)(=O)N1CCN(CC1)C1=NC(=NS1)CC1=CC=C(C=C1)C Chemical compound C(C)S(=O)(=O)N1CCN(CC1)C1=NC(=NS1)CC1=CC=C(C=C1)Cl.C(CCC)S(=O)(=O)N1CCN(CC1)C1=NC(=NS1)CC1=CC=C(C=C1)C DQLAVUXBXUVFTO-UHFFFAOYSA-N 0.000 claims 1
- SMZKAPMULBYOLI-UHFFFAOYSA-N C1(=CC=CC=C1)NC(=O)N1CCN(CC1)C1=NC(=NS1)CC1=CC=C(C=C1)F.C(C)C1=C(C=CC=C1)NC(=O)N1C(CN(CC1)C1=NC(=NS1)CC1=CC=C(C=C1)F)C Chemical compound C1(=CC=CC=C1)NC(=O)N1CCN(CC1)C1=NC(=NS1)CC1=CC=C(C=C1)F.C(C)C1=C(C=CC=C1)NC(=O)N1C(CN(CC1)C1=NC(=NS1)CC1=CC=C(C=C1)F)C SMZKAPMULBYOLI-UHFFFAOYSA-N 0.000 claims 1
- ZHXLJVNGSZUJFD-UHFFFAOYSA-N COC1=CC=C(C=C1)S(=O)(=O)N1C(CN(CC1)C1=NC(=NS1)CC1=CC=C(C=C1)C)C.FC1=CC=C(C=C1)S(=O)(=O)N1C(CN(CC1)C1=NC(=NS1)CC1=CC=C(C=C1)F)C Chemical compound COC1=CC=C(C=C1)S(=O)(=O)N1C(CN(CC1)C1=NC(=NS1)CC1=CC=C(C=C1)C)C.FC1=CC=C(C=C1)S(=O)(=O)N1C(CN(CC1)C1=NC(=NS1)CC1=CC=C(C=C1)F)C ZHXLJVNGSZUJFD-UHFFFAOYSA-N 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- GIXCQRCZBZYFPD-UHFFFAOYSA-N [4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]-[3-(trifluoromethyl)phenyl]methanone;[2-methyl-4-[3-[(4-methylphenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]-(3-methylphenyl)methanone Chemical compound CC1CN(C=2SN=C(CC=3C=CC(C)=CC=3)N=2)CCN1C(=O)C1=CC=CC(C)=C1.CC1CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CCN1C(=O)C1=CC=CC(C(F)(F)F)=C1 GIXCQRCZBZYFPD-UHFFFAOYSA-N 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- NUGVCEGCJYDNOV-UHFFFAOYSA-N n-(2,4-difluorophenyl)-4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide Chemical compound CC1CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CCN1C(=O)NC1=CC=C(F)C=C1F NUGVCEGCJYDNOV-UHFFFAOYSA-N 0.000 claims 1
- JTLNYDMKXDNZFZ-UHFFFAOYSA-N n-(2,4-dimethylphenyl)-4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide Chemical compound CC1CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CCN1C(=O)NC1=CC=C(C)C=C1C JTLNYDMKXDNZFZ-UHFFFAOYSA-N 0.000 claims 1
- DFRQRPWPTGPUAK-UHFFFAOYSA-N n-(2,6-dichlorophenyl)-4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide Chemical compound CC1CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CCN1C(=O)NC1=C(Cl)C=CC=C1Cl DFRQRPWPTGPUAK-UHFFFAOYSA-N 0.000 claims 1
- NLTPWKIYEXZOFG-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide Chemical compound CC1=CC=CC(C)=C1NC(=O)N1CCN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 NLTPWKIYEXZOFG-UHFFFAOYSA-N 0.000 claims 1
- NTCIRCJZNHTNJL-UHFFFAOYSA-N n-(2-fluorophenyl)-4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide;4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-n-[2-(trifluoromethyl)phenyl]piperazine-1-carboxamide Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CC2)C(=O)NC=2C(=CC=CC=2)F)=N1.C1=CC(F)=CC=C1CC1=NSC(N2CCN(CC2)C(=O)NC=2C(=CC=CC=2)C(F)(F)F)=N1 NTCIRCJZNHTNJL-UHFFFAOYSA-N 0.000 claims 1
- PMDHDMZYLKRHFT-UHFFFAOYSA-N n-(3,4-difluorophenyl)-4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide;n-(2,4-dimethoxyphenyl)-4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide Chemical compound CC1CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CCN1C(=O)NC1=CC=C(F)C(F)=C1.COC1=CC(OC)=CC=C1NC(=O)N1CCN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 PMDHDMZYLKRHFT-UHFFFAOYSA-N 0.000 claims 1
- PGSWWAAIUVONDR-UHFFFAOYSA-N n-(3,4-difluorophenyl)-4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CC2)C(=O)NC=2C=C(F)C(F)=CC=2)=N1 PGSWWAAIUVONDR-UHFFFAOYSA-N 0.000 claims 1
- ATHPNMZKUODHAE-UHFFFAOYSA-N n-(3-cyanophenyl)-4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide Chemical compound CC1CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CCN1C(=O)NC1=CC=CC(C#N)=C1 ATHPNMZKUODHAE-UHFFFAOYSA-N 0.000 claims 1
- OLNBXIKJVDEMOE-UHFFFAOYSA-N n-(3-fluorophenyl)-4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide;1-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]-2-phenylbutan-1-one Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CC2)C(=O)NC=2C=C(F)C=CC=2)=N1.C=1C=CC=CC=1C(CC)C(=O)N(C(C1)C)CCN1C(SN=1)=NC=1CC1=CC=C(F)C=C1 OLNBXIKJVDEMOE-UHFFFAOYSA-N 0.000 claims 1
- ZAADMBMNSTXZSU-UHFFFAOYSA-N n-[2-[4-(3-benzyl-1,2,4-thiadiazol-5-yl)piperazin-1-yl]ethyl]-3-fluorobenzamide;2-(4-fluorophenyl)-n-[2-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl]acetamide Chemical compound FC1=CC=CC(C(=O)NCCN2CCN(CC2)C=2SN=C(CC=3C=CC=CC=3)N=2)=C1.C1=CC(F)=CC=C1CC(=O)NCCN1CCN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 ZAADMBMNSTXZSU-UHFFFAOYSA-N 0.000 claims 1
- AZPXRCLJFBQZGH-UHFFFAOYSA-N n-[2-[4-[3-[(4-chlorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl]-3-fluorobenzamide;n-[2-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl]-4-methylbenzamide Chemical compound C1=CC(C)=CC=C1C(=O)NCCN1CCN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1.FC1=CC=CC(C(=O)NCCN2CCN(CC2)C=2SN=C(CC=3C=CC(Cl)=CC=3)N=2)=C1 AZPXRCLJFBQZGH-UHFFFAOYSA-N 0.000 claims 1
- WSXVESOBRPVRQI-UHFFFAOYSA-N n-[4-[2-methyl-4-[3-[(4-methylphenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]sulfonylphenyl]acetamide;n-[4-[4-[3-[(4-methylphenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]sulfonylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1S(=O)(=O)N1CCN(C=2SN=C(CC=3C=CC(C)=CC=3)N=2)CC1.CC1CN(C=2SN=C(CC=3C=CC(C)=CC=3)N=2)CCN1S(=O)(=O)C1=CC=C(NC(C)=O)C=C1 WSXVESOBRPVRQI-UHFFFAOYSA-N 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- JOMNTHCQHJPVAZ-UHFFFAOYSA-N 2-methylpiperazine Chemical compound CC1CNCCN1 JOMNTHCQHJPVAZ-UHFFFAOYSA-N 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 41
- 239000000203 mixture Substances 0.000 description 23
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 229960005141 piperazine Drugs 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 231100000135 cytotoxicity Toxicity 0.000 description 14
- 230000003013 cytotoxicity Effects 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 210000003523 substantia nigra Anatomy 0.000 description 14
- 239000003981 vehicle Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 13
- 229910001868 water Inorganic materials 0.000 description 13
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 12
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 239000000543 intermediate Substances 0.000 description 12
- 210000002569 neuron Anatomy 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 11
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 11
- 238000004220 aggregation Methods 0.000 description 11
- 230000007850 degeneration Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 230000002776 aggregation Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 8
- 102000019355 Synuclein Human genes 0.000 description 8
- 108050006783 Synuclein Proteins 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 229940126545 compound 53 Drugs 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 150000004885 piperazines Chemical class 0.000 description 7
- 230000035484 reaction time Effects 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- 230000001960 triggered effect Effects 0.000 description 7
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical class ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 5
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 5
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical class ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 210000005064 dopaminergic neuron Anatomy 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000002736 nonionic surfactant Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- LXKNAUOWEJWGTE-UHFFFAOYSA-N 2-(3-methoxyphenyl)acetonitrile Chemical compound COC1=CC=CC(CC#N)=C1 LXKNAUOWEJWGTE-UHFFFAOYSA-N 0.000 description 4
- LHRLXWNAZAZANY-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-5-piperazin-1-yl-1,2,4-thiadiazole Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCNCC2)=N1 LHRLXWNAZAZANY-UHFFFAOYSA-N 0.000 description 4
- DTJVECUKADWGMO-UHFFFAOYSA-N 4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1 DTJVECUKADWGMO-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical class ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000003941 amyloidogenesis Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 231100000263 cytotoxicity test Toxicity 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000012948 isocyanate Substances 0.000 description 4
- 150000002513 isocyanates Chemical class 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 3
- RZNHSEZOLFEFGB-UHFFFAOYSA-N 2-methoxybenzoyl chloride Chemical compound COC1=CC=CC=C1C(Cl)=O RZNHSEZOLFEFGB-UHFFFAOYSA-N 0.000 description 3
- PUGFKQSEHPLELH-UHFFFAOYSA-N 3-benzyl-5-chloro-1,2,4-thiadiazole Chemical compound S1C(Cl)=NC(CC=2C=CC=CC=2)=N1 PUGFKQSEHPLELH-UHFFFAOYSA-N 0.000 description 3
- OXZYBOLWRXENKT-UHFFFAOYSA-N 4-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=C(C(Cl)=O)C=C1 OXZYBOLWRXENKT-UHFFFAOYSA-N 0.000 description 3
- RAIOGYGCVOVRIV-UHFFFAOYSA-N 5-chloro-3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazole Chemical compound C1=CC(F)=CC=C1CC1=NSC(Cl)=N1 RAIOGYGCVOVRIV-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical class ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001095 motoneuron effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- QSBILPAYBAZLKS-UHFFFAOYSA-N n-[2-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl]-2-phenylbutanamide Chemical compound C=1C=CC=CC=1C(CC)C(=O)NCCN(CC1)CCN1C(SN=1)=NC=1CC1=CC=C(F)C=C1 QSBILPAYBAZLKS-UHFFFAOYSA-N 0.000 description 3
- NSNPSJGHTQIXDO-UHFFFAOYSA-N naphthalene-1-carbonyl chloride Chemical compound C1=CC=C2C(C(=O)Cl)=CC=CC2=C1 NSNPSJGHTQIXDO-UHFFFAOYSA-N 0.000 description 3
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- SUSQOBVLVYHIEX-UHFFFAOYSA-N phenylacetonitrile Chemical compound N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- AYKYOOPFBCOXSL-UHFFFAOYSA-N (4-hydroxyphenyl)acetonitrile Chemical compound OC1=CC=C(CC#N)C=C1 AYKYOOPFBCOXSL-UHFFFAOYSA-N 0.000 description 2
- ZRSGZIMDIHBXIN-UHFFFAOYSA-N 1,3-benzodioxole-5-carbonyl chloride Chemical compound ClC(=O)C1=CC=C2OCOC2=C1 ZRSGZIMDIHBXIN-UHFFFAOYSA-N 0.000 description 2
- IVTZRJKKXSKXKO-UHFFFAOYSA-N 1-(2-fluorophenyl)piperazine Chemical compound FC1=CC=CC=C1N1CCNCC1 IVTZRJKKXSKXKO-UHFFFAOYSA-N 0.000 description 2
- WICKLEOONJPMEQ-UHFFFAOYSA-N 1-(2-methylphenyl)piperazine Chemical compound CC1=CC=CC=C1N1CCNCC1 WICKLEOONJPMEQ-UHFFFAOYSA-N 0.000 description 2
- PXHWQGRCERBVPN-UHFFFAOYSA-N 1-[(4-bromo-2-fluorophenyl)methyl]-1,4-diazepane Chemical compound FC1=CC(Br)=CC=C1CN1CCNCCC1 PXHWQGRCERBVPN-UHFFFAOYSA-N 0.000 description 2
- WGEIOMTZIIOUMA-QPJJXVBHSA-N 1-[(e)-3-phenylprop-2-enyl]piperazine Chemical compound C1CNCCN1C\C=C\C1=CC=CC=C1 WGEIOMTZIIOUMA-QPJJXVBHSA-N 0.000 description 2
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 2
- ZNJHENRZPYCHJO-UHFFFAOYSA-N 1-propan-2-ylbenzotriazole-5-carbonyl chloride Chemical compound ClC(=O)C1=CC=C2N(C(C)C)N=NC2=C1 ZNJHENRZPYCHJO-UHFFFAOYSA-N 0.000 description 2
- JSWRVDNTKPAJLB-UHFFFAOYSA-N 2,4-difluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C(F)=C1 JSWRVDNTKPAJLB-UHFFFAOYSA-N 0.000 description 2
- KVIUXRJCBBXEGJ-UHFFFAOYSA-N 2,4-dimethoxybenzoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C(OC)=C1 KVIUXRJCBBXEGJ-UHFFFAOYSA-N 0.000 description 2
- QRHUZEVERIHEPT-UHFFFAOYSA-N 2,6-difluorobenzoyl chloride Chemical compound FC1=CC=CC(F)=C1C(Cl)=O QRHUZEVERIHEPT-UHFFFAOYSA-N 0.000 description 2
- UFFBMTHBGFGIHF-UHFFFAOYSA-N 2,6-dimethylaniline Chemical compound CC1=CC=CC(C)=C1N UFFBMTHBGFGIHF-UHFFFAOYSA-N 0.000 description 2
- JHQBLYITVCBGTO-UHFFFAOYSA-N 2-(4-fluorophenyl)acetonitrile Chemical compound FC1=CC=C(CC#N)C=C1 JHQBLYITVCBGTO-UHFFFAOYSA-N 0.000 description 2
- RNHKXHKUKJXLAU-UHFFFAOYSA-N 2-(4-methylphenyl)acetonitrile Chemical compound CC1=CC=C(CC#N)C=C1 RNHKXHKUKJXLAU-UHFFFAOYSA-N 0.000 description 2
- RAAGZOYMEQDCTD-UHFFFAOYSA-N 2-fluorobenzoyl chloride Chemical compound FC1=CC=CC=C1C(Cl)=O RAAGZOYMEQDCTD-UHFFFAOYSA-N 0.000 description 2
- MVIVDSWUOGNODP-UHFFFAOYSA-N 2-iodobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1I MVIVDSWUOGNODP-UHFFFAOYSA-N 0.000 description 2
- BWWHTIHDQBHTHP-UHFFFAOYSA-N 2-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1C(Cl)=O BWWHTIHDQBHTHP-UHFFFAOYSA-N 0.000 description 2
- RPQWXGVZELKOEU-UHFFFAOYSA-N 3,4-difluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1F RPQWXGVZELKOEU-UHFFFAOYSA-N 0.000 description 2
- GGHLXLVPNZMBQR-UHFFFAOYSA-N 3,5-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC(Cl)=CC(Cl)=C1 GGHLXLVPNZMBQR-UHFFFAOYSA-N 0.000 description 2
- XZORUOZBSPNRFA-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-5-[4-(3-methoxyphenyl)sulfonylpiperazin-1-yl]-1,2,4-thiadiazole Chemical compound COC1=CC=CC(S(=O)(=O)N2CCN(CC2)C=2SN=C(CC=3C=CC(F)=CC=3)N=2)=C1 XZORUOZBSPNRFA-UHFFFAOYSA-N 0.000 description 2
- AYHCBPBDGBGNTM-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-5-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]-1,2,4-thiadiazole Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1CCN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 AYHCBPBDGBGNTM-UHFFFAOYSA-N 0.000 description 2
- DXMZPVSODQXOTL-UHFFFAOYSA-N 3-[(4-methylphenyl)methyl]-5-(3-methylpiperazin-1-yl)-1,2,4-thiadiazole Chemical compound C1CNC(C)CN1C1=NC(CC=2C=CC(C)=CC=2)=NS1 DXMZPVSODQXOTL-UHFFFAOYSA-N 0.000 description 2
- WHIHIKVIWVIIER-UHFFFAOYSA-N 3-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(Cl)=C1 WHIHIKVIWVIIER-UHFFFAOYSA-N 0.000 description 2
- SYVNVEGIRVXRQH-UHFFFAOYSA-N 3-fluorobenzoyl chloride Chemical compound FC1=CC=CC(C(Cl)=O)=C1 SYVNVEGIRVXRQH-UHFFFAOYSA-N 0.000 description 2
- RUQIUASLAXJZIE-UHFFFAOYSA-N 3-methoxybenzoyl chloride Chemical compound COC1=CC=CC(C(Cl)=O)=C1 RUQIUASLAXJZIE-UHFFFAOYSA-N 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-M 4-aminosalicylate(1-) Chemical compound NC1=CC=C(C([O-])=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-M 0.000 description 2
- DENKGPBHLYFNGK-UHFFFAOYSA-N 4-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Br)C=C1 DENKGPBHLYFNGK-UHFFFAOYSA-N 0.000 description 2
- OUOWCSJYDCPVDM-UHFFFAOYSA-N 4-butylbenzoyl chloride Chemical compound CCCCC1=CC=C(C(Cl)=O)C=C1 OUOWCSJYDCPVDM-UHFFFAOYSA-N 0.000 description 2
- IWLGXPWQZDOMSB-UHFFFAOYSA-N 4-chloro-3-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC(C(Cl)=O)=CC=C1Cl IWLGXPWQZDOMSB-UHFFFAOYSA-N 0.000 description 2
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 2
- IVYMIRMKXZAHRV-UHFFFAOYSA-N 4-chlorophenylacetonitrile Chemical compound ClC1=CC=C(CC#N)C=C1 IVYMIRMKXZAHRV-UHFFFAOYSA-N 0.000 description 2
- HRXZRAXKKNUKRF-UHFFFAOYSA-N 4-ethylaniline Chemical compound CCC1=CC=C(N)C=C1 HRXZRAXKKNUKRF-UHFFFAOYSA-N 0.000 description 2
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 2
- XRAHLPNMIIAEPP-UHFFFAOYSA-N 4-hexylbenzoyl chloride Chemical compound CCCCCCC1=CC=C(C(Cl)=O)C=C1 XRAHLPNMIIAEPP-UHFFFAOYSA-N 0.000 description 2
- NQUVCRCCRXRJCK-UHFFFAOYSA-N 4-methylbenzoyl chloride Chemical compound CC1=CC=C(C(Cl)=O)C=C1 NQUVCRCCRXRJCK-UHFFFAOYSA-N 0.000 description 2
- FBBRKYLXMNQFQU-UHFFFAOYSA-N 4-pentylbenzoyl chloride Chemical compound CCCCCC1=CC=C(C(Cl)=O)C=C1 FBBRKYLXMNQFQU-UHFFFAOYSA-N 0.000 description 2
- JPVUWCPKMYXOKW-UHFFFAOYSA-N 4-phenylbenzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1C1=CC=CC=C1 JPVUWCPKMYXOKW-UHFFFAOYSA-N 0.000 description 2
- WNLMYNASWOULQY-UHFFFAOYSA-N 4-tert-butylbenzoyl chloride Chemical compound CC(C)(C)C1=CC=C(C(Cl)=O)C=C1 WNLMYNASWOULQY-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- JCROPKNMTWZFMR-UHFFFAOYSA-N 5-[4-(4-methoxyphenyl)sulfonyl-3-methylpiperazin-1-yl]-3-[(4-methylphenyl)methyl]-1,2,4-thiadiazole Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N1C(C)CN(C=2SN=C(CC=3C=CC(C)=CC=3)N=2)CC1 JCROPKNMTWZFMR-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 0 CCCN(*c1c(*)c(*)c(*)c(*)c1*)*(C)CNc1nc(C(*)(*)c2c(*)c(C)c(*)c(C)c2*)n[s]1 Chemical compound CCCN(*c1c(*)c(*)c(*)c(*)c1*)*(C)CNc1nc(C(*)(*)c2c(*)c(C)c(*)c(C)c2*)n[s]1 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 150000001556 benzimidazoles Chemical class 0.000 description 2
- 150000008359 benzonitriles Chemical class 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000006315 carbonylation Effects 0.000 description 2
- 238000005810 carbonylation reaction Methods 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000006950 reactive oxygen species formation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- PKQKHWNHCKNYSW-UHFFFAOYSA-N (+-)-2-(4'-isobutylphenyl)propionitrile Chemical compound CC(C)CC1=CC=C(C(C)C#N)C=C1 PKQKHWNHCKNYSW-UHFFFAOYSA-N 0.000 description 1
- DSGKWFGEUBCEIE-UHFFFAOYSA-N (2-carbonochloridoylphenyl) acetate Chemical compound CC(=O)OC1=CC=CC=C1C(Cl)=O DSGKWFGEUBCEIE-UHFFFAOYSA-N 0.000 description 1
- FLJKUQHGMJYZGT-UHFFFAOYSA-N (2-chloro-4-nitrophenyl)-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]methanone Chemical compound CC1CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CCN1C(=O)C1=CC=C([N+]([O-])=O)C=C1Cl FLJKUQHGMJYZGT-UHFFFAOYSA-N 0.000 description 1
- PNCPLSQYXAEWCK-UHFFFAOYSA-N (2-fluorophenyl)-(1h-pyrrol-3-yl)methanone Chemical compound FC1=CC=CC=C1C(=O)C1=CNC=C1 PNCPLSQYXAEWCK-UHFFFAOYSA-N 0.000 description 1
- CCXWLGSXPAYKRD-UHFFFAOYSA-N (2-fluorophenyl)-[4-[3-[(3-methoxyphenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]methanone Chemical compound COC1=CC=CC(CC=2N=C(SN=2)N2CC(C)N(CC2)C(=O)C=2C(=CC=CC=2)F)=C1 CCXWLGSXPAYKRD-UHFFFAOYSA-N 0.000 description 1
- CIMVUHANJQHJAH-UHFFFAOYSA-N (2-fluorophenyl)-[4-[3-[(4-methylphenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]methanone Chemical compound C1=CC(C)=CC=C1CC1=NSC(N2CCN(CC2)C(=O)C=2C(=CC=CC=2)F)=N1 CIMVUHANJQHJAH-UHFFFAOYSA-N 0.000 description 1
- WMGVPDQNPUQRND-UHFFFAOYSA-N (2-methylphenyl)acetonitrile Chemical compound CC1=CC=CC=C1CC#N WMGVPDQNPUQRND-UHFFFAOYSA-N 0.000 description 1
- JOMNTHCQHJPVAZ-RXMQYKEDSA-N (2r)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1 JOMNTHCQHJPVAZ-RXMQYKEDSA-N 0.000 description 1
- NSMWYRLQHIXVAP-OLQVQODUSA-N (2r,5s)-2,5-dimethylpiperazine Chemical compound C[C@H]1CN[C@H](C)CN1 NSMWYRLQHIXVAP-OLQVQODUSA-N 0.000 description 1
- JOMNTHCQHJPVAZ-YFKPBYRVSA-N (2s)-2-methylpiperazine Chemical compound C[C@H]1CNCCN1 JOMNTHCQHJPVAZ-YFKPBYRVSA-N 0.000 description 1
- DRPKNTNHBSFTOD-UHFFFAOYSA-N (3,5-dichlorophenyl)-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CC2)C(=O)C=2C=C(Cl)C=C(Cl)C=2)=N1 DRPKNTNHBSFTOD-UHFFFAOYSA-N 0.000 description 1
- YZBVBZTYEPPZDJ-UHFFFAOYSA-N (3-chlorophenyl)-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]methanone Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CC2)C(=O)C=2C=C(Cl)C=CC=2)=N1 YZBVBZTYEPPZDJ-UHFFFAOYSA-N 0.000 description 1
- KUVAEMGNHJQSMH-UHFFFAOYSA-N (3-dodecanoyloxy-2-hydroxypropyl) dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCC KUVAEMGNHJQSMH-UHFFFAOYSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- HULWUSGQJORLBS-UHFFFAOYSA-N (4-bromophenyl)-[4-[3-[(3-methoxyphenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]methanone Chemical compound COC1=CC=CC(CC=2N=C(SN=2)N2CC(C)N(CC2)C(=O)C=2C=CC(Br)=CC=2)=C1 HULWUSGQJORLBS-UHFFFAOYSA-N 0.000 description 1
- DNTPLKBWAHHBQL-UHFFFAOYSA-N (4-bromophenyl)-[4-[3-[(4-methylphenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]methanone Chemical compound C1=CC(C)=CC=C1CC1=NSC(N2CCN(CC2)C(=O)C=2C=CC(Br)=CC=2)=N1 DNTPLKBWAHHBQL-UHFFFAOYSA-N 0.000 description 1
- FMAUUKOCEAERHW-UHFFFAOYSA-N (4-butylphenyl)-[4-[3-[(4-methylphenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]methanone Chemical compound C1=CC(CCCC)=CC=C1C(=O)N1CCN(C=2SN=C(CC=3C=CC(C)=CC=3)N=2)CC1 FMAUUKOCEAERHW-UHFFFAOYSA-N 0.000 description 1
- JXIUFEAYGLHJRS-UHFFFAOYSA-N (4-chlorophenyl)-[4-[3-[(3-methoxyphenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]methanone Chemical compound COC1=CC=CC(CC=2N=C(SN=2)N2CC(C)N(CC2)C(=O)C=2C=CC(Cl)=CC=2)=C1 JXIUFEAYGLHJRS-UHFFFAOYSA-N 0.000 description 1
- WMGNNULKZBYAAX-UHFFFAOYSA-N (4-chlorophenyl)-[4-[3-[(4-methylphenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]methanone Chemical compound C1=CC(C)=CC=C1CC1=NSC(N2CCN(CC2)C(=O)C=2C=CC(Cl)=CC=2)=N1 WMGNNULKZBYAAX-UHFFFAOYSA-N 0.000 description 1
- IEZOOEHMEWHFJE-UHFFFAOYSA-N (4-ethylphenyl)-[4-[3-[(3-methoxyphenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]methanone Chemical compound C1=CC(CC)=CC=C1C(=O)N1C(C)CN(C=2SN=C(CC=3C=C(OC)C=CC=3)N=2)CC1 IEZOOEHMEWHFJE-UHFFFAOYSA-N 0.000 description 1
- NNRHWKYNNDWUJK-UHFFFAOYSA-N (4-fluorophenyl)-[4-[3-[(3-methoxyphenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]methanone Chemical compound COC1=CC=CC(CC=2N=C(SN=2)N2CC(C)N(CC2)C(=O)C=2C=CC(F)=CC=2)=C1 NNRHWKYNNDWUJK-UHFFFAOYSA-N 0.000 description 1
- PPJXBLPYXYFUMJ-UHFFFAOYSA-N (4-hexylphenyl)-[4-[3-[(4-methylphenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]methanone Chemical compound C1=CC(CCCCCC)=CC=C1C(=O)N1CCN(C=2SN=C(CC=3C=CC(C)=CC=3)N=2)CC1 PPJXBLPYXYFUMJ-UHFFFAOYSA-N 0.000 description 1
- HGFHDGZFTKNCCO-UHFFFAOYSA-N (4-tert-butylphenyl)-[4-[3-[(3-methoxyphenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]methanone Chemical compound COC1=CC=CC(CC=2N=C(SN=2)N2CC(C)N(CC2)C(=O)C=2C=CC(=CC=2)C(C)(C)C)=C1 HGFHDGZFTKNCCO-UHFFFAOYSA-N 0.000 description 1
- QLJLZJMNBYBSTH-UHFFFAOYSA-N (4-tert-butylphenyl)-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]methanone Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)N1CCN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 QLJLZJMNBYBSTH-UHFFFAOYSA-N 0.000 description 1
- CFTTXTITLDLKKP-UHFFFAOYSA-N (4-tert-butylphenyl)-[4-[3-[(4-methylphenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]methanone Chemical compound C1=CC(C)=CC=C1CC1=NSC(N2CCN(CC2)C(=O)C=2C=CC(=CC=2)C(C)(C)C)=N1 CFTTXTITLDLKKP-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LKZLVUNCGIWEOS-DHZHZOJOSA-N (e)-1-[4-[3-[(4-chlorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]-3-phenylprop-2-en-1-one Chemical compound C1=CC(Cl)=CC=C1CC1=NSC(N2CCN(CC2)C(=O)\C=C\C=2C=CC=CC=2)=N1 LKZLVUNCGIWEOS-DHZHZOJOSA-N 0.000 description 1
- WOGITNXCNOTRLK-VOTSOKGWSA-N (e)-3-phenylprop-2-enoyl chloride Chemical compound ClC(=O)\C=C\C1=CC=CC=C1 WOGITNXCNOTRLK-VOTSOKGWSA-N 0.000 description 1
- VOSTUOLSYXVSND-UHFFFAOYSA-N 1,2,3-benzothiadiazole-5-carbonyl chloride Chemical compound ClC(=O)C1=CC=C2SN=NC2=C1 VOSTUOLSYXVSND-UHFFFAOYSA-N 0.000 description 1
- LSKOUPSEWMJCEP-UHFFFAOYSA-N 1,2,3-trifluoro-4-isocyanatobenzene Chemical compound FC1=CC=C(N=C=O)C(F)=C1F LSKOUPSEWMJCEP-UHFFFAOYSA-N 0.000 description 1
- 125000004516 1,2,4-thiadiazol-5-yl group Chemical group S1N=CN=C1* 0.000 description 1
- FYWJWWMKCARWQG-UHFFFAOYSA-N 1,2-dichloro-3-isocyanatobenzene Chemical compound ClC1=CC=CC(N=C=O)=C1Cl FYWJWWMKCARWQG-UHFFFAOYSA-N 0.000 description 1
- YBWJVFMNWMLZEN-UHFFFAOYSA-N 1,2-difluoro-4-isocyanatobenzene Chemical compound FC1=CC=C(N=C=O)C=C1F YBWJVFMNWMLZEN-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- VDYWXVDWKFAUKE-UHFFFAOYSA-N 1,3,5-trichloro-2-isocyanatobenzene Chemical compound ClC1=CC(Cl)=C(N=C=O)C(Cl)=C1 VDYWXVDWKFAUKE-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- JSRUBHLGDKFGFL-UHFFFAOYSA-N 1,3-benzodioxol-5-yl-[4-[3-[(3-methoxyphenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]methanone Chemical compound COC1=CC=CC(CC=2N=C(SN=2)N2CC(C)N(CC2)C(=O)C=2C=C3OCOC3=CC=2)=C1 JSRUBHLGDKFGFL-UHFFFAOYSA-N 0.000 description 1
- ITPLFTBJFZHSEM-UHFFFAOYSA-N 1,3-benzodioxol-5-yl-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]methanone Chemical compound C1CN(C(=O)C=2C=C3OCOC3=CC=2)C(C)CN1C(SN=1)=NC=1CC1=CC=C(F)C=C1 ITPLFTBJFZHSEM-UHFFFAOYSA-N 0.000 description 1
- ICUBASIDCXDQAW-UHFFFAOYSA-N 1,3-benzodioxole-5-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C2OCOC2=C1 ICUBASIDCXDQAW-UHFFFAOYSA-N 0.000 description 1
- XQOLJTWXFUSVOR-UHFFFAOYSA-N 1,3-benzothiazole-6-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C2N=CSC2=C1 XQOLJTWXFUSVOR-UHFFFAOYSA-N 0.000 description 1
- AIQYHXAROYBPBR-UHFFFAOYSA-N 1,3-dibromo-2-isocyanato-5-propan-2-ylbenzene Chemical compound CC(C)C1=CC(Br)=C(N=C=O)C(Br)=C1 AIQYHXAROYBPBR-UHFFFAOYSA-N 0.000 description 1
- HMVKMAMIRAVXAN-UHFFFAOYSA-N 1,3-dichloro-2-isocyanatobenzene Chemical compound ClC1=CC=CC(Cl)=C1N=C=O HMVKMAMIRAVXAN-UHFFFAOYSA-N 0.000 description 1
- XEFUJGURFLOFAN-UHFFFAOYSA-N 1,3-dichloro-5-isocyanatobenzene Chemical compound ClC1=CC(Cl)=CC(N=C=O)=C1 XEFUJGURFLOFAN-UHFFFAOYSA-N 0.000 description 1
- YXHDLKWTPVMIOH-UHFFFAOYSA-N 1,3-difluoro-2-isocyanatobenzene Chemical compound FC1=CC=CC(F)=C1N=C=O YXHDLKWTPVMIOH-UHFFFAOYSA-N 0.000 description 1
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
- SNHIIFOXCRYGGY-UHFFFAOYSA-N 1,4-difluoro-2-isocyanatobenzene Chemical compound FC1=CC=C(F)C(N=C=O)=C1 SNHIIFOXCRYGGY-UHFFFAOYSA-N 0.000 description 1
- NBOOZXVYXHATOW-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-ylmethyl)piperazine Chemical compound C=1C=C2OCOC2=CC=1CN1CCNCC1 NBOOZXVYXHATOW-UHFFFAOYSA-N 0.000 description 1
- LIKXJDINUMWKQA-UHFFFAOYSA-N 1-(2,3-dimethylphenyl)piperazine Chemical compound CC1=CC=CC(N2CCNCC2)=C1C LIKXJDINUMWKQA-UHFFFAOYSA-N 0.000 description 1
- VDKKBWVLLSVWKI-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)cyclopropane-1-carbonitrile Chemical compound ClC1=CC(Cl)=CC=C1C1(C#N)CC1 VDKKBWVLLSVWKI-UHFFFAOYSA-N 0.000 description 1
- RUIMBVCRNZHCRQ-UHFFFAOYSA-N 1-(2,4-dimethylphenyl)piperazine Chemical compound CC1=CC(C)=CC=C1N1CCNCC1 RUIMBVCRNZHCRQ-UHFFFAOYSA-N 0.000 description 1
- YRIFWVMRUFKWLM-UHFFFAOYSA-N 1-(2,5-dimethylphenyl)piperazine Chemical compound CC1=CC=C(C)C(N2CCNCC2)=C1 YRIFWVMRUFKWLM-UHFFFAOYSA-N 0.000 description 1
- KZGDMXVKXALOSX-UHFFFAOYSA-N 1-(2-chloro-4-fluorophenyl)cyclohexane-1-carbonitrile Chemical compound ClC1=CC(F)=CC=C1C1(C#N)CCCCC1 KZGDMXVKXALOSX-UHFFFAOYSA-N 0.000 description 1
- BGCPHKLPEOZLGI-UHFFFAOYSA-N 1-(2-chloro-4-fluorophenyl)cyclopentane-1-carbonitrile Chemical compound ClC1=CC(F)=CC=C1C1(C#N)CCCC1 BGCPHKLPEOZLGI-UHFFFAOYSA-N 0.000 description 1
- WIFXEJWTWHLDBA-UHFFFAOYSA-N 1-(2-chloro-6-fluorophenyl)cyclohexane-1-carbonitrile Chemical compound FC1=CC=CC(Cl)=C1C1(C#N)CCCCC1 WIFXEJWTWHLDBA-UHFFFAOYSA-N 0.000 description 1
- KIROJLODCPJLTM-UHFFFAOYSA-N 1-(2-chloro-6-fluorophenyl)cyclopentane-1-carbonitrile Chemical compound FC1=CC=CC(Cl)=C1C1(C#N)CCCC1 KIROJLODCPJLTM-UHFFFAOYSA-N 0.000 description 1
- PWZDJIUQHUGFRJ-UHFFFAOYSA-N 1-(2-chlorophenyl)piperazine Chemical compound ClC1=CC=CC=C1N1CCNCC1 PWZDJIUQHUGFRJ-UHFFFAOYSA-N 0.000 description 1
- FBQIUSDQWOLCNY-UHFFFAOYSA-N 1-(2-ethoxyphenyl)piperazine Chemical compound CCOC1=CC=CC=C1N1CCNCC1 FBQIUSDQWOLCNY-UHFFFAOYSA-N 0.000 description 1
- NLLWMLADVNXWKT-UHFFFAOYSA-N 1-(2-fluorophenyl)cyclohexane-1-carbonitrile Chemical compound FC1=CC=CC=C1C1(C#N)CCCCC1 NLLWMLADVNXWKT-UHFFFAOYSA-N 0.000 description 1
- KFRPRFWZCDHYKA-UHFFFAOYSA-N 1-(2-fluorophenyl)cyclopentane-1-carbonitrile Chemical compound FC1=CC=CC=C1C1(C#N)CCCC1 KFRPRFWZCDHYKA-UHFFFAOYSA-N 0.000 description 1
- DDMVHGULHRJOEC-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazin-1-ium;chloride Chemical compound Cl.COC1=CC=CC=C1N1CCNCC1 DDMVHGULHRJOEC-UHFFFAOYSA-N 0.000 description 1
- VNZLQLYBRIOLFZ-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCNCC1 VNZLQLYBRIOLFZ-UHFFFAOYSA-N 0.000 description 1
- PXFJLKKZSWWVRX-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)piperazine Chemical compound C1=C(Cl)C(Cl)=CC=C1N1CCNCC1 PXFJLKKZSWWVRX-UHFFFAOYSA-N 0.000 description 1
- SFLNVAVCCYTHCQ-UHFFFAOYSA-N 1-(3,4-dimethylphenyl)piperazine Chemical compound C1=C(C)C(C)=CC=C1N1CCNCC1 SFLNVAVCCYTHCQ-UHFFFAOYSA-N 0.000 description 1
- KKIMDKMETPPURN-UHFFFAOYSA-N 1-(3-(trifluoromethyl)phenyl)piperazine Chemical compound FC(F)(F)C1=CC=CC(N2CCNCC2)=C1 KKIMDKMETPPURN-UHFFFAOYSA-N 0.000 description 1
- LMLYKFFZJKETHE-UHFFFAOYSA-N 1-(3-chlorophenyl)cyclohexane-1-carbonitrile Chemical compound ClC1=CC=CC(C2(CCCCC2)C#N)=C1 LMLYKFFZJKETHE-UHFFFAOYSA-N 0.000 description 1
- VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 description 1
- UOFSKBVHBCPJEQ-UHFFFAOYSA-N 1-(3-fluorophenyl)cyclohexane-1-carbonitrile Chemical compound FC1=CC=CC(C2(CCCCC2)C#N)=C1 UOFSKBVHBCPJEQ-UHFFFAOYSA-N 0.000 description 1
- JASTZOAHAWBRLM-UHFFFAOYSA-N 1-(3-isocyanatophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(N=C=O)=C1 JASTZOAHAWBRLM-UHFFFAOYSA-N 0.000 description 1
- PUPFPJGLDBUOOI-UHFFFAOYSA-N 1-(3-isocyanatophenyl)pyrrole Chemical compound O=C=NC1=CC=CC(N2C=CC=C2)=C1 PUPFPJGLDBUOOI-UHFFFAOYSA-N 0.000 description 1
- JIWHIRLNKIUYSM-UHFFFAOYSA-N 1-(3-methylphenyl)piperazine Chemical compound CC1=CC=CC(N2CCNCC2)=C1 JIWHIRLNKIUYSM-UHFFFAOYSA-N 0.000 description 1
- IBQMAPSJLHRQPE-UHFFFAOYSA-N 1-(4-(trifluoromethyl)phenyl)piperazine Chemical compound C1=CC(C(F)(F)F)=CC=C1N1CCNCC1 IBQMAPSJLHRQPE-UHFFFAOYSA-N 0.000 description 1
- XQONXPWVIZZJIL-UHFFFAOYSA-N 1-(4-chlorophenyl)cyclobutane-1-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C1(C#N)CCC1 XQONXPWVIZZJIL-UHFFFAOYSA-N 0.000 description 1
- OSHOYPXOCQTDGJ-UHFFFAOYSA-N 1-(4-chlorophenyl)cyclohexane-1-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C1(C#N)CCCCC1 OSHOYPXOCQTDGJ-UHFFFAOYSA-N 0.000 description 1
- BVWSEHMDAKSWQW-UHFFFAOYSA-N 1-(4-chlorophenyl)cyclopropane-1-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C1(C#N)CC1 BVWSEHMDAKSWQW-UHFFFAOYSA-N 0.000 description 1
- CXHLRVDEACWSNN-UHFFFAOYSA-N 1-(4-fluorophenyl)cyclohexane-1-carbonitrile Chemical compound C1=CC(F)=CC=C1C1(C#N)CCCCC1 CXHLRVDEACWSNN-UHFFFAOYSA-N 0.000 description 1
- MAGOCEYAQAZRNE-UHFFFAOYSA-N 1-(4-fluorophenyl)cyclopentane-1-carbonitrile Chemical compound C1=CC(F)=CC=C1C1(C#N)CCCC1 MAGOCEYAQAZRNE-UHFFFAOYSA-N 0.000 description 1
- AVJKDKWRVSSJPK-UHFFFAOYSA-N 1-(4-fluorophenyl)piperazine Chemical compound C1=CC(F)=CC=C1N1CCNCC1 AVJKDKWRVSSJPK-UHFFFAOYSA-N 0.000 description 1
- XZPOEEDBGHTYQC-UHFFFAOYSA-N 1-(4-isocyanatophenyl)pyrrole Chemical compound C1=CC(N=C=O)=CC=C1N1C=CC=C1 XZPOEEDBGHTYQC-UHFFFAOYSA-N 0.000 description 1
- LSIROHVGZARUJC-UHFFFAOYSA-N 1-(4-methoxyphenyl)-2-methylpiperazine Chemical compound C1=CC(OC)=CC=C1N1C(C)CNCC1 LSIROHVGZARUJC-UHFFFAOYSA-N 0.000 description 1
- YQXUSXSQFVWPRQ-UHFFFAOYSA-N 1-(4-methoxyphenyl)cyclohexane-1-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1(C#N)CCCCC1 YQXUSXSQFVWPRQ-UHFFFAOYSA-N 0.000 description 1
- DOZAMVFROCVJLO-UHFFFAOYSA-N 1-(4-methoxyphenyl)cyclopentane-1-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1(C#N)CCCC1 DOZAMVFROCVJLO-UHFFFAOYSA-N 0.000 description 1
- OIQRGAQXQLASRC-UHFFFAOYSA-N 1-(4-methoxyphenyl)cyclopropane-1-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1(C#N)CC1 OIQRGAQXQLASRC-UHFFFAOYSA-N 0.000 description 1
- JFUXEEYLCATFIB-UHFFFAOYSA-N 1-(4-methylphenyl)cyclohexane-1-carbonitrile Chemical compound C1=CC(C)=CC=C1C1(C#N)CCCCC1 JFUXEEYLCATFIB-UHFFFAOYSA-N 0.000 description 1
- NMDIWHQRZLXXNV-UHFFFAOYSA-N 1-(4-methylphenyl)cyclopropane-1-carbonitrile Chemical compound C1=CC(C)=CC=C1C1(C#N)CC1 NMDIWHQRZLXXNV-UHFFFAOYSA-N 0.000 description 1
- ONEYFZXGNFNRJH-UHFFFAOYSA-N 1-(4-methylphenyl)piperazine Chemical compound C1=CC(C)=CC=C1N1CCNCC1 ONEYFZXGNFNRJH-UHFFFAOYSA-N 0.000 description 1
- VWOJSRICSKDKAW-UHFFFAOYSA-N 1-(4-nitrophenyl)piperazine Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1CCNCC1 VWOJSRICSKDKAW-UHFFFAOYSA-N 0.000 description 1
- KPXVKKBJROCIJB-UHFFFAOYSA-N 1-(4-piperazin-1-ylphenyl)ethanone Chemical compound C1=CC(C(=O)C)=CC=C1N1CCNCC1 KPXVKKBJROCIJB-UHFFFAOYSA-N 0.000 description 1
- FVDJRHNUZNLRJC-UHFFFAOYSA-N 1-(5-chloro-2-methylphenyl)piperazine Chemical compound CC1=CC=C(Cl)C=C1N1CCNCC1 FVDJRHNUZNLRJC-UHFFFAOYSA-N 0.000 description 1
- OBYMZHLTKVXPQF-UHFFFAOYSA-N 1-(chloromethyl)-4-isocyanatobenzene Chemical compound ClCC1=CC=C(N=C=O)C=C1 OBYMZHLTKVXPQF-UHFFFAOYSA-N 0.000 description 1
- SROZUOLPZNBAAB-UHFFFAOYSA-N 1-[(2-chloro-6-fluorophenyl)methyl]-1,4-diazepane Chemical compound FC1=CC=CC(Cl)=C1CN1CCNCCC1 SROZUOLPZNBAAB-UHFFFAOYSA-N 0.000 description 1
- PUTBARDRYLXING-UHFFFAOYSA-N 1-[(4-bromophenyl)methyl]-1,4-diazepane Chemical compound C1=CC(Br)=CC=C1CN1CCNCCC1 PUTBARDRYLXING-UHFFFAOYSA-N 0.000 description 1
- KZCHYFUMQQWGJK-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-1,4-diazepane Chemical compound C1=CC(F)=CC=C1CN1CCNCCC1 KZCHYFUMQQWGJK-UHFFFAOYSA-N 0.000 description 1
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- YOBUPGXTLFRIJD-UHFFFAOYSA-N 1-[2-nitro-4-(trifluoromethyl)phenyl]piperazine Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC=C1N1CCNCC1 YOBUPGXTLFRIJD-UHFFFAOYSA-N 0.000 description 1
- HYLBGAZVIXKCIN-UHFFFAOYSA-N 1-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]-3-phenylpropan-1-one Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CC2)C(=O)CCC=2C=CC=CC=2)=N1 HYLBGAZVIXKCIN-UHFFFAOYSA-N 0.000 description 1
- QNFXLCHANYHGIF-UHFFFAOYSA-N 1-acetyl-2,3-dihydroindole-5-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C2N(C(=O)C)CCC2=C1 QNFXLCHANYHGIF-UHFFFAOYSA-N 0.000 description 1
- HVLITELPDNDMFO-UHFFFAOYSA-N 1-benzofuran-5-carbonyl chloride Chemical compound ClC(=O)C1=CC=C2OC=CC2=C1 HVLITELPDNDMFO-UHFFFAOYSA-N 0.000 description 1
- YICARPJDZQGVQC-UHFFFAOYSA-N 1-benzothiophene-5-carbonyl chloride Chemical compound ClC(=O)C1=CC=C2SC=CC2=C1 YICARPJDZQGVQC-UHFFFAOYSA-N 0.000 description 1
- IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 1
- GOOVAYJIVMBWPP-UHFFFAOYSA-N 1-bromo-2-isocyanatobenzene Chemical compound BrC1=CC=CC=C1N=C=O GOOVAYJIVMBWPP-UHFFFAOYSA-N 0.000 description 1
- NPRYGRLJCFTSBA-UHFFFAOYSA-N 1-bromo-3,5-difluoro-2-isocyanatobenzene Chemical compound FC1=CC(F)=C(N=C=O)C(Br)=C1 NPRYGRLJCFTSBA-UHFFFAOYSA-N 0.000 description 1
- VQVBCZQTXSHJGF-UHFFFAOYSA-N 1-bromo-3-isocyanatobenzene Chemical compound BrC1=CC=CC(N=C=O)=C1 VQVBCZQTXSHJGF-UHFFFAOYSA-N 0.000 description 1
- CZQIJQFTRGDODI-UHFFFAOYSA-N 1-bromo-4-isocyanatobenzene Chemical compound BrC1=CC=C(N=C=O)C=C1 CZQIJQFTRGDODI-UHFFFAOYSA-N 0.000 description 1
- WEPYOPYMWSHRIW-UHFFFAOYSA-N 1-chloro-2-isocyanato-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(Cl)C(N=C=O)=C1 WEPYOPYMWSHRIW-UHFFFAOYSA-N 0.000 description 1
- NOHQUGRVHSJYMR-UHFFFAOYSA-N 1-chloro-2-isocyanatobenzene Chemical compound ClC1=CC=CC=C1N=C=O NOHQUGRVHSJYMR-UHFFFAOYSA-N 0.000 description 1
- NGQMCUWZGVMILT-UHFFFAOYSA-N 1-chloro-3-isocyanato-2-methylbenzene Chemical compound CC1=C(Cl)C=CC=C1N=C=O NGQMCUWZGVMILT-UHFFFAOYSA-N 0.000 description 1
- HHIRBXHEYVDUAM-UHFFFAOYSA-N 1-chloro-3-isocyanatobenzene Chemical compound ClC1=CC=CC(N=C=O)=C1 HHIRBXHEYVDUAM-UHFFFAOYSA-N 0.000 description 1
- NBJZEUQTGLSUOB-UHFFFAOYSA-N 1-chloro-4-isocyanato-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(N=C=O)=CC=C1Cl NBJZEUQTGLSUOB-UHFFFAOYSA-N 0.000 description 1
- ZCPHLSPLEGBTCZ-UHFFFAOYSA-N 1-chloro-4-isocyanato-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(N=C=O)=CC=C1Cl ZCPHLSPLEGBTCZ-UHFFFAOYSA-N 0.000 description 1
- ADAKRBAJFHTIEW-UHFFFAOYSA-N 1-chloro-4-isocyanatobenzene Chemical compound ClC1=CC=C(N=C=O)C=C1 ADAKRBAJFHTIEW-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- BUIQXUQLYZPMLS-UHFFFAOYSA-N 1-ethoxy-2-isocyanatobenzene Chemical compound CCOC1=CC=CC=C1N=C=O BUIQXUQLYZPMLS-UHFFFAOYSA-N 0.000 description 1
- YMAVXDRFOILNKI-UHFFFAOYSA-N 1-ethyl-2-isocyanato-3-methylbenzene Chemical compound CCC1=CC=CC(C)=C1N=C=O YMAVXDRFOILNKI-UHFFFAOYSA-N 0.000 description 1
- ZVFNUQWYLXXSJM-UHFFFAOYSA-N 1-ethyl-2-isocyanatobenzene Chemical compound CCC1=CC=CC=C1N=C=O ZVFNUQWYLXXSJM-UHFFFAOYSA-N 0.000 description 1
- BZWCKYVPHPOLDL-UHFFFAOYSA-N 1-fluoro-2-isocyanato-3-(trifluoromethyl)benzene Chemical compound FC1=CC=CC(C(F)(F)F)=C1N=C=O BZWCKYVPHPOLDL-UHFFFAOYSA-N 0.000 description 1
- NAIKHCBDZGSGHH-UHFFFAOYSA-N 1-fluoro-2-isocyanato-4-(trifluoromethyl)benzene Chemical compound FC1=CC=C(C(F)(F)F)C=C1N=C=O NAIKHCBDZGSGHH-UHFFFAOYSA-N 0.000 description 1
- GLSUJZPVKMKUPJ-UHFFFAOYSA-N 1-fluoro-2-isocyanato-4-methylbenzene Chemical compound CC1=CC=C(F)C(N=C=O)=C1 GLSUJZPVKMKUPJ-UHFFFAOYSA-N 0.000 description 1
- VZNCSZQPNIEEMN-UHFFFAOYSA-N 1-fluoro-2-isocyanatobenzene Chemical compound FC1=CC=CC=C1N=C=O VZNCSZQPNIEEMN-UHFFFAOYSA-N 0.000 description 1
- RIKWVZGZRYDACA-UHFFFAOYSA-N 1-fluoro-3-isocyanatobenzene Chemical compound FC1=CC=CC(N=C=O)=C1 RIKWVZGZRYDACA-UHFFFAOYSA-N 0.000 description 1
- OPPYFFRLKJUEOS-UHFFFAOYSA-N 1-fluoro-4-isocyanato-2-(trifluoromethyl)benzene Chemical compound FC1=CC=C(N=C=O)C=C1C(F)(F)F OPPYFFRLKJUEOS-UHFFFAOYSA-N 0.000 description 1
- KCHOHFPMTUPOJU-UHFFFAOYSA-N 1-fluoro-4-isocyanato-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(N=C=O)=CC=C1F KCHOHFPMTUPOJU-UHFFFAOYSA-N 0.000 description 1
- DSVGFKBFFICWLZ-UHFFFAOYSA-N 1-fluoro-4-isocyanatobenzene Chemical compound FC1=CC=C(N=C=O)C=C1 DSVGFKBFFICWLZ-UHFFFAOYSA-N 0.000 description 1
- KJMZSDMQWFWLCX-UHFFFAOYSA-N 1-heptoxy-4-isocyanatobenzene Chemical compound CCCCCCCOC1=CC=C(N=C=O)C=C1 KJMZSDMQWFWLCX-UHFFFAOYSA-N 0.000 description 1
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical compound CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 1
- WRAZHLRMDRTLOZ-UHFFFAOYSA-N 1-isocyanato-2,4-dimethoxybenzene Chemical compound COC1=CC=C(N=C=O)C(OC)=C1 WRAZHLRMDRTLOZ-UHFFFAOYSA-N 0.000 description 1
- CTMGYQHKKIEXKF-UHFFFAOYSA-N 1-isocyanato-2-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=CC=C1N=C=O CTMGYQHKKIEXKF-UHFFFAOYSA-N 0.000 description 1
- GZWGTVZRRFPVAS-UHFFFAOYSA-N 1-isocyanato-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1N=C=O GZWGTVZRRFPVAS-UHFFFAOYSA-N 0.000 description 1
- SUVCZZADQDCIEQ-UHFFFAOYSA-N 1-isocyanato-2-methoxybenzene Chemical compound COC1=CC=CC=C1N=C=O SUVCZZADQDCIEQ-UHFFFAOYSA-N 0.000 description 1
- WQXASSKJZYKJSI-UHFFFAOYSA-N 1-isocyanato-2-methylsulfanylbenzene Chemical compound CSC1=CC=CC=C1N=C=O WQXASSKJZYKJSI-UHFFFAOYSA-N 0.000 description 1
- JRVZITODZAQRQM-UHFFFAOYSA-N 1-isocyanato-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1N=C=O JRVZITODZAQRQM-UHFFFAOYSA-N 0.000 description 1
- NSGTVMQTRFUUSL-UHFFFAOYSA-N 1-isocyanato-2-propylbenzene Chemical compound CCCC1=CC=CC=C1N=C=O NSGTVMQTRFUUSL-UHFFFAOYSA-N 0.000 description 1
- NRSSOFNMWSJECS-UHFFFAOYSA-N 1-isocyanato-3,5-bis(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(N=C=O)=CC(C(F)(F)F)=C1 NRSSOFNMWSJECS-UHFFFAOYSA-N 0.000 description 1
- LEKQOUWMYSIQII-UHFFFAOYSA-N 1-isocyanato-3,5-dimethoxybenzene Chemical compound COC1=CC(OC)=CC(N=C=O)=C1 LEKQOUWMYSIQII-UHFFFAOYSA-N 0.000 description 1
- DZSGDHNHQAJZCO-UHFFFAOYSA-N 1-isocyanato-3,5-dimethylbenzene Chemical compound CC1=CC(C)=CC(N=C=O)=C1 DZSGDHNHQAJZCO-UHFFFAOYSA-N 0.000 description 1
- NPOVTGVGOBJZPY-UHFFFAOYSA-N 1-isocyanato-3-methoxybenzene Chemical compound COC1=CC=CC(N=C=O)=C1 NPOVTGVGOBJZPY-UHFFFAOYSA-N 0.000 description 1
- CPPGZWWUPFWALU-UHFFFAOYSA-N 1-isocyanato-3-methylbenzene Chemical compound CC1=CC=CC(N=C=O)=C1 CPPGZWWUPFWALU-UHFFFAOYSA-N 0.000 description 1
- BKJABLMNBSVKCV-UHFFFAOYSA-N 1-isocyanato-3-methylsulfanylbenzene Chemical compound CSC1=CC=CC(N=C=O)=C1 BKJABLMNBSVKCV-UHFFFAOYSA-N 0.000 description 1
- GFFGYTMCNVMFAJ-UHFFFAOYSA-N 1-isocyanato-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(N=C=O)=C1 GFFGYTMCNVMFAJ-UHFFFAOYSA-N 0.000 description 1
- LGPKFIGMLPDYEA-UHFFFAOYSA-N 1-isocyanato-4-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=C(N=C=O)C=C1 LGPKFIGMLPDYEA-UHFFFAOYSA-N 0.000 description 1
- QZTWVDCKDWZCLV-UHFFFAOYSA-N 1-isocyanato-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(N=C=O)C=C1 QZTWVDCKDWZCLV-UHFFFAOYSA-N 0.000 description 1
- NYQSIHZNEJCZKX-UHFFFAOYSA-N 1-isocyanato-4-(trifluoromethylsulfanyl)benzene Chemical compound FC(F)(F)SC1=CC=C(N=C=O)C=C1 NYQSIHZNEJCZKX-UHFFFAOYSA-N 0.000 description 1
- XGRQPTXFVDRJMY-UHFFFAOYSA-N 1-isocyanato-4-methoxy-2-methylbenzene Chemical compound COC1=CC=C(N=C=O)C(C)=C1 XGRQPTXFVDRJMY-UHFFFAOYSA-N 0.000 description 1
- FMDGXCSMDZMDHZ-UHFFFAOYSA-N 1-isocyanato-4-methoxybenzene Chemical compound COC1=CC=C(N=C=O)C=C1 FMDGXCSMDZMDHZ-UHFFFAOYSA-N 0.000 description 1
- QNKQBDZVEKZFBN-UHFFFAOYSA-N 1-isocyanato-4-methylsulfanylbenzene Chemical compound CSC1=CC=C(N=C=O)C=C1 QNKQBDZVEKZFBN-UHFFFAOYSA-N 0.000 description 1
- GFNKTLQTQSALEJ-UHFFFAOYSA-N 1-isocyanato-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(N=C=O)C=C1 GFNKTLQTQSALEJ-UHFFFAOYSA-N 0.000 description 1
- PNBUGOFIKAHZRW-UHFFFAOYSA-N 1-isocyanato-4-phenoxybenzene Chemical compound C1=CC(N=C=O)=CC=C1OC1=CC=CC=C1 PNBUGOFIKAHZRW-UHFFFAOYSA-N 0.000 description 1
- BDQNKCYCTYYMAA-UHFFFAOYSA-N 1-isocyanatonaphthalene Chemical compound C1=CC=C2C(N=C=O)=CC=CC2=C1 BDQNKCYCTYYMAA-UHFFFAOYSA-N 0.000 description 1
- WNWYKNCOAJIRNK-UHFFFAOYSA-N 1-methylbenzotriazole-5-carbonyl chloride Chemical compound ClC(=O)C1=CC=C2N(C)N=NC2=C1 WNWYKNCOAJIRNK-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- DHIDUDPFTZJPCQ-UHFFFAOYSA-N 1-phenylcyclobutane-1-carbonitrile Chemical compound C=1C=CC=CC=1C1(C#N)CCC1 DHIDUDPFTZJPCQ-UHFFFAOYSA-N 0.000 description 1
- AUXIEQKHXAYAHG-UHFFFAOYSA-N 1-phenylcyclohexane-1-carbonitrile Chemical compound C=1C=CC=CC=1C1(C#N)CCCCC1 AUXIEQKHXAYAHG-UHFFFAOYSA-N 0.000 description 1
- ZHFURHRJUWYDKG-UHFFFAOYSA-N 1-phenylcyclopropane-1-carbonitrile Chemical compound C=1C=CC=CC=1C1(C#N)CC1 ZHFURHRJUWYDKG-UHFFFAOYSA-N 0.000 description 1
- NFKAWBGFIMBUMB-UHFFFAOYSA-N 1-phenylpentan-2-one Chemical compound CCCC(=O)CC1=CC=CC=C1 NFKAWBGFIMBUMB-UHFFFAOYSA-N 0.000 description 1
- XNPSIQMTHTWBQQ-UHFFFAOYSA-N 1-propan-2-yl-2-(trifluoromethyl)benzimidazole-5-carbonyl chloride Chemical compound ClC(=O)C1=CC=C2N(C(C)C)C(C(F)(F)F)=NC2=C1 XNPSIQMTHTWBQQ-UHFFFAOYSA-N 0.000 description 1
- YQQNLONQWMLAQX-UHFFFAOYSA-N 1-tert-butyl-2-isocyanatobenzene Chemical compound CC(C)(C)C1=CC=CC=C1N=C=O YQQNLONQWMLAQX-UHFFFAOYSA-N 0.000 description 1
- WUWBDQJTQTVBSQ-UHFFFAOYSA-N 1-tert-butyl-4-isocyanatobenzene Chemical compound CC(C)(C)C1=CC=C(N=C=O)C=C1 WUWBDQJTQTVBSQ-UHFFFAOYSA-N 0.000 description 1
- OLFLFCAHZFGBNS-UHFFFAOYSA-N 1664-31-9 Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)NCCN1CCCCC1 OLFLFCAHZFGBNS-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- CXAICGCTHOWKPP-UHFFFAOYSA-N 2,1,3-benzothiadiazole-4-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC2=NSN=C12 CXAICGCTHOWKPP-UHFFFAOYSA-N 0.000 description 1
- STVKFABXTFREFG-UHFFFAOYSA-N 2,1,3-benzothiadiazole-5-carbonyl chloride Chemical compound C1=C(C(=O)Cl)C=CC2=NSN=C21 STVKFABXTFREFG-UHFFFAOYSA-N 0.000 description 1
- PFLLNLOVUWBRRX-UHFFFAOYSA-N 2,1,3-benzothiadiazole-5-sulfonyl chloride Chemical compound C1=C(S(=O)(=O)Cl)C=CC2=NSN=C21 PFLLNLOVUWBRRX-UHFFFAOYSA-N 0.000 description 1
- SIYWVPMYOGMRDW-UHFFFAOYSA-N 2,1,3-benzoxadiazole-4-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC2=NON=C12 SIYWVPMYOGMRDW-UHFFFAOYSA-N 0.000 description 1
- ODCMBRSQNVPDOK-UHFFFAOYSA-N 2,1,3-benzoxadiazole-5-carbonyl chloride Chemical compound C1=C(C(=O)Cl)C=CC2=NON=C21 ODCMBRSQNVPDOK-UHFFFAOYSA-N 0.000 description 1
- LSSXEVHVRBTNAQ-UHFFFAOYSA-N 2,2-dimethyl-3h-1-benzofuran-7-carbonyl chloride Chemical compound C1=CC(C(Cl)=O)=C2OC(C)(C)CC2=C1 LSSXEVHVRBTNAQ-UHFFFAOYSA-N 0.000 description 1
- NEBPTMCRLHKPOB-UHFFFAOYSA-N 2,2-diphenylacetonitrile Chemical compound C=1C=CC=CC=1C(C#N)C1=CC=CC=C1 NEBPTMCRLHKPOB-UHFFFAOYSA-N 0.000 description 1
- DPVHBXFSKLKYIQ-UHFFFAOYSA-N 2,2-diphenylpropanenitrile Chemical compound C=1C=CC=CC=1C(C#N)(C)C1=CC=CC=C1 DPVHBXFSKLKYIQ-UHFFFAOYSA-N 0.000 description 1
- UOJCTEGNHXRPKO-UHFFFAOYSA-N 2,3,4,5,6-pentafluorobenzenesulfonyl chloride Chemical compound FC1=C(F)C(F)=C(S(Cl)(=O)=O)C(F)=C1F UOJCTEGNHXRPKO-UHFFFAOYSA-N 0.000 description 1
- XWCKIXLTBNGIHV-UHFFFAOYSA-N 2,3,4,5-tetrafluorobenzoyl chloride Chemical compound FC1=CC(C(Cl)=O)=C(F)C(F)=C1F XWCKIXLTBNGIHV-UHFFFAOYSA-N 0.000 description 1
- XFTDZYFHXRZLEF-UHFFFAOYSA-N 2,3,4-trifluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C(F)=C1F XFTDZYFHXRZLEF-UHFFFAOYSA-N 0.000 description 1
- NXRQXCFBZGIRGN-UHFFFAOYSA-N 2,3,4-trifluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C(F)=C1F NXRQXCFBZGIRGN-UHFFFAOYSA-N 0.000 description 1
- AELMDUZWKHVPIF-UHFFFAOYSA-N 2,3,5,6-tetrafluorobenzoyl chloride Chemical compound FC1=CC(F)=C(F)C(C(Cl)=O)=C1F AELMDUZWKHVPIF-UHFFFAOYSA-N 0.000 description 1
- ZCXRROBIIMQMHR-UHFFFAOYSA-N 2,3,5,6-tetramethylbenzenesulfonyl chloride Chemical compound CC1=CC(C)=C(C)C(S(Cl)(=O)=O)=C1C ZCXRROBIIMQMHR-UHFFFAOYSA-N 0.000 description 1
- DMUGJQMADYEWSQ-UHFFFAOYSA-N 2,3,6-trifluorobenzoyl chloride Chemical compound FC1=CC=C(F)C(C(Cl)=O)=C1F DMUGJQMADYEWSQ-UHFFFAOYSA-N 0.000 description 1
- PQODWTNHDKDHIW-UHFFFAOYSA-N 2,3-dichlorobenzenesulfonyl chloride Chemical compound ClC1=CC=CC(S(Cl)(=O)=O)=C1Cl PQODWTNHDKDHIW-UHFFFAOYSA-N 0.000 description 1
- CDCFERWURRNLLA-UHFFFAOYSA-N 2,3-difluorobenzoyl chloride Chemical compound FC1=CC=CC(C(Cl)=O)=C1F CDCFERWURRNLLA-UHFFFAOYSA-N 0.000 description 1
- IEWVBBWTJOHHCY-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-5-carbonyl chloride Chemical compound O1CCOC2=C1C=CC=C2C(=O)Cl IEWVBBWTJOHHCY-UHFFFAOYSA-N 0.000 description 1
- QECXDXFCJKMZLA-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-6-carbonyl chloride Chemical compound O1CCOC2=CC(C(=O)Cl)=CC=C21 QECXDXFCJKMZLA-UHFFFAOYSA-N 0.000 description 1
- JWHSRWUHRLYAPM-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-6-sulfonyl chloride Chemical compound O1CCOC2=CC(S(=O)(=O)Cl)=CC=C21 JWHSRWUHRLYAPM-UHFFFAOYSA-N 0.000 description 1
- RVWYPBARHGPULM-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-5-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C2OCCC2=C1 RVWYPBARHGPULM-UHFFFAOYSA-N 0.000 description 1
- KNBGUBMIJPZGHF-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-7-carbonyl chloride Chemical compound ClC(=O)C1=CC=CC2=C1OCC2 KNBGUBMIJPZGHF-UHFFFAOYSA-N 0.000 description 1
- WFNKMVDATNLZBX-UHFFFAOYSA-N 2,3-dimethylbenzoyl chloride Chemical compound CC1=CC=CC(C(Cl)=O)=C1C WFNKMVDATNLZBX-UHFFFAOYSA-N 0.000 description 1
- KNHJIEOCVVIBIV-UHFFFAOYSA-N 2,3-dimethylphenyl isocyanate Chemical compound CC1=CC=CC(N=C=O)=C1C KNHJIEOCVVIBIV-UHFFFAOYSA-N 0.000 description 1
- OZGSEIVTQLXWRO-UHFFFAOYSA-N 2,4,6-trichlorobenzoyl chloride Chemical compound ClC(=O)C1=C(Cl)C=C(Cl)C=C1Cl OZGSEIVTQLXWRO-UHFFFAOYSA-N 0.000 description 1
- SIFIJQFBERMWMU-UHFFFAOYSA-N 2,4,6-trifluorobenzoyl chloride Chemical compound FC1=CC(F)=C(C(Cl)=O)C(F)=C1 SIFIJQFBERMWMU-UHFFFAOYSA-N 0.000 description 1
- PVJZBZSCGJAWNG-UHFFFAOYSA-N 2,4,6-trimethylbenzenesulfonyl chloride Chemical compound CC1=CC(C)=C(S(Cl)(=O)=O)C(C)=C1 PVJZBZSCGJAWNG-UHFFFAOYSA-N 0.000 description 1
- UKRQMDIFLKHCRO-UHFFFAOYSA-N 2,4,6-trimethylbenzoyl chloride Chemical compound CC1=CC(C)=C(C(Cl)=O)C(C)=C1 UKRQMDIFLKHCRO-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- OLBJNSPBWLCTOT-UHFFFAOYSA-N 2,4-dichloro-1-isocyanatobenzene Chemical compound ClC1=CC=C(N=C=O)C(Cl)=C1 OLBJNSPBWLCTOT-UHFFFAOYSA-N 0.000 description 1
- DFBKCDYLPLBSJP-UHFFFAOYSA-N 2,4-dichloro-5-methylbenzenesulfonyl chloride Chemical compound CC1=CC(S(Cl)(=O)=O)=C(Cl)C=C1Cl DFBKCDYLPLBSJP-UHFFFAOYSA-N 0.000 description 1
- FDTPBIKNYWQLAE-UHFFFAOYSA-N 2,4-dichlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C(Cl)=C1 FDTPBIKNYWQLAE-UHFFFAOYSA-N 0.000 description 1
- CEOCVKWBUWKBKA-UHFFFAOYSA-N 2,4-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1Cl CEOCVKWBUWKBKA-UHFFFAOYSA-N 0.000 description 1
- HNENEALJPWJWJY-UHFFFAOYSA-N 2,4-difluoro-1-isocyanatobenzene Chemical compound FC1=CC=C(N=C=O)C(F)=C1 HNENEALJPWJWJY-UHFFFAOYSA-N 0.000 description 1
- FJSAJUXIHJIAMD-UHFFFAOYSA-N 2,4-difluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C(F)=C1 FJSAJUXIHJIAMD-UHFFFAOYSA-N 0.000 description 1
- GEQNZVKIDIPGCO-UHFFFAOYSA-N 2,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C(OC)=C1 GEQNZVKIDIPGCO-UHFFFAOYSA-N 0.000 description 1
- AYGZKRRIULCJKC-UHFFFAOYSA-N 2,4-dimethoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C(OC)=C1 AYGZKRRIULCJKC-UHFFFAOYSA-N 0.000 description 1
- BXCOSWRSIISQSL-UHFFFAOYSA-N 2,5-dichlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(Cl)C(S(Cl)(=O)=O)=C1 BXCOSWRSIISQSL-UHFFFAOYSA-N 0.000 description 1
- SHELADVIRCCTFN-UHFFFAOYSA-N 2,5-dimethoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(OC)C(S(Cl)(=O)=O)=C1 SHELADVIRCCTFN-UHFFFAOYSA-N 0.000 description 1
- FZVZUIBYLZZOEW-UHFFFAOYSA-N 2,5-dimethylbenzenesulfonyl chloride Chemical compound CC1=CC=C(C)C(S(Cl)(=O)=O)=C1 FZVZUIBYLZZOEW-UHFFFAOYSA-N 0.000 description 1
- SOXVXJQIQVOCAY-UHFFFAOYSA-N 2,5-dimethylphenyl isocyanate Chemical compound CC1=CC=C(C)C(N=C=O)=C1 SOXVXJQIQVOCAY-UHFFFAOYSA-N 0.000 description 1
- MRGIKDMKHORAMU-UHFFFAOYSA-N 2,6-dichloro-4-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC(Cl)=C(S(Cl)(=O)=O)C(Cl)=C1 MRGIKDMKHORAMU-UHFFFAOYSA-N 0.000 description 1
- JDMFXJULNGEPOI-UHFFFAOYSA-N 2,6-dichloroaniline Chemical compound NC1=C(Cl)C=CC=C1Cl JDMFXJULNGEPOI-UHFFFAOYSA-N 0.000 description 1
- WGGKQIKICKLWGN-UHFFFAOYSA-N 2,6-dichlorobenzenesulfonyl chloride Chemical compound ClC1=CC=CC(Cl)=C1S(Cl)(=O)=O WGGKQIKICKLWGN-UHFFFAOYSA-N 0.000 description 1
- JBLIDPPHFGWTKU-UHFFFAOYSA-N 2,6-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=C(Cl)C=CC=C1Cl JBLIDPPHFGWTKU-UHFFFAOYSA-N 0.000 description 1
- QXWAUQMMMIMLTO-UHFFFAOYSA-N 2,6-difluorobenzenesulfonyl chloride Chemical compound FC1=CC=CC(F)=C1S(Cl)(=O)=O QXWAUQMMMIMLTO-UHFFFAOYSA-N 0.000 description 1
- NDXRPDJVAUCBOH-UHFFFAOYSA-N 2,6-dimethoxybenzoyl chloride Chemical compound COC1=CC=CC(OC)=C1C(Cl)=O NDXRPDJVAUCBOH-UHFFFAOYSA-N 0.000 description 1
- ZQPBOYASBNAXOZ-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)acetonitrile Chemical compound N#CCC1=CC=C2OCOC2=C1 ZQPBOYASBNAXOZ-UHFFFAOYSA-N 0.000 description 1
- YDNOJUAQBFXZCR-UHFFFAOYSA-N 2-(2,3,4,5,6-pentafluorophenyl)acetonitrile Chemical compound FC1=C(F)C(F)=C(CC#N)C(F)=C1F YDNOJUAQBFXZCR-UHFFFAOYSA-N 0.000 description 1
- CZLINJDTCHACEH-UHFFFAOYSA-N 2-(2,3-dichlorophenyl)acetonitrile Chemical compound ClC1=CC=CC(CC#N)=C1Cl CZLINJDTCHACEH-UHFFFAOYSA-N 0.000 description 1
- SDKQOGSGNPGPRN-UHFFFAOYSA-N 2-(2,4,6-trimethylphenyl)acetonitrile Chemical compound CC1=CC(C)=C(CC#N)C(C)=C1 SDKQOGSGNPGPRN-UHFFFAOYSA-N 0.000 description 1
- VJARIBGMDPJLCL-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)acetonitrile Chemical compound ClC1=CC=C(CC#N)C(Cl)=C1 VJARIBGMDPJLCL-UHFFFAOYSA-N 0.000 description 1
- AGAOESUOSOGZOD-UHFFFAOYSA-N 2-(2,4-difluorophenyl)acetonitrile Chemical compound FC1=CC=C(CC#N)C(F)=C1 AGAOESUOSOGZOD-UHFFFAOYSA-N 0.000 description 1
- UIMMFRUOZOWROM-UHFFFAOYSA-N 2-(2,5-difluorophenyl)acetonitrile Chemical compound FC1=CC=C(F)C(CC#N)=C1 UIMMFRUOZOWROM-UHFFFAOYSA-N 0.000 description 1
- HCELORQTHSKCQL-UHFFFAOYSA-N 2-(2,5-dimethylphenyl)acetonitrile Chemical compound CC1=CC=C(C)C(CC#N)=C1 HCELORQTHSKCQL-UHFFFAOYSA-N 0.000 description 1
- AOEJUUCUKRUCEF-UHFFFAOYSA-N 2-(2,6-dichlorophenyl)acetonitrile Chemical compound ClC1=CC=CC(Cl)=C1CC#N AOEJUUCUKRUCEF-UHFFFAOYSA-N 0.000 description 1
- OXTFFPWHLJQPEE-UHFFFAOYSA-N 2-(2,6-dichlorophenyl)ethanimidamide Chemical compound NC(=N)CC1=C(Cl)C=CC=C1Cl OXTFFPWHLJQPEE-UHFFFAOYSA-N 0.000 description 1
- GVAYBGQTAADLJS-UHFFFAOYSA-N 2-(2,6-difluorophenyl)acetonitrile Chemical compound FC1=CC=CC(F)=C1CC#N GVAYBGQTAADLJS-UHFFFAOYSA-N 0.000 description 1
- BVCOJESIQPNOIF-UHFFFAOYSA-N 2-(2-bromophenyl)acetonitrile Chemical compound BrC1=CC=CC=C1CC#N BVCOJESIQPNOIF-UHFFFAOYSA-N 0.000 description 1
- GSMCLMKFBYLWRP-UHFFFAOYSA-N 2-(2-chloro-4-fluorophenyl)acetonitrile Chemical compound FC1=CC=C(CC#N)C(Cl)=C1 GSMCLMKFBYLWRP-UHFFFAOYSA-N 0.000 description 1
- ZGSAFMIRVLOISC-UHFFFAOYSA-N 2-(2-chloro-6-fluorophenyl)acetonitrile Chemical compound FC1=CC=CC(Cl)=C1CC#N ZGSAFMIRVLOISC-UHFFFAOYSA-N 0.000 description 1
- MRDUURPIPLIGQX-UHFFFAOYSA-N 2-(2-chlorophenyl)acetonitrile Chemical compound ClC1=CC=CC=C1CC#N MRDUURPIPLIGQX-UHFFFAOYSA-N 0.000 description 1
- DAVJMKMVLKOQQC-UHFFFAOYSA-N 2-(2-fluorophenyl)acetonitrile Chemical compound FC1=CC=CC=C1CC#N DAVJMKMVLKOQQC-UHFFFAOYSA-N 0.000 description 1
- DWJKILXTMUGXOU-UHFFFAOYSA-N 2-(2-methoxyphenyl)acetonitrile Chemical compound COC1=CC=CC=C1CC#N DWJKILXTMUGXOU-UHFFFAOYSA-N 0.000 description 1
- YPRFCQAWSNWRLM-UHFFFAOYSA-N 2-(2-nitrophenyl)acetonitrile Chemical compound [O-][N+](=O)C1=CC=CC=C1CC#N YPRFCQAWSNWRLM-UHFFFAOYSA-N 0.000 description 1
- QWZNCAFWRZZJMA-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)acetonitrile Chemical compound ClC1=CC=C(CC#N)C=C1Cl QWZNCAFWRZZJMA-UHFFFAOYSA-N 0.000 description 1
- GNPYERUNJMDEFQ-UHFFFAOYSA-N 2-(3,4-difluorophenyl)acetonitrile Chemical compound FC1=CC=C(CC#N)C=C1F GNPYERUNJMDEFQ-UHFFFAOYSA-N 0.000 description 1
- ASLSUMISAQDOOB-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)acetonitrile Chemical compound COC1=CC=C(CC#N)C=C1OC ASLSUMISAQDOOB-UHFFFAOYSA-N 0.000 description 1
- OBMYMTSBABEPIB-UHFFFAOYSA-N 2-(3,5-difluorophenyl)acetonitrile Chemical compound FC1=CC(F)=CC(CC#N)=C1 OBMYMTSBABEPIB-UHFFFAOYSA-N 0.000 description 1
- WMVPARKLYWQLNN-UHFFFAOYSA-N 2-(3,5-difluorophenyl)acetyl chloride Chemical compound FC1=CC(F)=CC(CC(Cl)=O)=C1 WMVPARKLYWQLNN-UHFFFAOYSA-N 0.000 description 1
- UUZYFBXKWIQKTF-UHFFFAOYSA-N 2-(3-bromophenyl)acetonitrile Chemical compound BrC1=CC=CC(CC#N)=C1 UUZYFBXKWIQKTF-UHFFFAOYSA-N 0.000 description 1
- GTIKLPYCSAMPNG-UHFFFAOYSA-N 2-(3-chlorophenyl)acetonitrile Chemical compound ClC1=CC=CC(CC#N)=C1 GTIKLPYCSAMPNG-UHFFFAOYSA-N 0.000 description 1
- DEJPYROXSVVWIE-UHFFFAOYSA-N 2-(3-fluorophenyl)acetonitrile Chemical compound FC1=CC=CC(CC#N)=C1 DEJPYROXSVVWIE-UHFFFAOYSA-N 0.000 description 1
- UZUYKYNVSJTWEH-UHFFFAOYSA-N 2-(3-methoxyphenyl)acetyl chloride Chemical compound COC1=CC=CC(CC(Cl)=O)=C1 UZUYKYNVSJTWEH-UHFFFAOYSA-N 0.000 description 1
- WOJADIOTNFDWNQ-UHFFFAOYSA-N 2-(3-methylphenyl)acetonitrile Chemical compound CC1=CC=CC(CC#N)=C1 WOJADIOTNFDWNQ-UHFFFAOYSA-N 0.000 description 1
- QFKZBYXKHJHWSO-UHFFFAOYSA-N 2-(4-aminophenyl)-3-[4-(dimethylamino)phenyl]propanenitrile Chemical compound C1=CC(N(C)C)=CC=C1CC(C#N)C1=CC=C(N)C=C1 QFKZBYXKHJHWSO-UHFFFAOYSA-N 0.000 description 1
- YCWRFIYBUQBHJI-UHFFFAOYSA-N 2-(4-aminophenyl)acetonitrile Chemical compound NC1=CC=C(CC#N)C=C1 YCWRFIYBUQBHJI-UHFFFAOYSA-N 0.000 description 1
- QLASQEZPJFNZQC-UHFFFAOYSA-N 2-(4-bromo-2-fluorophenyl)acetonitrile Chemical compound FC1=CC(Br)=CC=C1CC#N QLASQEZPJFNZQC-UHFFFAOYSA-N 0.000 description 1
- MFHFWRBXPQDZSA-UHFFFAOYSA-N 2-(4-bromophenyl)acetonitrile Chemical compound BrC1=CC=C(CC#N)C=C1 MFHFWRBXPQDZSA-UHFFFAOYSA-N 0.000 description 1
- RTQOANCZEAIDEZ-UHFFFAOYSA-N 2-(4-chloro-2-fluorophenyl)acetonitrile Chemical compound FC1=CC(Cl)=CC=C1CC#N RTQOANCZEAIDEZ-UHFFFAOYSA-N 0.000 description 1
- YBUDMLBUDBGODD-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-morpholin-4-ylacetonitrile Chemical compound C1=CC(Cl)=CC=C1C(C#N)N1CCOCC1 YBUDMLBUDBGODD-UHFFFAOYSA-N 0.000 description 1
- SIOJFYRPBYGHOO-UHFFFAOYSA-N 2-(4-fluorophenyl)acetyl chloride Chemical compound FC1=CC=C(CC(Cl)=O)C=C1 SIOJFYRPBYGHOO-UHFFFAOYSA-N 0.000 description 1
- ZHLCCUQAQOFEBB-UHFFFAOYSA-N 2-(4-methoxyphenoxy)-5-nitrobenzoyl chloride Chemical compound C1=CC(OC)=CC=C1OC1=CC=C([N+]([O-])=O)C=C1C(Cl)=O ZHLCCUQAQOFEBB-UHFFFAOYSA-N 0.000 description 1
- PACGLQCRGWFBJH-UHFFFAOYSA-N 2-(4-methoxyphenyl)acetonitrile Chemical compound COC1=CC=C(CC#N)C=C1 PACGLQCRGWFBJH-UHFFFAOYSA-N 0.000 description 1
- CXJOONIFSVSFAD-UHFFFAOYSA-N 2-(4-methoxyphenyl)acetyl chloride Chemical compound COC1=CC=C(CC(Cl)=O)C=C1 CXJOONIFSVSFAD-UHFFFAOYSA-N 0.000 description 1
- PXNJGLAVKOXITN-UHFFFAOYSA-N 2-(4-nitrophenyl)acetonitrile Chemical compound [O-][N+](=O)C1=CC=C(CC#N)C=C1 PXNJGLAVKOXITN-UHFFFAOYSA-N 0.000 description 1
- RBHDFGBPJGEYCK-UHFFFAOYSA-N 2-(5-methyl-1h-indol-3-yl)ethylazanium;chloride Chemical compound Cl.CC1=CC=C2NC=C(CCN)C2=C1 RBHDFGBPJGEYCK-UHFFFAOYSA-N 0.000 description 1
- JLTBWYIUMFEOTN-UHFFFAOYSA-N 2-(trifluoromethoxy)benzenesulfonyl chloride Chemical compound FC(F)(F)OC1=CC=CC=C1S(Cl)(=O)=O JLTBWYIUMFEOTN-UHFFFAOYSA-N 0.000 description 1
- ZIZGWNOAHUCACM-UHFFFAOYSA-N 2-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC=CC=C1S(Cl)(=O)=O ZIZGWNOAHUCACM-UHFFFAOYSA-N 0.000 description 1
- JDSQBDGCMUXRBM-UHFFFAOYSA-N 2-[2-(2-butoxypropoxy)propoxy]propan-1-ol Chemical group CCCCOC(C)COC(C)COC(C)CO JDSQBDGCMUXRBM-UHFFFAOYSA-N 0.000 description 1
- YXGWYBUKRTYHJM-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]acetonitrile Chemical compound FC(F)(F)C1=CC(CC#N)=CC(C(F)(F)F)=C1 YXGWYBUKRTYHJM-UHFFFAOYSA-N 0.000 description 1
- JOIYKSLWXLFGGR-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenyl]acetonitrile Chemical compound FC(F)(F)C1=CC=CC(CC#N)=C1 JOIYKSLWXLFGGR-UHFFFAOYSA-N 0.000 description 1
- GNZAZCZXNSRWEU-UHFFFAOYSA-N 2-[4-(3-benzyl-1,2,4-thiadiazol-5-yl)piperazin-1-yl]ethanamine Chemical compound C1CN(CCN)CCN1C1=NC(CC=2C=CC=CC=2)=NS1 GNZAZCZXNSRWEU-UHFFFAOYSA-N 0.000 description 1
- LYFCAROXYJTUQF-UHFFFAOYSA-N 2-[4-(trifluoromethoxy)phenyl]acetonitrile Chemical compound FC(F)(F)OC1=CC=C(CC#N)C=C1 LYFCAROXYJTUQF-UHFFFAOYSA-N 0.000 description 1
- QNKOCFJZJWOXDE-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]acetonitrile Chemical compound FC(F)(F)C1=CC=C(CC#N)C=C1 QNKOCFJZJWOXDE-UHFFFAOYSA-N 0.000 description 1
- HNTNMUACVLPQQK-UHFFFAOYSA-N 2-[4-[(4-methylphenyl)methoxy]phenyl]acetonitrile Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CC#N)C=C1 HNTNMUACVLPQQK-UHFFFAOYSA-N 0.000 description 1
- QKXYFPTXAVZZDW-UHFFFAOYSA-N 2-[4-[3-[(4-methylphenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethanamine Chemical compound C1=CC(C)=CC=C1CC1=NSC(N2CCN(CCN)CC2)=N1 QKXYFPTXAVZZDW-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- RZCQJXVXRYIJQE-UHFFFAOYSA-N 2-bromo-5-methoxybenzoyl chloride Chemical compound COC1=CC=C(Br)C(C(Cl)=O)=C1 RZCQJXVXRYIJQE-UHFFFAOYSA-N 0.000 description 1
- VFPWGZNNRSQPBT-UHFFFAOYSA-N 2-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1Br VFPWGZNNRSQPBT-UHFFFAOYSA-N 0.000 description 1
- NZCKTGCKFJDGFD-UHFFFAOYSA-N 2-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Br NZCKTGCKFJDGFD-UHFFFAOYSA-N 0.000 description 1
- QALFGTMEHRWMMM-UHFFFAOYSA-N 2-bromobenzoyl chloride;3-(trifluoromethyl)benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Br.FC(F)(F)C1=CC=CC(C(Cl)=O)=C1 QALFGTMEHRWMMM-UHFFFAOYSA-N 0.000 description 1
- XVIPJBUXMFLHSI-UHFFFAOYSA-N 2-chloro-1-fluoro-4-isocyanatobenzene Chemical compound FC1=CC=C(N=C=O)C=C1Cl XVIPJBUXMFLHSI-UHFFFAOYSA-N 0.000 description 1
- FGEAOSXMQZWHIQ-UHFFFAOYSA-N 2-chloro-2-phenylacetyl chloride Chemical compound ClC(=O)C(Cl)C1=CC=CC=C1 FGEAOSXMQZWHIQ-UHFFFAOYSA-N 0.000 description 1
- NJXDBSSSDPOAFI-UHFFFAOYSA-N 2-chloro-4-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC=C(S(Cl)(=O)=O)C(Cl)=C1 NJXDBSSSDPOAFI-UHFFFAOYSA-N 0.000 description 1
- GNJOWOAPHOFJBW-UHFFFAOYSA-N 2-chloro-4-cyanobenzenesulfonyl chloride Chemical compound ClC1=CC(C#N)=CC=C1S(Cl)(=O)=O GNJOWOAPHOFJBW-UHFFFAOYSA-N 0.000 description 1
- FCFPJKHVCHKCMP-UHFFFAOYSA-N 2-chloro-4-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C(Cl)=C1 FCFPJKHVCHKCMP-UHFFFAOYSA-N 0.000 description 1
- POIAZJJVWRVLBO-UHFFFAOYSA-N 2-chloro-4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C(Cl)=C1 POIAZJJVWRVLBO-UHFFFAOYSA-N 0.000 description 1
- HMUCCFLZRSIZGK-UHFFFAOYSA-N 2-chloro-4-methylpyridine-3-carboxamide Chemical compound CC1=CC=NC(Cl)=C1C(N)=O HMUCCFLZRSIZGK-UHFFFAOYSA-N 0.000 description 1
- ZEYKLMDPUOVUCR-UHFFFAOYSA-N 2-chloro-5-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC=C(Cl)C(S(Cl)(=O)=O)=C1 ZEYKLMDPUOVUCR-UHFFFAOYSA-N 0.000 description 1
- BSHJRTMGKFPQGZ-UHFFFAOYSA-N 2-chloro-5-nitro-1,3-benzothiazole Chemical compound [O-][N+](=O)C1=CC=C2SC(Cl)=NC2=C1 BSHJRTMGKFPQGZ-UHFFFAOYSA-N 0.000 description 1
- XZVGQEYEEUNMQM-UHFFFAOYSA-N 2-chloro-6,7-dihydro-5h-cyclopenta[b]pyridin-7-ol Chemical compound C1=C(Cl)N=C2C(O)CCC2=C1 XZVGQEYEEUNMQM-UHFFFAOYSA-N 0.000 description 1
- GFNAJZAKJGKJCS-UHFFFAOYSA-N 2-chloro-6-fluorobenzoyl chloride Chemical compound FC1=CC=CC(Cl)=C1C(Cl)=O GFNAJZAKJGKJCS-UHFFFAOYSA-N 0.000 description 1
- KMVZDSQHLDGKGV-UHFFFAOYSA-N 2-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=CC=C1S(Cl)(=O)=O KMVZDSQHLDGKGV-UHFFFAOYSA-N 0.000 description 1
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 1
- LXUMGICEIYXURI-UHFFFAOYSA-N 2-chlorocyclobutene-1-carbaldehyde Chemical compound ClC1=C(CC1)C=O LXUMGICEIYXURI-UHFFFAOYSA-N 0.000 description 1
- ZFQDREVAYVNITB-UHFFFAOYSA-N 2-cyano-5-methylbenzenesulfonyl chloride Chemical compound CC1=CC=C(C#N)C(S(Cl)(=O)=O)=C1 ZFQDREVAYVNITB-UHFFFAOYSA-N 0.000 description 1
- NQAYCMBZPAARNO-UHFFFAOYSA-N 2-cyanobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1C#N NQAYCMBZPAARNO-UHFFFAOYSA-N 0.000 description 1
- IZSWBXTYTALSOZ-UHFFFAOYSA-N 2-cyclohexyl-2-phenylacetonitrile Chemical compound C=1C=CC=CC=1C(C#N)C1CCCCC1 IZSWBXTYTALSOZ-UHFFFAOYSA-N 0.000 description 1
- VDXGNTYFJGXXAA-UHFFFAOYSA-N 2-cyclopentyloxy-4-isocyanato-1-methoxybenzene Chemical compound COC1=CC=C(N=C=O)C=C1OC1CCCC1 VDXGNTYFJGXXAA-UHFFFAOYSA-N 0.000 description 1
- WBIQQQGBSDOWNP-UHFFFAOYSA-N 2-dodecylbenzenesulfonic acid Chemical class CCCCCCCCCCCCC1=CC=CC=C1S(O)(=O)=O WBIQQQGBSDOWNP-UHFFFAOYSA-N 0.000 description 1
- PJGFNNXYKMSCCU-UHFFFAOYSA-N 2-ethylbenzoyl chloride Chemical compound CCC1=CC=CC=C1C(Cl)=O PJGFNNXYKMSCCU-UHFFFAOYSA-N 0.000 description 1
- XBTHHWYOEISJNF-UHFFFAOYSA-N 2-fluoro-1-isocyanato-3-(trifluoromethyl)benzene Chemical compound FC1=C(N=C=O)C=CC=C1C(F)(F)F XBTHHWYOEISJNF-UHFFFAOYSA-N 0.000 description 1
- OFVKAIZITGCCDN-UHFFFAOYSA-N 2-fluoro-5-(trifluoromethyl)benzoyl chloride Chemical compound FC1=CC=C(C(F)(F)F)C=C1C(Cl)=O OFVKAIZITGCCDN-UHFFFAOYSA-N 0.000 description 1
- ZSZKAQCISWFDCQ-UHFFFAOYSA-N 2-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=CC=C1S(Cl)(=O)=O ZSZKAQCISWFDCQ-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- GXUQMKBQDGPMKZ-UHFFFAOYSA-N 2-hydroxy-2-(3-phenoxyphenyl)acetonitrile Chemical compound N#CC(O)C1=CC=CC(OC=2C=CC=CC=2)=C1 GXUQMKBQDGPMKZ-UHFFFAOYSA-N 0.000 description 1
- FEUFNKALUGDEMQ-UHFFFAOYSA-N 2-isocyanato-1,3-di(propan-2-yl)benzene Chemical compound CC(C)C1=CC=CC(C(C)C)=C1N=C=O FEUFNKALUGDEMQ-UHFFFAOYSA-N 0.000 description 1
- RZMPHPHMBXRRPB-UHFFFAOYSA-N 2-isocyanato-1,3-dimethoxybenzene Chemical compound COC1=CC=CC(OC)=C1N=C=O RZMPHPHMBXRRPB-UHFFFAOYSA-N 0.000 description 1
- YQLRKXVEALTVCZ-UHFFFAOYSA-N 2-isocyanato-1,3-dimethylbenzene Chemical compound CC1=CC=CC(C)=C1N=C=O YQLRKXVEALTVCZ-UHFFFAOYSA-N 0.000 description 1
- XIXJQNFTNSQTBT-UHFFFAOYSA-N 2-isocyanatonaphthalene Chemical compound C1=CC=CC2=CC(N=C=O)=CC=C21 XIXJQNFTNSQTBT-UHFFFAOYSA-N 0.000 description 1
- QECYXMKYZQXEHM-UHFFFAOYSA-N 2-methoxy-4-nitrobenzenesulfonyl chloride Chemical compound COC1=CC([N+]([O-])=O)=CC=C1S(Cl)(=O)=O QECYXMKYZQXEHM-UHFFFAOYSA-N 0.000 description 1
- QDMCWIHRLTVLIY-UHFFFAOYSA-N 2-methyl-1-(3-methylphenyl)piperazine Chemical compound CC1CNCCN1C1=CC=CC(C)=C1 QDMCWIHRLTVLIY-UHFFFAOYSA-N 0.000 description 1
- XYBLCORUTWKJOI-UHFFFAOYSA-N 2-methyl-4-piperazin-1-ylquinoline Chemical compound C=12C=CC=CC2=NC(C)=CC=1N1CCNCC1 XYBLCORUTWKJOI-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- XPJTUCSESGEMOI-UHFFFAOYSA-N 2-methylsulfonylbenzenesulfonyl chloride Chemical compound CS(=O)(=O)C1=CC=CC=C1S(Cl)(=O)=O XPJTUCSESGEMOI-UHFFFAOYSA-N 0.000 description 1
- DSVAZLXLRDXHKO-UHFFFAOYSA-N 2-naphthalen-1-ylacetyl chloride Chemical compound C1=CC=C2C(CC(=O)Cl)=CC=CC2=C1 DSVAZLXLRDXHKO-UHFFFAOYSA-N 0.000 description 1
- QEJGMKHQXSZCOS-UHFFFAOYSA-N 2-naphthalen-2-ylacetyl chloride Chemical compound C1=CC=CC2=CC(CC(=O)Cl)=CC=C21 QEJGMKHQXSZCOS-UHFFFAOYSA-N 0.000 description 1
- IXQJQHORYHYKBD-UHFFFAOYSA-N 2-phenyl-2-piperidin-1-ylacetonitrile Chemical compound C=1C=CC=CC=1C(C#N)N1CCCCC1 IXQJQHORYHYKBD-UHFFFAOYSA-N 0.000 description 1
- QGXMHCMPIAYMGT-UHFFFAOYSA-N 2-phenylbutanoyl chloride Chemical compound CCC(C(Cl)=O)C1=CC=CC=C1 QGXMHCMPIAYMGT-UHFFFAOYSA-N 0.000 description 1
- NVAOLENBKNECGF-UHFFFAOYSA-N 2-phenylpropanenitrile Chemical compound N#CC(C)C1=CC=CC=C1 NVAOLENBKNECGF-UHFFFAOYSA-N 0.000 description 1
- UORNTHBBLYBAJJ-UHFFFAOYSA-N 2-piperazin-1-ylphenol Chemical compound OC1=CC=CC=C1N1CCNCC1 UORNTHBBLYBAJJ-UHFFFAOYSA-N 0.000 description 1
- ICXIVBYQRNOIJJ-UHFFFAOYSA-N 2-tert-butylbenzenesulfonyl chloride Chemical compound CC(C)(C)C1=CC=CC=C1S(Cl)(=O)=O ICXIVBYQRNOIJJ-UHFFFAOYSA-N 0.000 description 1
- JVOVWZAGQKKACR-UHFFFAOYSA-N 2-thiophen-2-ylbenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1C1=CC=CS1 JVOVWZAGQKKACR-UHFFFAOYSA-N 0.000 description 1
- VAYMIYBJLRRIFR-UHFFFAOYSA-N 2-tolyl isocyanate Chemical compound CC1=CC=CC=C1N=C=O VAYMIYBJLRRIFR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- HSEHKULCGSMHAE-UHFFFAOYSA-N 3,4,5-trifluorobenzenesulfonyl chloride Chemical compound FC1=CC(S(Cl)(=O)=O)=CC(F)=C1F HSEHKULCGSMHAE-UHFFFAOYSA-N 0.000 description 1
- NYIBPWGZGSXURD-UHFFFAOYSA-N 3,4-dichlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1Cl NYIBPWGZGSXURD-UHFFFAOYSA-N 0.000 description 1
- VTXNOVCTHUBABW-UHFFFAOYSA-N 3,4-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C(Cl)=C1 VTXNOVCTHUBABW-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- MFUVCHZWGSJKEQ-UHFFFAOYSA-N 3,4-dichlorphenylisocyanate Chemical compound ClC1=CC=C(N=C=O)C=C1Cl MFUVCHZWGSJKEQ-UHFFFAOYSA-N 0.000 description 1
- FSGLUBQENACWCC-UHFFFAOYSA-N 3,4-difluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C=C1F FSGLUBQENACWCC-UHFFFAOYSA-N 0.000 description 1
- LCMXYORUTQLVDS-UHFFFAOYSA-N 3,4-dihydro-2h-1,5-benzodioxepine-6-carbonyl chloride Chemical compound O1CCCOC2=C1C=CC=C2C(=O)Cl LCMXYORUTQLVDS-UHFFFAOYSA-N 0.000 description 1
- ADAGPISZFDLGCR-UHFFFAOYSA-N 3,4-dihydro-2h-1,5-benzodioxepine-7-sulfonyl chloride Chemical compound O1CCCOC2=CC(S(=O)(=O)Cl)=CC=C21 ADAGPISZFDLGCR-UHFFFAOYSA-N 0.000 description 1
- RSJSYCZYQNJQPY-UHFFFAOYSA-N 3,4-dimethoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1OC RSJSYCZYQNJQPY-UHFFFAOYSA-N 0.000 description 1
- RGAKSNQOIIYQRM-UHFFFAOYSA-N 3,4-dimethylbenzoyl chloride Chemical compound CC1=CC=C(C(Cl)=O)C=C1C RGAKSNQOIIYQRM-UHFFFAOYSA-N 0.000 description 1
- BTRCVKADYDVSLI-UHFFFAOYSA-N 3,5-bis(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(S(Cl)(=O)=O)=C1 BTRCVKADYDVSLI-UHFFFAOYSA-N 0.000 description 1
- YNPAAILIMIGQIH-UHFFFAOYSA-N 3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonyl chloride Chemical compound ClC1=CC([N+](=O)[O-])=CC=C1OC1=C(Cl)C=C(S(Cl)(=O)=O)C=C1Cl YNPAAILIMIGQIH-UHFFFAOYSA-N 0.000 description 1
- RPXHXVTVWPSZMA-UHFFFAOYSA-N 3,5-dichloro-n-[2-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl]benzamide Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CCNC(=O)C=3C=C(Cl)C=C(Cl)C=3)CC2)=N1 RPXHXVTVWPSZMA-UHFFFAOYSA-N 0.000 description 1
- RJSQINMKOSOUGT-UHFFFAOYSA-N 3,5-dichlorobenzenesulfonyl chloride Chemical compound ClC1=CC(Cl)=CC(S(Cl)(=O)=O)=C1 RJSQINMKOSOUGT-UHFFFAOYSA-N 0.000 description 1
- FTHPLWDYWAKYCY-UHFFFAOYSA-N 3,5-dimethoxybenzoyl chloride Chemical compound COC1=CC(OC)=CC(C(Cl)=O)=C1 FTHPLWDYWAKYCY-UHFFFAOYSA-N 0.000 description 1
- NNOHXABAQAGKRZ-UHFFFAOYSA-N 3,5-dinitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC(C(Cl)=O)=CC([N+]([O-])=O)=C1 NNOHXABAQAGKRZ-UHFFFAOYSA-N 0.000 description 1
- ZZGWJBAJNLBBRB-UHFFFAOYSA-N 3-(2-methyl-1,3-thiazol-4-yl)benzenesulfonyl chloride Chemical compound S1C(C)=NC(C=2C=C(C=CC=2)S(Cl)(=O)=O)=C1 ZZGWJBAJNLBBRB-UHFFFAOYSA-N 0.000 description 1
- HPNXILHANJPJMT-UHFFFAOYSA-N 3-(2-methyl-1,3-thiazol-4-yl)benzoyl chloride Chemical compound S1C(C)=NC(C=2C=C(C=CC=2)C(Cl)=O)=C1 HPNXILHANJPJMT-UHFFFAOYSA-N 0.000 description 1
- ZLLPUDLQNCNHFM-UHFFFAOYSA-N 3-(2-methylpyrimidin-4-yl)benzenesulfonyl chloride Chemical compound CC1=NC=CC(C=2C=C(C=CC=2)S(Cl)(=O)=O)=N1 ZLLPUDLQNCNHFM-UHFFFAOYSA-N 0.000 description 1
- DANOKUDOZKTSKV-UHFFFAOYSA-N 3-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl chloride Chemical compound O1C(C)=NC(C=2C=C(C=CC=2)C(Cl)=O)=N1 DANOKUDOZKTSKV-UHFFFAOYSA-N 0.000 description 1
- YCAIYRWHKSJKEB-UHFFFAOYSA-N 3-(chloromethyl)benzoyl chloride Chemical compound ClCC1=CC=CC(C(Cl)=O)=C1 YCAIYRWHKSJKEB-UHFFFAOYSA-N 0.000 description 1
- RXYDVDHUAVNAND-UHFFFAOYSA-N 3-(dichloromethyl)benzoyl chloride Chemical compound ClC(Cl)C1=CC=CC(C(Cl)=O)=C1 RXYDVDHUAVNAND-UHFFFAOYSA-N 0.000 description 1
- ONCAZCNPWWQQMW-UHFFFAOYSA-N 3-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC=CC(S(Cl)(=O)=O)=C1 ONCAZCNPWWQQMW-UHFFFAOYSA-N 0.000 description 1
- VDNSOOGWMVIUAX-UHFFFAOYSA-N 3-[(3-methoxyphenyl)methyl]-1,2,4-thiadiazole Chemical compound COC1=CC=CC(CC2=NSC=N2)=C1 VDNSOOGWMVIUAX-UHFFFAOYSA-N 0.000 description 1
- VITPKHYCLSPTJG-UHFFFAOYSA-N 3-[(3-methoxyphenyl)methyl]-5-piperazin-1-yl-1,2,4-thiadiazole Chemical compound COC1=CC=CC(CC=2N=C(SN=2)N2CCNCC2)=C1 VITPKHYCLSPTJG-UHFFFAOYSA-N 0.000 description 1
- DVLMAQJOONNBBI-UHFFFAOYSA-N 3-[(4-chlorophenyl)methyl]-5-(4-ethylsulfonylpiperazin-1-yl)-1,2,4-thiadiazole Chemical compound C1CN(S(=O)(=O)CC)CCN1C1=NC(CC=2C=CC(Cl)=CC=2)=NS1 DVLMAQJOONNBBI-UHFFFAOYSA-N 0.000 description 1
- JYMCLUUFFDAQAM-UHFFFAOYSA-N 3-[(4-chlorophenyl)methyl]-5-[4-(2,5-dichlorophenyl)sulfonylpiperazin-1-yl]-1,2,4-thiadiazole Chemical compound C1=CC(Cl)=CC=C1CC1=NSC(N2CCN(CC2)S(=O)(=O)C=2C(=CC=C(Cl)C=2)Cl)=N1 JYMCLUUFFDAQAM-UHFFFAOYSA-N 0.000 description 1
- ZVADVJQCBNQKFP-UHFFFAOYSA-N 3-[(4-chlorophenyl)methyl]-5-[4-(3-phenylprop-2-enyl)piperazin-1-yl]-1,2,4-thiadiazole Chemical compound C1=CC(Cl)=CC=C1CC1=NSC(N2CCN(CC=CC=3C=CC=CC=3)CC2)=N1 ZVADVJQCBNQKFP-UHFFFAOYSA-N 0.000 description 1
- NVGVZLPYHYIXFI-UHFFFAOYSA-N 3-[(4-chlorophenyl)methyl]-5-[4-(4-methylphenyl)sulfonylpiperazin-1-yl]-1,2,4-thiadiazole Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1CCN(C=2SN=C(CC=3C=CC(Cl)=CC=3)N=2)CC1 NVGVZLPYHYIXFI-UHFFFAOYSA-N 0.000 description 1
- HPJNPWUVMYTPNJ-UHFFFAOYSA-N 3-[(4-chlorophenyl)methyl]-5-piperazin-1-yl-1,2,4-thiadiazole Chemical compound C1=CC(Cl)=CC=C1CC1=NSC(N2CCNCC2)=N1 HPJNPWUVMYTPNJ-UHFFFAOYSA-N 0.000 description 1
- DNVJNUAADRKIRR-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-5-[4-(2-methylphenyl)piperazin-1-yl]-1,2,4-thiadiazole Chemical compound CC1=CC=CC=C1N1CCN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 DNVJNUAADRKIRR-UHFFFAOYSA-N 0.000 description 1
- WWZNHJQVQCATBF-UHFFFAOYSA-N 3-[(4-fluorophenyl)methyl]-5-[4-(3-phenylprop-2-enyl)piperazin-1-yl]-1,2,4-thiadiazole Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CC=CC=3C=CC=CC=3)CC2)=N1 WWZNHJQVQCATBF-UHFFFAOYSA-N 0.000 description 1
- SGJWCZFXRJUKDN-UHFFFAOYSA-N 3-[(4-methylphenyl)methyl]-5-(4-quinolin-8-ylsulfonylpiperazin-1-yl)-1,2,4-thiadiazole Chemical compound C1=CC(C)=CC=C1CC1=NSC(N2CCN(CC2)S(=O)(=O)C=2C3=NC=CC=C3C=CC=2)=N1 SGJWCZFXRJUKDN-UHFFFAOYSA-N 0.000 description 1
- FGHCNZYZDMZPRX-UHFFFAOYSA-N 3-[(4-methylphenyl)methyl]-5-[3-methyl-4-(2,4,6-trimethylphenyl)sulfonylpiperazin-1-yl]-1,2,4-thiadiazole Chemical compound CC1CN(C=2SN=C(CC=3C=CC(C)=CC=3)N=2)CCN1S(=O)(=O)C1=C(C)C=C(C)C=C1C FGHCNZYZDMZPRX-UHFFFAOYSA-N 0.000 description 1
- RFFGHJVYXPQTMX-UHFFFAOYSA-N 3-[(4-methylphenyl)methyl]-5-[3-methyl-4-[3-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]-1,2,4-thiadiazole Chemical compound CC1CN(C=2SN=C(CC=3C=CC(C)=CC=3)N=2)CCN1S(=O)(=O)C1=CC=CC(C(F)(F)F)=C1 RFFGHJVYXPQTMX-UHFFFAOYSA-N 0.000 description 1
- KFJQRKRQLQQBMF-UHFFFAOYSA-N 3-[(4-methylphenyl)methyl]-5-[4-(2,4,6-trimethylphenyl)sulfonylpiperazin-1-yl]-1,2,4-thiadiazole Chemical compound C1=CC(C)=CC=C1CC1=NSC(N2CCN(CC2)S(=O)(=O)C=2C(=CC(C)=CC=2C)C)=N1 KFJQRKRQLQQBMF-UHFFFAOYSA-N 0.000 description 1
- CGLWEKCXGPEBCT-UHFFFAOYSA-N 3-[(4-methylphenyl)methyl]-5-[4-(3-phenylprop-2-enyl)piperazin-1-yl]-1,2,4-thiadiazole Chemical compound C1=CC(C)=CC=C1CC1=NSC(N2CCN(CC=CC=3C=CC=CC=3)CC2)=N1 CGLWEKCXGPEBCT-UHFFFAOYSA-N 0.000 description 1
- UMTGSTPPGSBOKZ-UHFFFAOYSA-N 3-[(4-methylphenyl)methyl]-5-[4-[3-(trifluoromethyl)phenyl]sulfonylpiperazin-1-yl]-1,2,4-thiadiazole Chemical compound C1=CC(C)=CC=C1CC1=NSC(N2CCN(CC2)S(=O)(=O)C=2C=C(C=CC=2)C(F)(F)F)=N1 UMTGSTPPGSBOKZ-UHFFFAOYSA-N 0.000 description 1
- WPWKJUVXEMKOHS-UHFFFAOYSA-N 3-[4-(hydroxymethyl)phenoxy]propanoic acid Chemical compound OCC1=CC=C(OCCC(O)=O)C=C1 WPWKJUVXEMKOHS-UHFFFAOYSA-N 0.000 description 1
- NJXPYZHXZZCTNI-UHFFFAOYSA-N 3-aminobenzonitrile Chemical compound NC1=CC=CC(C#N)=C1 NJXPYZHXZZCTNI-UHFFFAOYSA-N 0.000 description 1
- PJGOLCXVWIYXRQ-UHFFFAOYSA-N 3-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC(Br)=C1 PJGOLCXVWIYXRQ-UHFFFAOYSA-N 0.000 description 1
- PBOOZQFGWNZNQE-UHFFFAOYSA-N 3-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(Br)=C1 PBOOZQFGWNZNQE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ZSIYKAQPQRTBPF-UHFFFAOYSA-N 3-chloro-2-methylbenzenesulfonyl chloride Chemical compound CC1=C(Cl)C=CC=C1S(Cl)(=O)=O ZSIYKAQPQRTBPF-UHFFFAOYSA-N 0.000 description 1
- DXFXNSNBZNELII-UHFFFAOYSA-N 3-chloro-4-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C=C1Cl DXFXNSNBZNELII-UHFFFAOYSA-N 0.000 description 1
- GNYVVCRRZRVBDD-UHFFFAOYSA-N 3-chloro-4-methylbenzenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1Cl GNYVVCRRZRVBDD-UHFFFAOYSA-N 0.000 description 1
- OINWZUJVEXUHCC-UHFFFAOYSA-N 3-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=CC(S(Cl)(=O)=O)=C1 OINWZUJVEXUHCC-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- LMRKXSDOAFUINK-UHFFFAOYSA-N 3-chlorosulfonylbenzoic acid Chemical compound OC(=O)C1=CC=CC(S(Cl)(=O)=O)=C1 LMRKXSDOAFUINK-UHFFFAOYSA-N 0.000 description 1
- BHNRGBRMCNHNQD-UHFFFAOYSA-N 3-cyanobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC(C#N)=C1 BHNRGBRMCNHNQD-UHFFFAOYSA-N 0.000 description 1
- RPESZQVUWMFBEO-UHFFFAOYSA-N 3-cyanobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(C#N)=C1 RPESZQVUWMFBEO-UHFFFAOYSA-N 0.000 description 1
- OWWHXPWJCDTADU-UHFFFAOYSA-N 3-cyclopentyloxy-4-methoxybenzoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1OC1CCCC1 OWWHXPWJCDTADU-UHFFFAOYSA-N 0.000 description 1
- DPDAEMNQJYDHRQ-UHFFFAOYSA-N 3-fluoro-4-(trifluoromethyl)benzoyl chloride Chemical compound FC1=CC(C(Cl)=O)=CC=C1C(F)(F)F DPDAEMNQJYDHRQ-UHFFFAOYSA-N 0.000 description 1
- DPWCZSXNEGNALT-UHFFFAOYSA-N 3-fluoro-4-methylbenzoyl chloride Chemical compound CC1=CC=C(C(Cl)=O)C=C1F DPWCZSXNEGNALT-UHFFFAOYSA-N 0.000 description 1
- RISBVPGLKLSDBD-UHFFFAOYSA-N 3-fluoro-n-[2-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl]benzamide Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CCNC(=O)C=3C=C(F)C=CC=3)CC2)=N1 RISBVPGLKLSDBD-UHFFFAOYSA-N 0.000 description 1
- QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical compound NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 1
- OKYSUJVCDXZGKE-UHFFFAOYSA-N 3-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=CC(S(Cl)(=O)=O)=C1 OKYSUJVCDXZGKE-UHFFFAOYSA-N 0.000 description 1
- NZHPVPMRNASEQK-UHFFFAOYSA-N 3-isocyanatobenzonitrile Chemical compound O=C=NC1=CC=CC(C#N)=C1 NZHPVPMRNASEQK-UHFFFAOYSA-N 0.000 description 1
- JHJKSEKUZNJKGO-UHFFFAOYSA-N 3-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=CC(S(Cl)(=O)=O)=C1 JHJKSEKUZNJKGO-UHFFFAOYSA-N 0.000 description 1
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- KFPMLWUKHQMEBU-UHFFFAOYSA-N 3-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC(S(Cl)(=O)=O)=C1 KFPMLWUKHQMEBU-UHFFFAOYSA-N 0.000 description 1
- YHOYYHYBFSYOSQ-UHFFFAOYSA-N 3-methylbenzoyl chloride Chemical compound CC1=CC=CC(C(Cl)=O)=C1 YHOYYHYBFSYOSQ-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- MWWNNNAOGWPTQY-UHFFFAOYSA-N 3-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(S(Cl)(=O)=O)=C1 MWWNNNAOGWPTQY-UHFFFAOYSA-N 0.000 description 1
- NXTNASSYJUXJDV-UHFFFAOYSA-N 3-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(C(Cl)=O)=C1 NXTNASSYJUXJDV-UHFFFAOYSA-N 0.000 description 1
- MFEILWXBDBCWKF-UHFFFAOYSA-N 3-phenylpropanoyl chloride Chemical compound ClC(=O)CCC1=CC=CC=C1 MFEILWXBDBCWKF-UHFFFAOYSA-N 0.000 description 1
- QCGUTLAPXWBIMM-UHFFFAOYSA-N 4-(1,3-oxazol-5-yl)benzenesulfonyl chloride Chemical compound C1=CC(S(=O)(=O)Cl)=CC=C1C1=CN=CO1 QCGUTLAPXWBIMM-UHFFFAOYSA-N 0.000 description 1
- CRTUVOFOPIFTQS-UHFFFAOYSA-N 4-(2-chloro-6-nitrophenoxy)benzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(Cl)=C1OC1=CC=C(S(Cl)(=O)=O)C=C1 CRTUVOFOPIFTQS-UHFFFAOYSA-N 0.000 description 1
- DKNWPXFCLUKCQB-UHFFFAOYSA-N 4-(2-methoxyphenoxy)benzenesulfonyl chloride Chemical compound COC1=CC=CC=C1OC1=CC=C(S(Cl)(=O)=O)C=C1 DKNWPXFCLUKCQB-UHFFFAOYSA-N 0.000 description 1
- IJPKGMOVNZHZKZ-UHFFFAOYSA-N 4-(2-methylphenoxy)benzenesulfonyl chloride Chemical compound CC1=CC=CC=C1OC1=CC=C(S(Cl)(=O)=O)C=C1 IJPKGMOVNZHZKZ-UHFFFAOYSA-N 0.000 description 1
- OUAVTZYGHGCCCB-UHFFFAOYSA-N 4-(2-oxopyrrolidin-1-yl)benzenesulfonyl chloride Chemical compound C1=CC(S(=O)(=O)Cl)=CC=C1N1C(=O)CCC1 OUAVTZYGHGCCCB-UHFFFAOYSA-N 0.000 description 1
- DHVBZUPMGVOIOH-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)benzenesulfonyl chloride Chemical compound C1=C(Cl)C(Cl)=CC=C1C1=CC=C(S(Cl)(=O)=O)C=C1 DHVBZUPMGVOIOH-UHFFFAOYSA-N 0.000 description 1
- SCSJREMEEIARHE-UHFFFAOYSA-N 4-(3-chloro-2-cyanophenoxy)benzenesulfonyl chloride Chemical compound ClC1=CC=CC(OC=2C=CC(=CC=2)S(Cl)(=O)=O)=C1C#N SCSJREMEEIARHE-UHFFFAOYSA-N 0.000 description 1
- LXFBSCKJEIVRGP-UHFFFAOYSA-N 4-(4-chlorophenyl)-3h-1,3-thiazole-2-thione Chemical compound S1C(S)=NC(C=2C=CC(Cl)=CC=2)=C1 LXFBSCKJEIVRGP-UHFFFAOYSA-N 0.000 description 1
- NWYUSJMIHFIMTA-UHFFFAOYSA-N 4-(4-chlorophenyl)benzenesulfonyl chloride Chemical compound C1=CC(Cl)=CC=C1C1=CC=C(S(Cl)(=O)=O)C=C1 NWYUSJMIHFIMTA-UHFFFAOYSA-N 0.000 description 1
- CIDMHDJTWVMBIF-UHFFFAOYSA-N 4-(4-fluorophenyl)benzenesulfonyl chloride Chemical compound C1=CC(F)=CC=C1C1=CC=C(S(Cl)(=O)=O)C=C1 CIDMHDJTWVMBIF-UHFFFAOYSA-N 0.000 description 1
- AJWXJCPSCXFPJJ-UHFFFAOYSA-N 4-(4-methoxyphenyl)benzenesulfonyl chloride Chemical compound C1=CC(OC)=CC=C1C1=CC=C(S(Cl)(=O)=O)C=C1 AJWXJCPSCXFPJJ-UHFFFAOYSA-N 0.000 description 1
- DBYXACYHGMSPMQ-UHFFFAOYSA-N 4-(4-methylphenyl)benzenesulfonyl chloride Chemical compound C1=CC(C)=CC=C1C1=CC=C(S(Cl)(=O)=O)C=C1 DBYXACYHGMSPMQ-UHFFFAOYSA-N 0.000 description 1
- SMBDBBBBXFXBSK-UHFFFAOYSA-N 4-(5-methyl-1,2,4-oxadiazol-3-yl)benzoyl chloride Chemical compound O1C(C)=NC(C=2C=CC(=CC=2)C(Cl)=O)=N1 SMBDBBBBXFXBSK-UHFFFAOYSA-N 0.000 description 1
- QXTQWYZHHMQSQH-UHFFFAOYSA-N 4-(bromomethyl)benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(CBr)C=C1 QXTQWYZHHMQSQH-UHFFFAOYSA-N 0.000 description 1
- RCOVTJVRTZGSBP-UHFFFAOYSA-N 4-(chloromethyl)benzoyl chloride Chemical compound ClCC1=CC=C(C(Cl)=O)C=C1 RCOVTJVRTZGSBP-UHFFFAOYSA-N 0.000 description 1
- LCQXGFTXKWEWQC-UHFFFAOYSA-N 4-(dipropylsulfamoyl)benzoyl chloride Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(Cl)=O)C=C1 LCQXGFTXKWEWQC-UHFFFAOYSA-N 0.000 description 1
- IFHXVVWZBVKDQR-UHFFFAOYSA-N 4-(thiadiazol-4-yl)benzenesulfonyl chloride Chemical compound C1=CC(S(=O)(=O)Cl)=CC=C1C1=CSN=N1 IFHXVVWZBVKDQR-UHFFFAOYSA-N 0.000 description 1
- SZZWMNJQWMQKRY-UHFFFAOYSA-N 4-(thiadiazol-4-yl)benzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1C1=CSN=N1 SZZWMNJQWMQKRY-UHFFFAOYSA-N 0.000 description 1
- QLSUAELOZKXNPF-UHFFFAOYSA-N 4-[3-(trifluoromethyl)pyrazol-1-yl]benzoyl chloride Chemical compound N1=C(C(F)(F)F)C=CN1C1=CC=C(C(Cl)=O)C=C1 QLSUAELOZKXNPF-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- ALOQYFFSHSEVJH-UHFFFAOYSA-N 4-acetamido-3-chlorobenzenesulfonyl chloride Chemical compound CC(=O)NC1=CC=C(S(Cl)(=O)=O)C=C1Cl ALOQYFFSHSEVJH-UHFFFAOYSA-N 0.000 description 1
- NXAYRHQYINQHRF-UHFFFAOYSA-N 4-bromo-1-isocyanato-2-methylbenzene Chemical compound CC1=CC(Br)=CC=C1N=C=O NXAYRHQYINQHRF-UHFFFAOYSA-N 0.000 description 1
- IGYSFJHVFHNOEI-UHFFFAOYSA-N 4-bromo-2,2-diphenylbutanenitrile Chemical compound C=1C=CC=CC=1C(C#N)(CCBr)C1=CC=CC=C1 IGYSFJHVFHNOEI-UHFFFAOYSA-N 0.000 description 1
- SBMKFWMFNIEPDN-UHFFFAOYSA-N 4-bromo-2,5-difluorobenzenesulfonyl chloride Chemical compound FC1=CC(S(Cl)(=O)=O)=C(F)C=C1Br SBMKFWMFNIEPDN-UHFFFAOYSA-N 0.000 description 1
- YFXYEMZYOMNQLD-UHFFFAOYSA-N 4-bromo-2-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC(Br)=CC=C1S(Cl)(=O)=O YFXYEMZYOMNQLD-UHFFFAOYSA-N 0.000 description 1
- OECYEHWJPRPCOH-UHFFFAOYSA-N 4-bromo-2-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC(Br)=CC=C1S(Cl)(=O)=O OECYEHWJPRPCOH-UHFFFAOYSA-N 0.000 description 1
- UOIVESXBURLTPX-UHFFFAOYSA-N 4-bromo-2-ethylbenzenesulfonyl chloride Chemical compound CCC1=CC(Br)=CC=C1S(Cl)(=O)=O UOIVESXBURLTPX-UHFFFAOYSA-N 0.000 description 1
- LXTYHGYKFYTBGJ-UHFFFAOYSA-N 4-bromo-2-fluoro-1-isocyanatobenzene Chemical compound FC1=CC(Br)=CC=C1N=C=O LXTYHGYKFYTBGJ-UHFFFAOYSA-N 0.000 description 1
- PCFIABOQFAFDAU-UHFFFAOYSA-N 4-bromo-2-fluorobenzoyl chloride Chemical compound FC1=CC(Br)=CC=C1C(Cl)=O PCFIABOQFAFDAU-UHFFFAOYSA-N 0.000 description 1
- KNBSFUSBZNMAKU-UHFFFAOYSA-N 4-bromo-2-methylbenzenesulfonyl chloride Chemical compound CC1=CC(Br)=CC=C1S(Cl)(=O)=O KNBSFUSBZNMAKU-UHFFFAOYSA-N 0.000 description 1
- KMMHZIBWCXYAAH-UHFFFAOYSA-N 4-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(Br)C=C1 KMMHZIBWCXYAAH-UHFFFAOYSA-N 0.000 description 1
- HGKWMUBXVMFXNC-UHFFFAOYSA-N 4-butoxybenzenesulfonyl chloride Chemical compound CCCCOC1=CC=C(S(Cl)(=O)=O)C=C1 HGKWMUBXVMFXNC-UHFFFAOYSA-N 0.000 description 1
- ZIDVZMFYBGXIBH-UHFFFAOYSA-N 4-butyl-1-isocyanato-2-methylbenzene Chemical compound CCCCC1=CC=C(N=C=O)C(C)=C1 ZIDVZMFYBGXIBH-UHFFFAOYSA-N 0.000 description 1
- DPKMQUSDBQERSV-UHFFFAOYSA-N 4-butyl-n-[2-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl]benzamide Chemical compound C1=CC(CCCC)=CC=C1C(=O)NCCN1CCN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 DPKMQUSDBQERSV-UHFFFAOYSA-N 0.000 description 1
- SBDPJLJFODHSFF-UHFFFAOYSA-N 4-chloro-1-isocyanato-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(Cl)=CC=C1N=C=O SBDPJLJFODHSFF-UHFFFAOYSA-N 0.000 description 1
- SSULGNXFUGLULI-UHFFFAOYSA-N 4-chloro-3-(trifluoromethyl)benzenesulfonyl chloride Chemical compound FC(F)(F)C1=CC(S(Cl)(=O)=O)=CC=C1Cl SSULGNXFUGLULI-UHFFFAOYSA-N 0.000 description 1
- RPKWNMFDAOACCX-UHFFFAOYSA-M 4-chloro-3-nitrobenzenesulfonate Chemical compound [O-][N+](=O)C1=CC(S([O-])(=O)=O)=CC=C1Cl RPKWNMFDAOACCX-UHFFFAOYSA-M 0.000 description 1
- FMRUQLNATNVAOI-UHFFFAOYSA-N 4-chloro-n-[2-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl]benzamide Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CCNC(=O)C=3C=CC(Cl)=CC=3)CC2)=N1 FMRUQLNATNVAOI-UHFFFAOYSA-N 0.000 description 1
- PTCSSXYPZOFISK-UHFFFAOYSA-N 4-chlorosulfonylbenzoic acid Chemical compound OC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 PTCSSXYPZOFISK-UHFFFAOYSA-N 0.000 description 1
- HDJRNMVQLGESEX-UHFFFAOYSA-N 4-chlorothiadiazole Chemical class ClC1=CSN=N1 HDJRNMVQLGESEX-UHFFFAOYSA-N 0.000 description 1
- DBMFYTQPPBBKHI-UHFFFAOYSA-N 4-cyanobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(C#N)C=C1 DBMFYTQPPBBKHI-UHFFFAOYSA-N 0.000 description 1
- USEDMAWWQDFMFY-UHFFFAOYSA-N 4-cyanobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(C#N)C=C1 USEDMAWWQDFMFY-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- XLRPFBACBJJYFG-UHFFFAOYSA-N 4-cyclohexyl-5-sulfanylidene-1,2,4-triazolidin-3-one Chemical compound O=C1NNC(=S)N1C1CCCCC1 XLRPFBACBJJYFG-UHFFFAOYSA-N 0.000 description 1
- QMRQLPUIARUVNF-UHFFFAOYSA-N 4-ethyl-n-[2-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl]benzamide Chemical compound C1=CC(CC)=CC=C1C(=O)NCCN1CCN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 QMRQLPUIARUVNF-UHFFFAOYSA-N 0.000 description 1
- LACFLXDRFOQEFZ-UHFFFAOYSA-N 4-ethylbenzenesulfonyl chloride Chemical compound CCC1=CC=C(S(Cl)(=O)=O)C=C1 LACFLXDRFOQEFZ-UHFFFAOYSA-N 0.000 description 1
- AVTLLLZVYYPGFX-UHFFFAOYSA-N 4-ethylbenzoyl chloride Chemical compound CCC1=CC=C(C(Cl)=O)C=C1 AVTLLLZVYYPGFX-UHFFFAOYSA-N 0.000 description 1
- MNANIHSTOUUFNY-UHFFFAOYSA-N 4-fluoro-1-isocyanato-2-(trifluoromethyl)benzene Chemical compound FC1=CC=C(N=C=O)C(C(F)(F)F)=C1 MNANIHSTOUUFNY-UHFFFAOYSA-N 0.000 description 1
- CPPNERLQTDSECZ-UHFFFAOYSA-N 4-fluoro-1-isocyanato-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(F)=CC=C1N=C=O CPPNERLQTDSECZ-UHFFFAOYSA-N 0.000 description 1
- KRAMFLATTKXGOW-UHFFFAOYSA-N 4-fluoro-2-isocyanato-1-methylbenzene Chemical compound CC1=CC=C(F)C=C1N=C=O KRAMFLATTKXGOW-UHFFFAOYSA-N 0.000 description 1
- BUDISZQHCHGLJW-UHFFFAOYSA-N 4-fluoro-3-(trifluoromethyl)benzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1C(F)(F)F BUDISZQHCHGLJW-UHFFFAOYSA-N 0.000 description 1
- KPYQNFFAQCAYDO-UHFFFAOYSA-N 4-fluoro-n-[2-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl]benzamide Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CCNC(=O)C=3C=CC(F)=CC=3)CC2)=N1 KPYQNFFAQCAYDO-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- OTHIDQZVUQAMEW-UHFFFAOYSA-N 4-heptoxybenzoyl chloride Chemical compound CCCCCCCOC1=CC=C(C(Cl)=O)C=C1 OTHIDQZVUQAMEW-UHFFFAOYSA-N 0.000 description 1
- WHTFLTOKFXTJGV-UHFFFAOYSA-N 4-heptylbenzoyl chloride Chemical compound CCCCCCCC1=CC=C(C(Cl)=O)C=C1 WHTFLTOKFXTJGV-UHFFFAOYSA-N 0.000 description 1
- DQQOONVCLQZWOY-UHFFFAOYSA-N 4-hexoxybenzoyl chloride Chemical compound CCCCCCOC1=CC=C(C(Cl)=O)C=C1 DQQOONVCLQZWOY-UHFFFAOYSA-N 0.000 description 1
- POXFXTSTVWDWIR-UHFFFAOYSA-N 4-iodobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(I)C=C1 POXFXTSTVWDWIR-UHFFFAOYSA-N 0.000 description 1
- NJAKCIUOTIPYED-UHFFFAOYSA-N 4-iodobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(I)C=C1 NJAKCIUOTIPYED-UHFFFAOYSA-N 0.000 description 1
- HPZZFYLZFYDNMA-UHFFFAOYSA-N 4-isocyanato-2,1,3-benzothiadiazole Chemical compound O=C=NC1=CC=CC2=NSN=C12 HPZZFYLZFYDNMA-UHFFFAOYSA-N 0.000 description 1
- YZEHDFBYSOKBED-UHFFFAOYSA-N 4-isocyanato-n,n-dimethylaniline Chemical compound CN(C)C1=CC=C(N=C=O)C=C1 YZEHDFBYSOKBED-UHFFFAOYSA-N 0.000 description 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
- PXEFRDHZTILJRB-UHFFFAOYSA-N 4-methyl-2,3-dihydro-1,4-benzoxazine-7-carbonyl chloride Chemical compound ClC(=O)C1=CC=C2N(C)CCOC2=C1 PXEFRDHZTILJRB-UHFFFAOYSA-N 0.000 description 1
- PQOZDBIEDQALFA-UHFFFAOYSA-N 4-methyl-2,3-dihydro-1,4-benzoxazine-7-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C2N(C)CCOC2=C1 PQOZDBIEDQALFA-UHFFFAOYSA-N 0.000 description 1
- OQFYBGANSUNUAO-UHFFFAOYSA-N 4-methyl-3-nitrobenzenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1[N+]([O-])=O OQFYBGANSUNUAO-UHFFFAOYSA-N 0.000 description 1
- 125000006418 4-methylphenylsulfonyl group Chemical group 0.000 description 1
- TYJOQICPGZGYDT-UHFFFAOYSA-N 4-methylsulfonylbenzenesulfonyl chloride Chemical compound CS(=O)(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 TYJOQICPGZGYDT-UHFFFAOYSA-N 0.000 description 1
- ZZSBUDUHESWZJB-UHFFFAOYSA-N 4-morpholin-4-ylsulfonylbenzenesulfonyl chloride Chemical compound C1=CC(S(=O)(=O)Cl)=CC=C1S(=O)(=O)N1CCOCC1 ZZSBUDUHESWZJB-UHFFFAOYSA-N 0.000 description 1
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 1
- SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 1
- IGFHQQFPSIBGKE-UHFFFAOYSA-N 4-nonylphenol Chemical compound CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 1
- GKXOABVSZWCJJK-UHFFFAOYSA-N 4-oxo-1-phenylcyclohexane-1-carbonitrile Chemical compound C1CC(=O)CCC1(C#N)C1=CC=CC=C1 GKXOABVSZWCJJK-UHFFFAOYSA-N 0.000 description 1
- IBQDPNHVFRFCFK-UHFFFAOYSA-N 4-pentoxybenzoyl chloride Chemical compound CCCCCOC1=CC=C(C(Cl)=O)C=C1 IBQDPNHVFRFCFK-UHFFFAOYSA-N 0.000 description 1
- XDWXZRVWJHEWMT-UHFFFAOYSA-N 4-pentylbenzenesulfonyl chloride Chemical compound CCCCCC1=CC=C(S(Cl)(=O)=O)C=C1 XDWXZRVWJHEWMT-UHFFFAOYSA-N 0.000 description 1
- RYMHZBAYPLCCAC-UHFFFAOYSA-N 4-phenyldiazenylbenzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1N=NC1=CC=CC=C1 RYMHZBAYPLCCAC-UHFFFAOYSA-N 0.000 description 1
- GPEOAEVZTOQXLG-UHFFFAOYSA-N 4-piperazin-1-ium-1-ylphenolate Chemical compound C1=CC(O)=CC=C1N1CCNCC1 GPEOAEVZTOQXLG-UHFFFAOYSA-N 0.000 description 1
- CETRNHJIXGITKR-UHFFFAOYSA-N 4-propan-2-ylbenzenesulfonyl chloride Chemical compound CC(C)C1=CC=C(S(Cl)(=O)=O)C=C1 CETRNHJIXGITKR-UHFFFAOYSA-N 0.000 description 1
- LEFGAGRZHLNPLS-UHFFFAOYSA-N 4-propylbenzenesulfonyl chloride Chemical compound CCCC1=CC=C(S(Cl)(=O)=O)C=C1 LEFGAGRZHLNPLS-UHFFFAOYSA-N 0.000 description 1
- NZYPCJXREKMMCJ-UHFFFAOYSA-N 4-propylbenzoyl chloride Chemical compound CCCC1=CC=C(C(Cl)=O)C=C1 NZYPCJXREKMMCJ-UHFFFAOYSA-N 0.000 description 1
- AHXRGFFTKHQGOE-UHFFFAOYSA-N 4-pyrazol-1-ylbenzenesulfonyl chloride Chemical compound C1=CC(S(=O)(=O)Cl)=CC=C1N1N=CC=C1 AHXRGFFTKHQGOE-UHFFFAOYSA-N 0.000 description 1
- UHDHZXQMHIQHSO-UHFFFAOYSA-N 4-pyrazol-1-ylbenzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1N1N=CC=C1 UHDHZXQMHIQHSO-UHFFFAOYSA-N 0.000 description 1
- MGYGFNQQGAQEON-UHFFFAOYSA-N 4-tolyl isocyanate Chemical compound CC1=CC=C(N=C=O)C=C1 MGYGFNQQGAQEON-UHFFFAOYSA-N 0.000 description 1
- BEAYCJSJSMOLFG-UHFFFAOYSA-N 5,5,8,8-tetramethyl-6,7-dihydronaphthalene-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C2C(C)(C)CCC(C)(C)C2=C1 BEAYCJSJSMOLFG-UHFFFAOYSA-N 0.000 description 1
- IENGAZSTLAONAR-UHFFFAOYSA-N 5-(1,4-diazepan-1-yl)-3-phenyl-1,2,4-thiadiazole Chemical compound C1CCNCCN1C1=NC(C=2C=CC=CC=2)=NS1 IENGAZSTLAONAR-UHFFFAOYSA-N 0.000 description 1
- YUHVLZWWHKQAKJ-UHFFFAOYSA-N 5-(4-benzylpiperazin-1-yl)-3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazole Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CC=3C=CC=CC=3)CC2)=N1 YUHVLZWWHKQAKJ-UHFFFAOYSA-N 0.000 description 1
- ALPLCUGLQIFRSZ-UHFFFAOYSA-N 5-(4-benzylsulfonylpiperazin-1-yl)-3-[(4-chlorophenyl)methyl]-1,2,4-thiadiazole Chemical compound C1=CC(Cl)=CC=C1CC1=NSC(N2CCN(CC2)S(=O)(=O)CC=2C=CC=CC=2)=N1 ALPLCUGLQIFRSZ-UHFFFAOYSA-N 0.000 description 1
- MJAMUSZUMAHFLH-UHFFFAOYSA-N 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,6,7,7a-tetrahydrothieno[3,2-c]pyridin-2-one Chemical compound FC1=CC=CC=C1C(C(=O)C1CC1)N1CC2=CC(=O)SC2CC1 MJAMUSZUMAHFLH-UHFFFAOYSA-N 0.000 description 1
- YMWSCIOQDBZPDO-UHFFFAOYSA-N 5-[4-(4-chloro-3-nitrophenyl)sulfonylpiperazin-1-yl]-3-[(4-methylphenyl)methyl]-1,2,4-thiadiazole Chemical compound C1=CC(C)=CC=C1CC1=NSC(N2CCN(CC2)S(=O)(=O)C=2C=C(C(Cl)=CC=2)[N+]([O-])=O)=N1 YMWSCIOQDBZPDO-UHFFFAOYSA-N 0.000 description 1
- PUIYZYPQVSXMOH-UHFFFAOYSA-N 5-[4-(4-chlorophenyl)sulfonylpiperazin-1-yl]-3-[(4-methylphenyl)methyl]-1,2,4-thiadiazole Chemical compound C1=CC(C)=CC=C1CC1=NSC(N2CCN(CC2)S(=O)(=O)C=2C=CC(Cl)=CC=2)=N1 PUIYZYPQVSXMOH-UHFFFAOYSA-N 0.000 description 1
- WGOAQNQGOZTVID-UHFFFAOYSA-N 5-bromo-2,3-dihydro-1-benzofuran-7-carbonyl chloride Chemical compound ClC(=O)C1=CC(Br)=CC2=C1OCC2 WGOAQNQGOZTVID-UHFFFAOYSA-N 0.000 description 1
- WDCSWTWTTAMPFJ-UHFFFAOYSA-N 5-bromo-2,3-dihydro-1-benzofuran-7-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC(Br)=CC2=C1OCC2 WDCSWTWTTAMPFJ-UHFFFAOYSA-N 0.000 description 1
- IXSBNNRUQYYMRM-UHFFFAOYSA-N 5-bromo-2-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(Br)C=C1S(Cl)(=O)=O IXSBNNRUQYYMRM-UHFFFAOYSA-N 0.000 description 1
- ZFBZICACMDZKNQ-UHFFFAOYSA-N 5-chloro-2,1,3-benzoxadiazole-4-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=C(Cl)C=CC2=NON=C21 ZFBZICACMDZKNQ-UHFFFAOYSA-N 0.000 description 1
- FCJGLIMDVOTBLO-UHFFFAOYSA-N 5-chloro-2-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(Cl)C=C1S(Cl)(=O)=O FCJGLIMDVOTBLO-UHFFFAOYSA-N 0.000 description 1
- QJEPSSRHPXZRPX-UHFFFAOYSA-N 5-chloro-3-[(3-methoxyphenyl)methyl]-1,2,4-thiadiazole Chemical compound COC1=CC=CC(CC=2N=C(Cl)SN=2)=C1 QJEPSSRHPXZRPX-UHFFFAOYSA-N 0.000 description 1
- ZTHYORRNWREZMC-UHFFFAOYSA-N 5-chloro-3-[(4-chlorophenyl)methyl]-1,2,4-thiadiazole Chemical compound S1C(Cl)=NC(CC=2C=CC(Cl)=CC=2)=N1 ZTHYORRNWREZMC-UHFFFAOYSA-N 0.000 description 1
- LGBRTOPGROGHSE-UHFFFAOYSA-N 5-chloro-3-[(4-methylphenyl)methyl]-1,2,4-thiadiazole Chemical compound C1=CC(C)=CC=C1CC1=NSC(Cl)=N1 LGBRTOPGROGHSE-UHFFFAOYSA-N 0.000 description 1
- SJXHSFSHNKFRLN-UHFFFAOYSA-N 5-chlorosulfonyl-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC(S(Cl)(=O)=O)=CC=C1O SJXHSFSHNKFRLN-UHFFFAOYSA-N 0.000 description 1
- NPEWBMJAUUSBLE-UHFFFAOYSA-N 5-fluoro-2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=C(F)C=C1S(Cl)(=O)=O NPEWBMJAUUSBLE-UHFFFAOYSA-N 0.000 description 1
- GWLZJAWTWVSHCU-UHFFFAOYSA-N 5-isocyanato-1-benzothiophene Chemical compound O=C=NC1=CC=C2SC=CC2=C1 GWLZJAWTWVSHCU-UHFFFAOYSA-N 0.000 description 1
- WAIKTAFMGLVRJC-UHFFFAOYSA-N 5-isocyanato-2,3-dihydro-1-benzofuran Chemical compound O=C=NC1=CC=C2OCCC2=C1 WAIKTAFMGLVRJC-UHFFFAOYSA-N 0.000 description 1
- BLGDMQAEKJZPMD-UHFFFAOYSA-N 5-piperazin-1-yl-1,2,4-thiadiazole Chemical class C1CNCCN1C1=NC=NS1 BLGDMQAEKJZPMD-UHFFFAOYSA-N 0.000 description 1
- UZLJYDCBJULBQU-UHFFFAOYSA-N 6-chloro-2-(1,4-diazepan-1-yl)-1,3-benzothiazole Chemical compound S1C2=CC(Cl)=CC=C2N=C1N1CCCNCC1 UZLJYDCBJULBQU-UHFFFAOYSA-N 0.000 description 1
- MLPWRGALYUWZEV-UHFFFAOYSA-N 6-fluoro-8-isocyanato-4h-1,3-benzodioxine Chemical compound C1OCOC2=C1C=C(F)C=C2N=C=O MLPWRGALYUWZEV-UHFFFAOYSA-N 0.000 description 1
- LXYXLYBFNUDHOM-UHFFFAOYSA-N 6-isocyanato-1,1,4,4-tetramethyl-2,3-dihydronaphthalene Chemical compound O=C=NC1=CC=C2C(C)(C)CCC(C)(C)C2=C1 LXYXLYBFNUDHOM-UHFFFAOYSA-N 0.000 description 1
- OGVYMEFCSKVNQH-UHFFFAOYSA-N 6-isocyanato-2,3-dihydro-1,4-benzodioxine Chemical compound O1CCOC2=CC(N=C=O)=CC=C21 OGVYMEFCSKVNQH-UHFFFAOYSA-N 0.000 description 1
- DUCMKSIKRPVTAJ-UHFFFAOYSA-N 7-isocyanato-3,4-dihydro-2h-1,5-benzodioxepine Chemical compound O1CCCOC2=CC(N=C=O)=CC=C21 DUCMKSIKRPVTAJ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 230000006181 N-acylation Effects 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000011644 Neurologic Gait disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 206010071390 Resting tremor Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000032859 Synucleinopathies Diseases 0.000 description 1
- 241000611306 Taeniopygia guttata Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- IWTYTFSSTWXZFU-QPJJXVBHSA-N [(e)-3-chloroprop-1-enyl]benzene Chemical compound ClC\C=C\C1=CC=CC=C1 IWTYTFSSTWXZFU-QPJJXVBHSA-N 0.000 description 1
- POHOBSIFQXIULK-UHFFFAOYSA-N [4-(3-benzyl-1,2,4-thiadiazol-5-yl)-2-methylpiperazin-1-yl]-(3-fluorophenyl)methanone Chemical compound CC1CN(C=2SN=C(CC=3C=CC=CC=3)N=2)CCN1C(=O)C1=CC=CC(F)=C1 POHOBSIFQXIULK-UHFFFAOYSA-N 0.000 description 1
- UGLUEAQVSOOKEN-UHFFFAOYSA-N [4-(3-benzyl-1,2,4-thiadiazol-5-yl)-2-methylpiperazin-1-yl]-(4-fluorophenyl)methanone Chemical compound CC1CN(C=2SN=C(CC=3C=CC=CC=3)N=2)CCN1C(=O)C1=CC=C(F)C=C1 UGLUEAQVSOOKEN-UHFFFAOYSA-N 0.000 description 1
- LSEJCTUHKWVDEH-UHFFFAOYSA-N [4-(3-benzyl-1,2,4-thiadiazol-5-yl)piperazin-1-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1CCN(C=2SN=C(CC=3C=CC=CC=3)N=2)CC1 LSEJCTUHKWVDEH-UHFFFAOYSA-N 0.000 description 1
- DILSLUHXNKQDKM-UHFFFAOYSA-N [4-[3-[(3-methoxyphenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]-(4-methylphenyl)methanone Chemical compound COC1=CC=CC(CC=2N=C(SN=2)N2CC(C)N(CC2)C(=O)C=2C=CC(C)=CC=2)=C1 DILSLUHXNKQDKM-UHFFFAOYSA-N 0.000 description 1
- OEHQRBIFLCSWFB-UHFFFAOYSA-N [4-[3-[(3-methoxyphenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]-[4-(trifluoromethyl)phenyl]methanone Chemical compound COC1=CC=CC(CC=2N=C(SN=2)N2CC(C)N(CC2)C(=O)C=2C=CC(=CC=2)C(F)(F)F)=C1 OEHQRBIFLCSWFB-UHFFFAOYSA-N 0.000 description 1
- DOXQLMJSHCLTCT-UHFFFAOYSA-N [4-[3-[(3-methoxyphenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]-phenylmethanone Chemical compound COC1=CC=CC(CC=2N=C(SN=2)N2CC(C)N(CC2)C(=O)C=2C=CC=CC=2)=C1 DOXQLMJSHCLTCT-UHFFFAOYSA-N 0.000 description 1
- PHSCKFOSCGIWLK-UHFFFAOYSA-N [4-[3-[(4-chlorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]-(2-fluorophenyl)methanone Chemical compound FC1=CC=CC=C1C(=O)N1CCN(C=2SN=C(CC=3C=CC(Cl)=CC=3)N=2)CC1 PHSCKFOSCGIWLK-UHFFFAOYSA-N 0.000 description 1
- RILFJVBTZZAVCJ-UHFFFAOYSA-N [4-[3-[(4-chlorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]-(3-fluorophenyl)methanone Chemical compound FC1=CC=CC(C(=O)N2CCN(CC2)C=2SN=C(CC=3C=CC(Cl)=CC=3)N=2)=C1 RILFJVBTZZAVCJ-UHFFFAOYSA-N 0.000 description 1
- RLFJYFIIUWUAHU-UHFFFAOYSA-N [4-[3-[(4-chlorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]-(4-ethylphenyl)methanone Chemical compound C1=CC(CC)=CC=C1C(=O)N1CCN(C=2SN=C(CC=3C=CC(Cl)=CC=3)N=2)CC1 RLFJYFIIUWUAHU-UHFFFAOYSA-N 0.000 description 1
- LQVBXIUALGRVEH-UHFFFAOYSA-N [4-[3-[(4-chlorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]-(4-fluorophenyl)methanone Chemical compound C1=CC(F)=CC=C1C(=O)N1CCN(C=2SN=C(CC=3C=CC(Cl)=CC=3)N=2)CC1 LQVBXIUALGRVEH-UHFFFAOYSA-N 0.000 description 1
- UOFQKEQSLYQFFS-UHFFFAOYSA-N [4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]-(4-methyl-3-nitrophenyl)methanone Chemical compound CC1CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CCN1C(=O)C1=CC=C(C)C([N+]([O-])=O)=C1 UOFQKEQSLYQFFS-UHFFFAOYSA-N 0.000 description 1
- PWSPXUWVPAREON-UHFFFAOYSA-N [4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]-(4-phenylphenyl)methanone Chemical compound CC1CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CCN1C(=O)C(C=C1)=CC=C1C1=CC=CC=C1 PWSPXUWVPAREON-UHFFFAOYSA-N 0.000 description 1
- LKPDDPXVFVTBQD-UHFFFAOYSA-N [4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazin-1-yl]-phenylmethanone Chemical compound CC1CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CCN1C(=O)C1=CC=CC=C1 LKPDDPXVFVTBQD-UHFFFAOYSA-N 0.000 description 1
- DOCQLUTWWIQAIS-UHFFFAOYSA-N [4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]-(2-methylphenyl)methanone Chemical compound CC1=CC=CC=C1C(=O)N1CCN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 DOCQLUTWWIQAIS-UHFFFAOYSA-N 0.000 description 1
- XBKVHINBDSCXQV-UHFFFAOYSA-N [4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]-(4-hexylphenyl)methanone Chemical compound C1=CC(CCCCCC)=CC=C1C(=O)N1CCN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 XBKVHINBDSCXQV-UHFFFAOYSA-N 0.000 description 1
- MRQADHYVXIFGPB-UHFFFAOYSA-N [4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1CCN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 MRQADHYVXIFGPB-UHFFFAOYSA-N 0.000 description 1
- ARAJIDUXPGNGIE-UHFFFAOYSA-N [4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]-phenylmethanone Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CC2)C(=O)C=2C=CC=CC=2)=N1 ARAJIDUXPGNGIE-UHFFFAOYSA-N 0.000 description 1
- RUXIIFJLVGIWHA-UHFFFAOYSA-N [4-[3-[(4-methylphenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]-[4-(trifluoromethyl)phenyl]methanone Chemical compound C1=CC(C)=CC=C1CC1=NSC(N2CCN(CC2)C(=O)C=2C=CC(=CC=2)C(F)(F)F)=N1 RUXIIFJLVGIWHA-UHFFFAOYSA-N 0.000 description 1
- LHUYLGMVXVDVHK-UHFFFAOYSA-N [4-[3-[(4-methylphenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]-phenylmethanone Chemical compound C1=CC(C)=CC=C1CC1=NSC(N2CCN(CC2)C(=O)C=2C=CC=CC=2)=N1 LHUYLGMVXVDVHK-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000005305 alkyl chloride derivatives Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- IMUDHTPIFIBORV-UHFFFAOYSA-N aminoethylpiperazine Chemical compound NCCN1CCNCC1 IMUDHTPIFIBORV-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000003942 amyloidogenic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 150000003975 aryl alkyl amines Chemical class 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- BAHFPJFBMJTOPU-UHFFFAOYSA-N benzyl 3-oxopiperazine-1-carboxylate Chemical compound C1CNC(=O)CN1C(=O)OCC1=CC=CC=C1 BAHFPJFBMJTOPU-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- OJKZEZMAPKWHTG-UHFFFAOYSA-N bis(2h-triazol-4-yl)methanone Chemical compound C=1NN=NC=1C(=O)C1=CNN=N1 OJKZEZMAPKWHTG-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000002676 chrysenyl group Chemical group C1(=CC=CC=2C3=CC=C4C=CC=CC4=C3C=CC12)* 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical group OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- QSACPWSIIRFHHR-UHFFFAOYSA-N dimethylphenyl isocyanide Natural products CC1=CC=CC(C)=C1C#N QSACPWSIIRFHHR-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000004002 dopaminergic cell Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- MWGLPVVMBIZBNR-UHFFFAOYSA-N ethyl 5-(4-hydroxyphenyl)-1,3-oxazole-4-carboxylate Chemical compound N1=COC(C=2C=CC(O)=CC=2)=C1C(=O)OCC MWGLPVVMBIZBNR-UHFFFAOYSA-N 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 229940093476 ethylene glycol Drugs 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 125000003914 fluoranthenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC=C4C1=C23)* 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003427 indacenyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000028252 learning or memory Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000003924 mental process Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- XVSPEBNRFAFNAV-UHFFFAOYSA-N methyl 12-oxooctadecanoate Chemical compound CCCCCCC(=O)CCCCCCCCCCC(=O)OC XVSPEBNRFAFNAV-UHFFFAOYSA-N 0.000 description 1
- HUNUAFNLLYVTQD-UHFFFAOYSA-N methyl 2-chlorosulfonylbenzoate Chemical compound COC(=O)C1=CC=CC=C1S(Cl)(=O)=O HUNUAFNLLYVTQD-UHFFFAOYSA-N 0.000 description 1
- CVXXHXPNTZBZEL-UHFFFAOYSA-N methyl 4-carbonochloridoylbenzoate Chemical compound COC(=O)C1=CC=C(C(Cl)=O)C=C1 CVXXHXPNTZBZEL-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- VORCBMLEQCEVSD-UHFFFAOYSA-N n-(2-ethylphenyl)-4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide Chemical compound CCC1=CC=CC=C1NC(=O)N1C(C)CN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 VORCBMLEQCEVSD-UHFFFAOYSA-N 0.000 description 1
- XYNWNHDXNJJOHT-UHFFFAOYSA-N n-(3-fluorophenyl)-4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazine-1-carboxamide Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CC2)C(=O)NC=2C=C(F)C=CC=2)=N1 XYNWNHDXNJJOHT-UHFFFAOYSA-N 0.000 description 1
- ZPYYLWMIIUDQGQ-UHFFFAOYSA-N n-[2-[4-[3-[(4-chlorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl]-3-fluorobenzamide Chemical compound FC1=CC=CC(C(=O)NCCN2CCN(CC2)C=2SN=C(CC=3C=CC(Cl)=CC=3)N=2)=C1 ZPYYLWMIIUDQGQ-UHFFFAOYSA-N 0.000 description 1
- NHHIFALXDXPOKS-UHFFFAOYSA-N n-[2-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl]-2-methylbenzamide Chemical compound CC1=CC=CC=C1C(=O)NCCN1CCN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 NHHIFALXDXPOKS-UHFFFAOYSA-N 0.000 description 1
- PBYUEZLYBWKRTL-UHFFFAOYSA-N n-[2-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl]-3-phenylpropanamide Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CCNC(=O)CCC=3C=CC=CC=3)CC2)=N1 PBYUEZLYBWKRTL-UHFFFAOYSA-N 0.000 description 1
- IKVYRCVCWQPUSE-UHFFFAOYSA-N n-[2-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl]-4-hexylbenzamide Chemical compound C1=CC(CCCCCC)=CC=C1C(=O)NCCN1CCN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 IKVYRCVCWQPUSE-UHFFFAOYSA-N 0.000 description 1
- CBHRZQUDHWBNHR-UHFFFAOYSA-N n-[2-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl]-4-methylbenzamide Chemical compound C1=CC(C)=CC=C1C(=O)NCCN1CCN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 CBHRZQUDHWBNHR-UHFFFAOYSA-N 0.000 description 1
- VMMSIMVMXGKZLR-UHFFFAOYSA-N n-[2-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl]-4-pentylbenzamide Chemical compound C1=CC(CCCCC)=CC=C1C(=O)NCCN1CCN(C=2SN=C(CC=3C=CC(F)=CC=3)N=2)CC1 VMMSIMVMXGKZLR-UHFFFAOYSA-N 0.000 description 1
- SXHCHAVDOGDRGB-UHFFFAOYSA-N n-[2-[4-[3-[(4-fluorophenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]ethyl]benzamide Chemical compound C1=CC(F)=CC=C1CC1=NSC(N2CCN(CCNC(=O)C=3C=CC=CC=3)CC2)=N1 SXHCHAVDOGDRGB-UHFFFAOYSA-N 0.000 description 1
- XNKFOQOJLXCFBV-UHFFFAOYSA-N n-[4-[2-methyl-4-[3-[(4-methylphenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]sulfonylphenyl]acetamide Chemical compound CC1CN(C=2SN=C(CC=3C=CC(C)=CC=3)N=2)CCN1S(=O)(=O)C1=CC=C(NC(C)=O)C=C1 XNKFOQOJLXCFBV-UHFFFAOYSA-N 0.000 description 1
- JXIIUNVSLULMKK-UHFFFAOYSA-N n-[4-[4-[3-[(4-methylphenyl)methyl]-1,2,4-thiadiazol-5-yl]piperazin-1-yl]sulfonylphenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1S(=O)(=O)N1CCN(C=2SN=C(CC=3C=CC(C)=CC=3)N=2)CC1 JXIIUNVSLULMKK-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- DASJFYAPNPUBGG-UHFFFAOYSA-N naphthalene-1-sulfonyl chloride Chemical compound C1=CC=C2C(S(=O)(=O)Cl)=CC=CC2=C1 DASJFYAPNPUBGG-UHFFFAOYSA-N 0.000 description 1
- XNLBCXGRQWUJLU-UHFFFAOYSA-N naphthalene-2-carbonyl chloride Chemical compound C1=CC=CC2=CC(C(=O)Cl)=CC=C21 XNLBCXGRQWUJLU-UHFFFAOYSA-N 0.000 description 1
- LKRPTTXVDXZHTP-UHFFFAOYSA-N naphthalene-2-sulfonyl chloride;2,4,6-tri(propan-2-yl)benzenesulfonyl chloride Chemical compound C1=CC=CC2=CC(S(=O)(=O)Cl)=CC=C21.CC(C)C1=CC(C(C)C)=C(S(Cl)(=O)=O)C(C(C)C)=C1 LKRPTTXVDXZHTP-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000007996 neuronal plasticity Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- OSDZHDOKXGSWOD-UHFFFAOYSA-N nitroxyl;hydrochloride Chemical compound Cl.O=N OSDZHDOKXGSWOD-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
- 150000002888 oleic acid derivatives Chemical class 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- UNEIHNMKASENIG-UHFFFAOYSA-N para-chlorophenylpiperazine Chemical compound C1=CC(Cl)=CC=C1N1CCNCC1 UNEIHNMKASENIG-UHFFFAOYSA-N 0.000 description 1
- MRDGZSKYFPGAKP-UHFFFAOYSA-N para-methoxyphenylpiperazine Chemical compound C1=CC(OC)=CC=C1N1CCNCC1 MRDGZSKYFPGAKP-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- MYHOHFDYWMPGJY-UHFFFAOYSA-N pentafluorobenzoyl chloride Chemical compound FC1=C(F)C(F)=C(C(Cl)=O)C(F)=C1F MYHOHFDYWMPGJY-UHFFFAOYSA-N 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 125000001388 picenyl group Chemical group C1(=CC=CC2=CC=C3C4=CC=C5C=CC=CC5=C4C=CC3=C21)* 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- UTEQROVYZDJSOO-UHFFFAOYSA-N quinoxaline-6-carbonyl chloride Chemical compound N1=CC=NC2=CC(C(=O)Cl)=CC=C21 UTEQROVYZDJSOO-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical class OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000008418 synuclein deposition Effects 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 1
- RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to novel thiadiazole derivatives useful for treating certain neurological disorders characterised by cytotoxic ⁇ -synuclein amyloidogenesis.
- the invention further relates to methods of treatment or prevention of such neurological disorders by the administration of a pharmaceutical composition, comprising one or more thiadiazole derivatives in an amount which alleviates or prevents the cytotoxic properties of ⁇ -synuclein.
- the invention further relates to methods of preparing novel thiadiazole derivatives, as well as certain classes of intermediates useful in such preparation.
- ⁇ -Synuclein is a neuronal protein which originally has been associated with neuronal plasticity during Zebra finch song learning. Although its role at the molecular level is at present largely elusive it appears to have lipid bi-layer (or membrane) with binding properties important for preserving proper transport of neurotransmitter vesicles to the axonal ends of neurons presumably to ensure proper signalling at the synapse.
- human ⁇ -synuclein Apart from its physiological role in brain cells, human ⁇ -synuclein also possesses pathological features that underlies a plethora of neurodegenerative diseases including Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease.
- These neurological disorders are characterised by the presence of insoluble ⁇ -synuclein polymers or aggregates usually residing within neuronal cells, although in the case of Alzheimer's disease ⁇ -synuclein (or proteolytic fragments thereof) constitutes the non-amyloid component of extracellular " amyloid- ⁇ plaques ".
- ⁇ -synuclein disrupt cellular integrity leading to dysfunctioning or death of affected neurons resulting in cognitive and/or motoric decline as it is found in patients suffering from such diseases.
- the aggregation of ⁇ -synuclein is at present very poorly defined, but constitutes most likely a multi-step process wherein self-polymerization of ⁇ -synuclein into insoluble aggregates is preceded by the formation of soluble protofibrils of ⁇ - synuclein monomers. Self-association may be triggered by the formation of alternative conformations of ⁇ -synuclein monomers with high propensity to polymerize.
- ROS reactive oxygen species
- Dopaminergic neurons appear to be particularly sensitive because the concurrent dopamine metabolism may on the one hand contribute significantly to the oxidative stress load but may on the other hand result in kinetic stabilisation of highly toxic protofibrillar ⁇ -synuclein species by dopamine (or its metabolic derivatives).
- Parkinson's disease is characterised by a selective loss of dopaminergic substantia nigra cells and therefore treatment of animals (or neuronal cells) with paraquat is a common well-accepted experimental set-up for studying synucleopathies, in particular Parkinson's disease.
- insoluble aggregates affect cellular integrity
- soluble protofibrillar intermediates of the aggregation process are particularly toxic for the cell as opposed to mature insoluble fibrils which may be inert end-products or may even serve as cytoprotective reservoirs of otherwise harmful soluble species.
- Therapeutic attempts to inhibit formation of insoluble aggregates may therefore be conceptually wrong, possibly even promoting disease progress.
- WO 99/51584 discloses 5-piperazinyl-1 ,2,4-thiadiazoles as inhibitors of proton pump H + /K + -ATPase and therefor useful in the treatment of peptic ulcer. However these compounds are not suggested for use in the prevention or treatment of neurodegenerative disorders.
- the present invention relates to a class of 1 ,2,4-thiadiazole derivatives that have been shown to effectively counteract or inhibit the toxic properties of ⁇ -synuclein .
- Administration of these compounds to patients suffering from a neurodegenerative disease characterised by noxious ⁇ -synuclein amyloidogenesis therefore constitutes an effective therapeutic and/or prophylactic method of treatment.
- the present invention provides a class of novel
- the present invention provides these compounds for use as medicaments, more particularly for use in the treatment of ⁇ - synucleopathies.
- the invention also provides pharmaceutical compositions comprising an effective amount of one or more such 1 ,2,4-thiadiazole derivatives, said compositions being useful for the prevention and/or treatment of an ⁇ -synucleopathy such as, but not limited to, Parkinson's disease, diffuse Lewy body disease, multiple system atrophy and Alzheimer's disease.
- the present invention also relates to the use of the 1 ,2,4-thiadiazole derivatives of the present invention in the manufacture of a medicament for the treatment and/or prevention of ⁇ -synucleopathies, such as, but not limited to Parkinson's disease, diffuse Lewy body disease, multiple system atrophy and Alzheimer's disease.
- ⁇ -synucleopathies such as, but not limited to Parkinson's disease, diffuse Lewy body disease, multiple system atrophy and Alzheimer's disease.
- the present invention provides a method for preparing such novel 1 ,2,4-thiadiazole derivatives in a limited number of steps and starting from commercially available materials or easily obtainable analogues thereof.
- C 1-4 alkyl means straight and branched chain saturated acyclic hydrocarbon monovalent groups having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, n-butyl, 1 -methylethyl (isopropyl), 2-methylpropyl (isobutyl) and 1 ,1-dimethylethyl (ter-butyl).
- C 1-6 alkyl refers to such radicals having from 1 to 6 carbon atoms, including 2-methylbutyl, n-pentyl, dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, and the like.
- C 1-6 alkylene means a divalent hydrocarbon radical corresponding to the above defined C 1-6 alkyl, such as methylene, bis(methylene), tris(methylene), tetramethylene, hexamethylene and the like.
- C 3-6 cycloalkyl means a mono- or polycyclic saturated hydrocarbon monovalent group having from 3 to 6 carbon atoms, such as for instance cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
- aryl designate any mono- or polycyclic aromatic monovalent hydrocarbon group having from 6 up to 30 carbon atoms such as but not limited to phenyl, naphthyl, anthracenyl, phenantracyl, fluoranthenyl, chrysenyl, pyrenyl, biphenylyl, terphenyl, picenyl, indenyl, biphenyl, indacenyl, benzocyclobutenyl, benzocyclooctenyl and the like, including fused benzo-C 4-8 cycloalkyl groups such as, for instance, indanyl, tetrahydronaphtyl, fluorenyl and the like, all of the said radicals being optionally substituted with one or more substituents independently selected from the group consisting of halogen, amino, trifluoromethyl, hydroxyl, sulfhydr
- C 1 ⁇ alkoxy refers to substituents wherein a carbon atom of a C 1-4 alkyl, respectively a C 1-6 alkyl or an aryl group (each of them such as defined herein), is attached to an oxygen atom through a single bond such as, but not limited to, methoxy, ethoxy, propoxy, butoxy, pentoxy, isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, phenyloxy, and the like.
- stereoisomer refers to all possible different isomeric as well as conformational forms which the compounds of structural formula (A) may possess, in particular all possible stereochemical ⁇ and conformationally isomeric forms, all diastereomers, enantiomers and/or conformers of the basic molecular structure.
- Some compounds of the present invention may exist in different tautomeric forms, all of the latter being included within the scope of the present invention.
- enantiomer means each individual optically active form of a compound of the invention, having an optical purity or enantiomeric excess (as determined by methods standard in the art) of at least 80% (i.e. at least 90% of one enantiomer and at most 10% of the other enantiomer), preferably at least 90% and more preferably at least 98%.
- solvate includes any combination which may be formed by a derivative of this invention with a suitable inorganic solvent (e.g. hydrates) or organic solvent, such as but not limited to alcohols, ketones, esters, ethers, nitriles and the like.
- a suitable inorganic solvent e.g. hydrates
- organic solvent such as but not limited to alcohols, ketones, esters, ethers, nitriles and the like.
- ⁇ -synucleopathy refers to a disease characterised by the presence of pathological deposition of insoluble ⁇ - synuclein polymers or aggregates intracellular ⁇ and/or extracellularly.
- diseases include, but are not limited to, Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease.
- Parkinson's disease refers to a chronic progressive nervous disease characterised by neurodegeneration, especially degeneration of dopaminergic neurons. Symptoms include stooped posture, resting tremor, weakness of resting muscles, a shuffling gait, speech impediments, movement difficulties and an eventual slowing of mental processes and dementia.
- neuroprotective agent refers to drugs or chemical agents intended to prevent neurodegeneration, including drugs that slow down or stop the progression of neuronal degeneration.
- the present invention relates, in a first aspect, to a group novel 1 ,2,4- thiadiazole derivatives which have desirable biological properties such as an inhibitory effect on ⁇ -synuclein mediated toxicity. Based on this inhibitory activity, and the fact that these compounds are not toxic to neural cells, these compounds are useful in the prevention and/or treatment of ⁇ -synucleopathies.
- the class of novel 1 ,2,4-thiadiazole derivatives of this invention may be represented by the structural formula (A) of claim 1 , including stereoisomers, solvates and salts thereof.
- This broad class may be sub-divided into several sub-classes wherein each substituent Ri to Ri 3 , the divalent group (A'), and the linking moiety X may be defined in a more restricted manner, at will and independently from each other. Exemplary but non-limiting embodiments of such sub-classes are defined in claims 2 to 27.
- the ability of the compounds of the invention to inhibit ⁇ -synuclein mediated toxicity is based on their activity in the ⁇ -synuclein cytotoxicity test described in the examples section herein.
- mice with mitochondrial complex I inhibitors such as paraquat or MPTP (1-methyl-4-phenyl-1 ,2,3,6-tetrahydropyridine) are a well- accepted and commonly used experimental set-up to study neuronal degeneration.
- Paraquat triggers synuclein-aggregation, which allegedly triggers a specific loss of dopaminergic neurons and ultimately a decline in the locomotion function.
- one or more compounds are administered to paraquat-receiving mice and the onset of motoric dysfunction is assessed using a rotary rod device.
- a delay or absence in the occurrence of motoric problems in compound treated mice indicates that the compound(s) inhibit(s) synuclein- dependent degeneration of dopaminergic cells.
- These methods comprise administering to a subject suffering from or susceptible to such a disease or disorder, an effective amount of one or more inhibitors of ⁇ -synuclein cytotoxicity as defined by the broad structural formula (A) of the invention, or sub-classes thereof.
- effective amount designates an amount sufficient to effect beneficial or desired clinical or biochemical results.
- An effective amount can be administered one or more times.
- an effective amount of an inhibitor of ⁇ -synuclein cytotoxicity is an amount that is sufficient to palliate, ameliorate, stabilize, reverse, slow down or delay the progression of a disease state or condition.
- the " effective amount" is defined as an amount of compound capable of preventing deposition of insoluble ⁇ - synuclein polymers or aggregates and/or capable of preventing the cytotoxic effects triggered by aggregation or polymerization of ⁇ -synuclein, and is an amount that substantially reduces the symptoms of an ⁇ -synucleopathy, such as Parkinson's disease.
- Other forms of effective amount may be for the treatment or prevention of the learning or memory impairment related to Alzheimer's disease.
- mammal As used herein, the terms " mammal ", " subject “ or “patient” for the purposes of a therapeutic or prophylactic treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, such as but not limited to dogs, cats, pigs, horses, sheep, and the like. Most particularly, the mammal is a human being.
- 1 ,2,4-thiadiazole compounds of the present invention can be synthesised in an effective manner according to the methods described in the following examples. These methods comprise a limited number of steps and start from commercially available, or readily accessible, materials.
- 1 ,2,4- thiadiazole compounds having the structural formula (A) can be synthesised according to schemes 1 and 2 described hereafter:
- step (a) of scheme 1 the benzonitrile derivative having the structural formula (I), optionally substituted on the aromatic ring and/or in alpha position to the cyano group, may be reacted with ammonia yielding the corresponding amidine (II).
- amidines from nitriles and ammonia may be greatly facilitated by the presence of electron-withdrawing groups on the benzonitrile derivative (I).
- this reaction may be carried out in the presence of an effective amount of one or more Lewis acids such as but not limited to AICI 3 or ZnCI 2 at temperatures ranging from 20 c C up to a maximum of 150-200 0 C.
- Nitriles or cyanides that may be used in step (a) include, but are not limited to, 4- Aminobenzylcyanide, 4-bromo-2,2-diphenylbutyronitrile, 3-chlorobenzyl-cyanide, 4- chlorobenzyl-cyanide, cyclohexylphenyl-acetonitrile, 4-hydroxybenzyl-cyanide, ⁇ - methylbenzylcyanide, 2-methylbenzyl-cyanide, 3-methylbenzyl-cyanide, 4-methyl- benzylcyanide, 4-cyano-4-phenylcyclohexanone, 1-(2,4-dichlorophenyl)-1-cyclo- propylcyanide, 4-fluorophenylacetonitrile, diphenylacetonitrile, 3,4,5-trimethoxy- phenylacetonithle, 2,2-diphenylpropionitrile, 4-bromophenylacetonitrile, 1-phenyl- cyclobutanecarbonitrile, 2,
- the starting materials are selected from the group comprising 4-fluorobenzyl cyanide, 4-chlorobenzyl cyanide, 4-methylbenzyl cyanide, 3-methoxybenzyl cyanide and benzyl cyanide.
- amidine having the structural formula (II) may be commercially available, for example 2-(2,6-dichlorophenyl)ethanimidamide in its hydrochloride salt form, and may then be used as the starting point of scheme 1.
- the thiadiazole core of the compounds of this invention is synthesised in step (b) in a manner similar as described in WO 99/51584.
- the amidine compound having the structural formula (II) may be reacted with CCI 3 SCI to form the corresponding 3-substituted,5-chloro-thiadiazole (III) (step (b) of scheme 1 ) which may then be reacted with a piperazine derivative to obtain a final compound of the invention having the structural formula (IV) wherein R' is according to formula
- Piperazine compounds when used for the displacement reaction in step (c) directly yielding compounds of the present invention include, but are not limited to, 1- (4-nitrophenyl)piperazine, 1-(2-methoxyphenyl)piperazine, 1-(3-methoxyphenyl)- piperazine dihydrochloride, 1-phenylpiperazine, 1-(3-chlorophenyl)piperazine, 1-(4- chlorophenyl)piperazine, 1 -(3,4-dichlorophenyl)piperazine, 1 -(2,3-dimethylphenyl)- piperazine, 1-(2,4-dimethylphenyl)piperazine, 1-(2,5-dimethylphenyl)piperazine, 1- (3,4-dimethylphenyl)piperazine, 1 -(5-chloro,2-methylphenyl)piperazine, 2-methyl-1 - (3-methylphenyl)piperazine, 4-piperazinoacetophenone, 1 -(4-flu
- another saturated or partly unsaturated heterocyclic ring having the structural formula (A') with at least two nitrogen atoms in the said heterocyclic ring and with a total of 5 to 7 atoms such as, but not limited to, homopiperazinyl, may be introduced onto the thiadiazole core.
- reagents for such synthesis, yielding final compounds of the present invention with homopiperazinyl connected to the thiadiazole core include but are not limited to 1-(4-bromo-2-fluorobenzyl)-1 ,4-diazepane, 1-(4-bromo-2- fluorobenzyl)-1 ,4-diazepane, 1 -(mesitylmethyl)-i ,4-diazepane, 1 -(4-bromobenzyl)- 1 ,4-diazepane, 6-chloro-2-(1 ,4-diazepan-1-yl)-1 ,3-benzothiazole, 1-(2-chloro-6- fluorobenzyl)-1 ,4-diazepane, 1-(4-fluorobenzyl)-1 ,4-diazepane, and 5-(1 ,4-diazepan- 1 -yl)-3-phenyl
- Scheme 2 schematically illustrates methods to prepare compounds according to structural formula (A) wherein step (c) comprises two subsequent reaction sub- steps.
- a thiadiazole compound having the structural formula (III) may first be derivatised with the optionally R 6 -substituted heterocyclic ring with at least two nitrogen atoms in the said heterocyclic ring and with a total of 5 to 7 atoms.
- heterocyclic compounds for use in step (c) for the synthesis of appropriate intermediates comprise, but are not limited to, piperazine, 2- methylpiperazine (either (R)-(-)-2-methylpiperazine or (S)-(+)-2-methylpiperazine), trans-2,5-dimethylpiperazine, homopiperazine, 1-(2-aminoethyl)piperazine.
- piperazine 2- methylpiperazine (either (R)-(-)-2-methylpiperazine or (S)-(+)-2-methylpiperazine)
- trans-2,5-dimethylpiperazine homopiperazine
- 1-(2-aminoethyl)piperazine 1-(2-aminoethyl)piperazine
- these intermediate compounds having the structural formulae (IV-A) and (IV-B) may be reacted with a reagent susceptible to nucleophilic attack by a non-tertiary amino group, e.g. the NH group present in compounds according to structural formula (IVA), or the terminal amino group present in compounds according to structural formula (IVB).
- a reagent susceptible to nucleophilic attack by a non-tertiary amino group e.g. the NH group present in compounds according to structural formula (IVA), or the terminal amino group present in compounds according to structural formula (IVB).
- Suitable such reagents include, but are not limited to, acid chlorides such as carbonyl chlorides or sulfonyl chlorides, or activated acids such as carboxylic acid anhydrides.
- Particular carbonyl chlorides for use in this reaction sub-step include benzoyl chlorides (as shown in formula V-A) and phenyl acetyl chlorides (as shown in formula V-C).
- Particular sulfonyl chlorides for use in this reaction sub-step include phenylsulphonyl chlorides (as shown in formula V-B).
- Benzoyl chlorides suitable for use in the synthesis of the compounds of the present invention include, but are not limited to, benzoyl chloride, p-anisoyl-chloride, 2-bromobenzoyl chloride, 4-bromobenzoyl chloride, 3- chlorobenzoyl chloride, pentafluorobenzoyl chloride, 2-chlorobenzoyl chloride, p- toluoyl chloride, 4-chlorobenzoyl chloride, 2,4-dichlorobenzoyl chloride, 3,4- dichlorobenzoyl chloride, 4-nitrobenzoyl chloride, 4-fluorobenzoyl chloride, 2- fluorobenzoyl chloride, o-toluoyl chloride, m-toluoyl chloride, 4-cyanobenzoyl chloride, 3-nitrobenzoyl chloride, 4-tert-butyl-benzoyl chloride, 4-biphen
- the benzoyl chloride reagent may be selected from the group consisting of 2-fluorobenzoyl chloride, 4-ethylbenzoyl chloride, 4-butylbenzoyl chloride, 4-methoxybenzoyl chloride, piperonyloyl chloride, 4- hexylbenzoyl chloride, 3-chlorobenzoyl chloride, 4-fluorobenzoyl chloride, p-toluoyl chloride, 3-fluorobenzoyl chloride, 4-chlorobenzoyl chloride, benzoyl chloride, 4-tert- butylbenzoyl chloride, 4-biphenylcarbonyl chloride, o-anisoyl chloride, 1-naphthoyl chloride, 2-naphthoyl chloride, 4-pentylbenzoyl chloride, 4-bromobenzoyl chloride, 2,4-dimethoxybenzoyl chloride, 3,5-d
- carbonyl chlorides are known to the person skilled in the art and commercially available for use as acylating reagent for use in the reaction step illustrated in scheme 2.
- Particular carbonyl chlorides for use in the method of the invention include, but are not limited to, cinnamoyl chloride, hydrocinnamoyl chloride, 2-phenylbutyryl chloride, phenylacetyl chloride and 4-fluorophenylacetyl chloride.
- Phenylsulfonyl chlorides suitable for use in the synthesis of the compounds of the present invention include, but are not limited to, A- fluorobenzenesulfonyl chloride, 2-mesitylenesulfonyl chloride, 4-methoxybenzene- sulfonyl chloride, p-toluenesulfonyl chloride, pentafluorobenzenesulfonyl chloride, benzenesulfonyl chloride, 4-bromobenzenesulfonyl chloride, ⁇ /-acetylsulfanilyl chloride, 2,4,6-triisopropyl-benzenesulfonyl chloride 2-naphthalenesulfonylchloride, A- chloro-benzenesulfonyl chloride S.S-dichloro ⁇ -hydroxy-benzenesulfonylchloride, 2,5- dichloro
- Phenylacetyl chlorides (structural formula V-C) suitable for use in the synthesis of the compounds of the present invention include, but are not limited to, phenylacetyl chloride, 4-methoxyphenylacetyl chloride, 2-(2-naphthyl)acetyl chloride, 2-(3,5-difluorophenyl)ethanoyl chloride, 2-(1-naphthyl)ethanoyl chloride, A- chlorophenylacetyl chloride, 3-methoxyphenylacetyl chloride, and A- fluorophenylacetyl chloride.
- the intermediate compounds having the structural formulae (IV-A) and (IV-B) may also be reacted with an isocyanate (structural formula V-E shown above) to yield final compounds wherein X comprises a urea linkage.
- lsocyanates suitable for use in the synthesis of the compounds of the present invention include, but are not limited to, 4-fluorophenyl isocyanate, phenyl isocyanate, m-Tolyl isocyanate, p-Tolyl isocyanate, 4-Chlorophenyl isocyanate, Ethyl A- isocyanatobenzoate, 2-Fluorophenyl isocyanate, 3-Fluorophenyl isocyanate, alpha, alpha, alpha-Trifluoro-o-tolyl isocyanate, Tolylene-2,4-diisocyanate, Tolylene 2,6-diisocyanate, 4-Methoxyphenyl isocyanate, 4-Bromophen
- intermediates having the structural formula (IV-A) or (IV-B) may be derivatised with a carbonylation agent such as, but not limited to, trisphosgene, carbonyl diimidazole (hereinafter abbreviated as CDI) or carbonyl ditriazole.
- a carbonylation agent such as, but not limited to, trisphosgene, carbonyl diimidazole (hereinafter abbreviated as CDI) or carbonyl ditriazole.
- CDI carbonyl diimidazole
- the resulting imidazo-carbonyl compound may then be further reacted with an amino compound, particularly an aniline derivative wherein R 7 , R 8 , Rg, RTM, Rn are as defined above, thereby providing further compounds of the invention.
- the carbonylation and further urea formation with an amine may be most particularly carried out in a one-pot procedure.
- Amino compounds suitable for the latter reaction include arylamines, arylalkylamines, arylalkenylamines, arylalkynylamines wherein said one or more of the carbon atoms in the alkyl, alkenyl or alkynyl moiety is optionally replaced by a heteroatom selected from the group comprising O, N and S, and wherein each of said amino compounds is optionally substituted.
- Suitable aniline derivatives for the above reaction step include, but are not limited, to 2,6-dimethylaniline, 2-methylaniline, 3-fluoroaniline, 4-ethylaniline, 2, 4- dimethoxyaniline, 2,6-dichloroaniline, 3-cyanoaniline, and 2,4-fluoroaniline.
- step (c) comprises two sub-steps as described herein-above, the order of performing the different reactions is not critical for the invention and therefore can be changed.
- the optionally substituted heterocyclic ring with at least two nitrogen atoms in the said heterocyclic ring and with a total of 5 to 7 atoms may first be reacted with either one of the reagents having the structural formula (V-A), (V-B), or (V-C), or CDI followed by reaction with a compound having the structural formula (V-D).
- the resulting compound may then be used for reaction with the 3-substituted- 5-chloro-thiadiazole having the structural formula (III) to yield a final compound according to the invention.
- the 1 ,2,4-thiadiazole derivatives having the above structural formula (A) may be in the form of a pharmaceutically acceptable salt.
- the latter include any therapeutically active non-toxic addition salt which 1 ,2,4-thiadiazole compounds having the general formula (A) are able to form with a salt-forming agent.
- Such addition salts may conveniently be obtained by treating the said derivative of the invention with an appropriate salt-forming acid or base.
- derivatives having basic properties may be converted into the corresponding therapeutically active, non-toxic acid addition salt form by treating the free base form with a suitable amount of an appropriate acid following conventional procedures.
- appropriate salt-forming acids include, for instance, inorganic acids resulting in forming salts such as but not limited to hydrohalides (e.g.
- hydrochloride and hydrobromide sulfate, nitrate, phosphate, diphosphate, carbonate, bicarbonate, and the like; and organic monocarboxylic or dicarboxylic acids resulting in forming salts such as, for example, acetate, propanoate, hydroxyacetate, 2-hydroxypropanoate, 2- oxopropanoate, lactate, pyruvate, oxalate, malonate, succinate, maleate, fumarate, malate, tartrate, citrate, methanesulfonate, ethanesulfonate, benzoate, 2-hydroxy- benzoate, 4-amino-2-hydroxybenzoate, benzenesulfonate, p-toluenesulfonate, salicylate, p-aminosalicylate, pamoate, bitartrate, camphorsulfonate, edetate, 1 ,2- ethanedisulfonate, fumarate,
- the 1 ,2,4-thiadiazole derivatives of the general formula (A) having acidic properties may be converted in a similar manner into the corresponding therapeutically active, non-toxic base addition salt form.
- appropriate salt- forming bases include, for instance, inorganic bases like metallic hydroxides such as but not limited to those of alkali and alkaline-earth metals like calcium, lithium, magnesium, potassium and sodium, or zinc, resulting in the corresponding metal salt; organic bases such as but not limited to ammonia, alkylamines, benzathine, hydrabamine, arginine, lysine, N.N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylene-diamine, N-methylglucamine, procaine and the like.
- Reaction conditions for treating the 1 ,2,4-thiadiazole derivatives having the structural formula (A) of this invention with an appropriate salt-forming acid or base are similar to standard conditions involving the same acid or base but different organic compounds with basic or acidic properties, respectively.
- the pharmaceutically acceptable salt will be designed, i.e. the salt-forming acid or base will be selected so as to impart greater water-solubility, lower toxicity, greater stability and/or slower dissolution rate to the derivative of this invention.
- a 1 ,2,4-thiadiazole compound disclosed in this invention or a pharmaceutically acceptable salt, pro-drug or solvate thereof, for the therapeutic treatment (including prophylactic treatment) of mammals including humans it is usually formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition including one or more appropriate pharmaceutically acceptable excipients.
- this invention provides combinations, preferably synergistic combinations, of one or more derivatives represented by the general formula (A) with one or more biologically-active drugs being preferably selected from the group consisting of neuro-protective agents and ⁇ -synuclein deposition inhibitors.
- one or more biologically-active drugs being preferably selected from the group consisting of neuro-protective agents and ⁇ -synuclein deposition inhibitors.
- the evaluation of a synergistic effect in a drug combination may be made by analysing the quantification of the interactions between individual drugs, using the median effect principle described by Chou et al. in Adv. Enzyme Reg. (1984) 22:27. Briefly, this principle states that interactions (synergism, additivity, antagonism) between two drugs can be quantified using the combination index (hereinafter referred as Cl) defined by the following equation:
- ED x is the dose of the first or respectively second drug used alone (1a, 2a), or in combination with the second or respectively first drug (1c, 2c), which is needed to produce a given effect.
- this principle may be applied to a number of desirable effects such as, but not limited to, an activity against neurodegenerative disorders.
- pharmaceutically acceptable carrier or excipient as used herein in relation to pharmaceutical compositions and combined preparations means any material or substance with which the active principle, i.e. the 1 ,2,4-thiadiazole derivative of the general formula (A), and optionally the neuro-protective agent or ⁇ - synuclein deposition inhibitor, may be formulated in order to facilitate its application or dissemination to the locus to be treated, for instance by dissolving, dispersing or diffusing the said composition, and / or to facilitate its storage, transport or handling without impairing its effectiveness.
- the pharmaceutically acceptable carrier may be a solid or a liquid or a gas which has been compressed to form a liquid, i.e. the compositions of this invention can suitably be used as concentrates, emulsions, solutions, granulates, dusts, sprays, aerosols, pellets or powders.
- Suitable pharmaceutical carriers for use in the said pharmaceutical compositions and their formulation are well known to those skilled in the art. There is no particular restriction to their selection within the present invention although, due to the usually low or very low water-solubility of the derivatives of this invention, special attention will be paid to the selection of suitable carrier combinations that can assist in properly formulating them in view of the expected time release profile.
- Suitable pharmaceutical carriers include additives such as wetting agents, dispersing agents, stickers, adhesives, emulsifying or surface-active agents, thickening agents, complexing agents, gelling agents, solvents, coatings, antibacterial and antifungal agents (for example phenol, sorbic acid, chlorobutanol), isotonic agents (such as sugars or sodium chloride) and the like, provided the same are consistent with pharmaceutical practice, i.e. carriers and additives which do not create permanent damage to mammals.
- additives such as wetting agents, dispersing agents, stickers, adhesives, emulsifying or surface-active agents, thickening agents, complexing agents, gelling agents, solvents, coatings, antibacterial and antifungal agents (for example phenol, sorbic acid, chlorobutanol), isotonic agents (such as sugars or sodium chloride) and the like, provided the same are consistent with pharmaceutical practice, i.e. carriers and additives which do not create permanent damage to mammals.
- compositions of the present invention may be prepared in any known manner, for instance by homogeneously mixing, dissolving, spray-drying, coating and/or grinding the active ingredients, in a one-step or a multi-steps procedure, with the selected carrier material and, where appropriate, the other additives such as surface-active agents, may also be prepared by micronisation, for instance in view to obtain them in the form of microspheres usually having a diameter of about 1 to 10 ⁇ m, namely for the manufacture of microcapsules for controlled or sustained release of the biologically active ingredient(s).
- Suitable surface-active agents to be used in the pharmaceutical compositions of the present invention are non-ionic, cationic and/or anionic surfactants having good emulsifying, dispersing and/or wetting properties.
- Suitable anionic surfactants include both water-soluble soaps and water-soluble synthetic surface-active agents.
- Suitable soaps are alkaline or alkaline-earth metal salts, unsubstituted or substituted ammonium salts of higher fatty acids (C 10 -C 22 ), e.g. the sodium or potassium salts of oleic or stearic acid, or of natural fatty acid mixtures obtainable form coconut oil or tallow oil.
- Synthetic surfactants include sodium or calcium salts of polyacrylic acids; fatty sulphonates and sulphates; sulphonated benzimidazole derivatives and alkylarylsulphonates.
- Fatty sulphonates or sulphates are usually in the form of alkaline or alkaline-earth metal salts, unsubstituted ammonium salts or ammonium salts substituted with an alkyl or acyl radical having from 8 to 22 carbon atoms, e.g.
- Suitable sulphonated benzimidazole derivatives preferably contain 8 to 22 carbon atoms.
- alkylarylsulphonates are the sodium, calcium or alcanolamine salts of dodecylbenzene sulphonic acid or dibutyl-naphtalenesulphonic acid or a naphtalene- sulphonic acid/formaldehyde condensation product.
- corresponding phosphates e.g. salts of phosphoric acid ester and an adduct of p-nonylphenol with ethylene and / or propylene oxide, or phospholipids.
- Suitable phospholipids for this purpose are the natural (originating from animal or plant cells) or synthetic phospholipids of the cephalin or lecithin type such as e.g.
- phosphatidylethanolamine phosphatidylserine, phosphatidylglycerine, lysolecithin, cardiolipin, dioctanyl- phosphatidylcholine, dipalmitoylphoshatidylcholine and their mixtures.
- Suitable non-ionic surfactants include polyethoxylated and polypropoxylated derivatives of alkylphenols, fatty alcohols, fatty acids, aliphatic amines or amides containing at least 12 carbon atoms in the molecule, alkylarenesulphonates and dialkylsulphosuccinates, such as polyglycol ether derivatives of aliphatic and cycloaliphatic alcohols, saturated and unsaturated fatty acids and alkylphenols, said derivatives preferably containing 3 to 10 glycol ether groups and 8 to 20 carbon atoms in the (aliphatic) hydrocarbon moiety and 6 to 18 carbon atoms in the alkyl moiety of the alkylphenol.
- non-ionic surfactants are water-soluble adducts of polyethylene oxide with poylypropylene glycol, ethylenediamino- polypropylene glycol containing 1 to 10 carbon atoms in the alkyl chain, which adducts contain 20 to 250 ethyleneglycol ether groups and / or 10 to 100 propyleneglycol ether groups.
- Such compounds usually contain from 1 to 5 ethyleneglycol units per propyleneglycol unit.
- non-ionic surfactants are nonylphenol-polyethoxyethanol, castor oil polyglycolic ethers, polypropylene/ polyethylene oxide adducts, tributylphenoxypolyethoxyethanol, polyethyleneglycol and octylphenoxypolyethoxyethanol.
- Fatty acid esters of polyethylene sorbitan such as polyoxyethylene sorbitan trioleate
- glycerol glycerol
- sorbitan sucrose and pentaerythritol are also suitable non-ionic surfactants.
- Suitable cationic surfactants include quaternary ammonium salts, preferably halides, having four hydrocarbon radicals optionally substituted with halo, phenyl, substituted phenyl or hydroxy; for instance quaternary ammonium salts containing as N-substituent at least one C 8 -C 22 alkyl radical (e.g. cetyl, lauryl, palmityl, myristyl, oleyl and the like) and, as further substituents, unsubstituted or halogenated lower alkyl, benzyl and / or hydroxy-C 1-4 alkyl radicals.
- quaternary ammonium salts preferably halides, having four hydrocarbon radicals optionally substituted with halo, phenyl, substituted phenyl or hydroxy
- quaternary ammonium salts containing as N-substituent at least one C 8 -C 22 alkyl radical (e.g. cetyl, la
- Structure-forming, thickening or gel-forming agents may be included into the pharmaceutical compositions and combined preparations of the invention.
- Suitable such agents are in particular highly dispersed silicic acid, such as the product commercially available under the trade name Aerosil; bentonites; tetraalkyl ammonium salts of montmorillonites (e.g., products commercially available under the trade name Bentone), wherein each of the alkyl groups may contain from 1 to 20 carbon atoms; cetostearyl alcohol and modified castor oil products (e.g. the product commercially available under the trade name Antisettle).
- Gelling agents which may be included into the pharmaceutical compositions and combined preparations of the present invention include, but are not limited to, cellulose derivatives such as carboxymethylcellulose, cellulose acetate and the like; natural gums such as arabic gum, xanthum gum, tragacanth gum, guar gum and the like; gelatin; silicon dioxide; synthetic polymers such as carbomers, and mixtures thereof.
- Gelatin and modified celluloses represent a preferred class of gelling agents.
- additives such as magnesium oxide; azo dyes; organic and inorganic pigments such as titanium dioxide; UV-absorbers; stabilisers; odor masking agents; viscosity enhancers; antioxidants such as, for example, ascorbyl palmitate, sodium bisulfite, sodium metabisulfite and the like, and mixtures thereof; preservatives such as, for example, potassium sorbate, sodium benzoate, sorbic acid, propyl gallate, benzylalcohol, methyl paraben, propyl paraben and the like; sequestering agents such as ethylene-diamine tetraacetic acid; flavoring agents such as natural vanillin; buffers such as citric acid and acetic acid; extenders or bulking agents such as silicates, diatomaceous earth, magnesium oxide or aluminum oxide; densification agents such as magnesium salts; and mixtures thereof.
- additives such as magnesium oxide; azo dyes; organic and inorganic pigments such as titanium dioxide; UV-absorb
- Control release compositions may thus be achieved by selecting appropriate polymer carriers such as for example polyesters, polyamino- acids, polyvinylpyrrolidone, ethylene-vinyl acetate copolymers, methylcellulose, carboxy-methylcellulose, protamine sulfate and the like.
- the rate of drug release and duration of action may also be controlled by incorporating the active ingredient into particles, e.g. microcapsules, of a polymeric substance such as hydrogels, polylactic acid, hydroxymethyl-cellulose, polymethyl methacrylate and the other above- described polymers.
- Such methods include colloid drug delivery systems like liposomes, microspheres, microemulsions, nanoparticles, nanocapsules and so on.
- the pharmaceutical composition or combined preparation of the invention may also require protective coatings.
- compositions suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation thereof.
- Typical carriers for this purpose therefore include biocompatible aqueous buffers, ethanol, glycerol, propylene glycol, polyethylene glycol, complexing agents such as cyclodextrins and the like, and mixtures thereof.
- such compounds are preferably administered so that a daily dose in the range of, for example, 0.1 mg to 75 mg per kg body weight is received, said daily dose being given if required in divided sub-doses.
- lower doses will be administered when a parenteral route is employed.
- a dose in the range of, for example, 0.5 mg to 30 mg per kg body weight will preferably be used.
- a dose in the range of, for example, 0.5 mg to 25 mg per kg body weight will preferably be used.
- the envisaged administration route for the compounds of the invention is oral administration, particularly in tablet form.
- unit dosage forms will contain about 1 mg to 500 mg of a compound of this invention.
- Another embodiment of this invention includes the various precursor or " prodrug" forms of the compounds of the present invention. It may be desirable to formulate the compounds of the present invention in the form of a chemical species which itself is not significantly biologically-active, but which when delivered to the body of a human being or higher mammal will undergo a chemical reaction catalysed by the normal function of the body, inter alia, enzymes present in the stomach or in blood serum, said chemical reaction having the effect of releasing a compound as defined herein.
- the term " pro-drug” thus relates to these species which are converted in vivo into the active pharmaceutical ingredient.
- the pro-drugs of the present invention can have any form suitable to the formulator, e.g. esters.
- the pro-drug may necessarily exist in a form wherein a covalent bond is cleaved by the action of an enzyme present at the target locus.
- a C-C covalent bond may be selectively cleaved by one or more enzymes at said target locus and, therefore, a pro-drug in a form other than an easily hydrolysable precursor, inter alia an ester, an amide, and the like, may be used.
- therapeutically suitable pro-drug is defined herein as a compound modified in such a way as to be transformed in vivo to the therapeutically active form, whether by way of a single or by multiple biological transformations, when in contact with the tissues of humans or mammals to which the pro-drug has been administered, and without undue toxicity, irritation, or allergic response, and achieving the intended therapeutic outcome.
- Figure 1 shows the sensitivity of an ⁇ -synuclein expressing neuroblastoma cell line to paraquat according to one embodiment of the invention.
- Figure 2 shows the inhibition of ⁇ -synuclein mediated toxicity by two exemplary compounds of this invention, being N-(2,6-dimethylphenyl)-4-[3-(4- fluorobenzyl)-1 ,2,4-thiadiazol-5-yl]-2-methylpiperazine-1-carboxamide (compound 19, squares) and 2-phenyl-N- ⁇ 2-[4-[3-(4-fluorobenzyl)-1 ,2,4-thiadiazol-5-yl]piperazin-1- yl]ethyl ⁇ butanamide (compound 111 , triangles).
- Figure 3 shows inhibition of paraquat-triggered degeneration of substantia nigra cells, using 1-[4-methoxyphenylsulfonyl]-4-[3-(3-methoxybenzyl)-1 ,2,4-thia- diazol-5-yl]piperazine (compound 53), in vivo.
- the nitrile compound is treated with gaseous HCI in a mixture of anhydrous chloroform and methanol to yield the imino ether hydrochloride. Subsequently, the mixture is treated with dry ammonia to yield the amidine compound.
- step (b) of scheme 1 The intermediate 3-benzyl-5-chloro-1 , 2,4-thiadiazole derivatives in step (b) of scheme 1 have been obtained according to the following procedure.
- dichloromethane (DCM) (130 ml) was charged and the appropriate amidine hydrochloride (0.1 mol) was suspended in it upon efficient stirring.
- perchloromethyl mercaptane (16.73 g) was added to the suspension.
- the stirred solution was cooled to -14°C by using ammonium chloride-ice cooling bath.
- aqueous NaOH solution (0.5 mole dissolved in 30 ml distilled water) was added dropwise to the solution upon efficient stirring while keeping the inner temperature accurately below -8°C.
- the reaction mixture was stirred for another hour while the temperature was let to rise to room temperature.
- the precipitated NaCI was filtered off and washed with DCM.
- the organic phase of the filtrate was separated and saved.
- the aqueous phase was washed with 3x20 ml DCM.
- the collected organic phases including the previously saved solution were washed with water (4x20 ml).
- the organic phase was dried over anhydrous sodium sulphate and evaporated to dryness.
- the residue was distilled in high motor vacuum using a vacuum-jacketed Vigreaux-column.
- the purity of the product was checked by TLC in an eluent mixture DCM: EtOH 5:1 containing some drop of 25% aq. ammonium hydroxide solution. If the TLC showed apolar impurities the product was dissolved in 5% aqueous HCI solution and the impurities were washed away with ethyl-acetate. The aqueous phase was made alkaline (pH: 10-11 ) with 10% aqueous NaOH solution and the product was extracted with DCM. The following data were obtained for certain species:
- the organic phase was first washed with a 5% aqueous citric acid solution, water, a 5% aqueous Na2CO3 solution, and water, respectively.
- the organic phase was separated, dried over MgSO4, filtered and, evaporated to dryness. The residue was crystallised by diethyl ether to yield the desired compound.
- compound 32 1-[4-methoxyphenylsulfonyl]-4-[3-(4-fluorobenzyl)-1 ,2,4- thiadiazol-5-yl]piperazine: starting from 400 mg 1-[3-(4-fluoro-benzyl)- [1 ,2,4]thiadiazol-5-yl]-piperazine (1.237 mmole) and 1 molar equivalent of 4-methoxy-phenylsulphonyl chloride, 453 mg of the title compound was obtained after 3 hours of reaction (70 % yield).
- compound 44 1 -[3-methoxyphenylsulfonyl]-4-[3-(4-fluorobenzyl)-1 ,2,4- thiadiazol-5-yl]piperazine: starting from 80 mg 1-[3-(4-Fluoro-benzyl)- [1 ,2,4]thiadiazol-5-yl]-piperazine (0.287 mmol) and 1 molar equivalent of 3-methoxyphenylsulfonyl chloride, 102 mg of the title compound was obtained after 4 hours of reaction in 79% yield.
- compound 53 1-[4-methoxyphenylsulfonyl]-4-[3-(3-methoxybenzyl)-1 ,2,4- thiadiazol-5-yl]piperazine: starting from 150 mg 1 -[3-(3-methoxybenzyl)- [1 ,2,4]thiadiazol-5-yl]-piperazine (0.517 mmol) and 1 molar equivalent of 4-methoxyphenylsulfonyl chloride, 156 mg of the title compound was obtained after 5 hours of reaction in 66% yield.
- ⁇ -synuclein expression plasmid was constructed by sub-cloning the Ncol/Xhol fragment from 212T-SYN(WT) (Griffioen et al., Biochem Biophys Acta (2006) 1762(3):312-318) containing the cDNA of human wild type ⁇ -synuclein correspondingly into a standard mammalian expression vector pcDNA3.1 resulting in plasmid pcDNA3.1-SYNwt. Plasmid pcDNA3.1 and pcDNA3.1-SYNwt were transfected to human neuroblastoma cells (ATCC No. CRL-2267) and independent clonal lines with the plasmids stably integrated into the genome were selected.
- M17 transfected with pcDNA3.1
- M17-SYNwt transfected with pcDNA3.1-SYNwt
- Example 10 Use of ⁇ -synuclein expressing cells as a model for neuronal degradation
- LDH lactate dehydrogenase
- the detailed method for determining ⁇ -synuclein cytotoxicity was as follows: From appropriate precultures of M17 and M17-SYN cells were seeded at 50000 cells/cm 2 in Optimem Reduced Serum without phenol red (InVitrogen, Cat. 31985- 047) supplemented with 5% fetal calf serum, 1 mM sodium pyruvate, 1 x nonessential amino acids, 500 ⁇ g/ml G418 0,5 x antibiotic/antimycotic. After 3 hours of incubation at 37°C/5% CO 2 paraquat was added to the cells (final concentration of 32 mM), together with the test compound and the cells were further incubated for 40 hours.
- Example 11 use of the ⁇ -synuclein expressing cells in the screening of exemplary compounds
- This ⁇ -synuclein expressing neuroblastoma cells made it possible to assess the ability of novel compounds to counteract ⁇ -synuclein cytotoxicity.
- Active inhibitors of ⁇ -synuclein cytotoxicity were found to provoke a decrease of LDH leakage in paraquat-treated M17-SYNwt cells. Since this method monitors leaked LDH from degenerated or dead cells only non-toxic compounds will be identified as active inhibitors of ⁇ -synuclein-mediated cytotoxicity. Lack of toxicity is an important characteristic for compounds to be used as a medicament to patients in need.
- a compound was considered to be active in this test when it inhibits ⁇ -synuclein cyto- toxicity by more than 25% relative to untreated M17-SYNwt cells at a concentration of 20 ⁇ g/mL or lower.
- the control group consisted of M17-SYNwt cells treated with DMSO
- the untreated paraquat group consisted of M17-SYNwt cells treated with paraquat and DMSO
- the treated paraquat group consisted of M17- SYNwt cells treated with paraquat and the test compound dissolved in DMSO.
- Example 13 in vivo inhibition of synuclein-mediated instigated loss of substantia nigra neurons
- mice were treated with paraguat (intraperitoneal) at a dose not higher than 8 mg/kg/day for a continuous period of 15-100 days. These mice were also chronically co-treated during that period with: compound 60 (1-[4-methoxyphenylsulfonyl]-4-[3-(4-methylbenzyl)-1 ,2,4- thiadiazol-5-yl]-2-methylpiperazine), or - compound 32 (1-[4-methoxyphenylsulfonyl]-4-[3-(4-fluorobenzyl)-1 ,2,4- thiadiazol-5-yl]piperazine), or - compound 53 (1-[4-methoxyphenylsulfonyl]-4-[3-(3-methoxy-benzyl)-1 ,2,4- thiadiazol-5-yl]piperazine), each being administered at a dose not higher than
- mice were sacrificed and the corresponding brains were used for immunohistochemical analysis.
- the substantia nigra brain region has a relatively high percentage of cells with high levels of tyrosine hydroxylase.
- antibodies raised against tyrosin hydroxylase anti-tyrosin hydroxylase
- tyrosine hydroxylase containing neurons in the brains were detected.
- Figure 3 shows that compound 53 protects dopaminergic substantia nigra neurons against paraquat-triggered degeneration.
- brains were collected and used for immunohistochemistry (6 sections per brain per staining).
- Mouse brain were fixed overnight in 4% paraformaldehyde, and stored in PBS with 0.1% sodium azide. Free- floating vibratome-sections of 40 ⁇ m were prepared and stored in PBS containing 0.1% sodium azide.
- 6-hvdroxydopamine 6-hvdroxydopamine
- Unilateral substantia nigra lesions are obtained by stereotactic striatal injections of 6-hydroxydopamine in brains of living rats as described by Vercammen et al. in Molecular Therapy, 14(5) 716-723 (2006).
- These rats are also chronically co- treated with the same exemplary compounds and at the same dose as mentioned in example 13, or by vehicle only (no active compound).
- Daily treatment of compound or vehicle is started preferably 1 or 2 days before administration of 6-OHDA and lasts between 7 to 30 days after the 6-OHDA injection.
- substantia nigra brain region has a relatively high percentage of cells with high levels of tyrosine hydroxylase.
- tyrosin hydroxylase anti-tyrosine hydroxylase
- tyrosine hydroxylase containing neurons in the brains are detected.
- the nigral lesion volumes and/or the tyrosine hydroxylase positive cell numbers are quantified as described in Vercammen et al. (cited supra).
- - tyrosine hydroxylase positive cell numbers are higher in rats treated with a compound according to this invention as compared to vehicle treated rats, thus providing confirmation that the compound is able to inhibit 6-OHDA triggered degeneration of substantia nigra cells in vivo.
- Example 15 - in vitro inhibition of ⁇ -synuclein aggregation ⁇ -synucleinopathies are characterised by aggregation of ⁇ -synuclein in neurons. Aggregation of purified ⁇ -synuclein is performed essentially as described by Gerard et al. FASEB. 20(3):524-6 (2006). 20-100 ⁇ g purified ⁇ -synuclein (Sigma; S7820) at a concentration of about 2.5 ⁇ g/mL is incubated in the presence of spermin (250 ⁇ M) or paraquat (32 mM) or 6-hydroxydopamine (400 ⁇ M) or vehicle in a 384 well plate.
- spermin 250 ⁇ M
- paraquat 32 mM
- 6-hydroxydopamine 400 ⁇ M
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA200870233A EA018067B1 (en) | 2006-02-07 | 2007-02-07 | Thiadiazole derivatives for the treatment of neuro degenerative diseases |
AU2007213954A AU2007213954B2 (en) | 2006-02-07 | 2007-02-07 | Thiadiazole derivatives for the treatment of neuro degenerative diseases |
EP07711455A EP1981504B1 (en) | 2006-02-07 | 2007-02-07 | Thiadiazole derivatives for the treatment of neuro degenerative diseases |
PL07711455T PL1981504T3 (en) | 2006-02-07 | 2007-02-07 | Thiadiazole derivatives for the treatment of neuro degenerative diseases |
AT07711455T ATE474579T1 (en) | 2006-02-07 | 2007-02-07 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
JP2008553672A JP5283511B2 (en) | 2006-02-07 | 2007-02-07 | Thiadiazole derivatives for the treatment of neurodegenerative diseases |
DK07711455.1T DK1981504T3 (en) | 2006-02-07 | 2007-02-07 | Thiadiazole derivatives for the treatment of neurodegenerative diseases |
CN2007800045833A CN101378757B (en) | 2006-02-07 | 2007-02-07 | Thiadiazole derivatives for the treatment of neuro degenerative diseases |
DE602007007890T DE602007007890D1 (en) | 2006-02-07 | 2007-02-07 | THIADIAZOL DERIVATIVES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
BRPI0707700A BRPI0707700B8 (en) | 2006-02-07 | 2007-02-07 | pharmaceutical composition comprising a 1,2,4-thiadiazole derivative and 1,2,4-thiadiazole derivative |
CA2641453A CA2641453C (en) | 2006-02-07 | 2007-02-07 | Thiadiazole derivatives for the treatment of neuro degenerative diseases |
US12/187,115 US8541406B2 (en) | 2006-02-07 | 2008-08-06 | Thiadiazole derivatives for the treatment of neurodegenerative diseases |
HK09100186.5A HK1122989A1 (en) | 2006-02-07 | 2009-01-08 | Thiadiazole derivatives for the treatment of neuro degenerative diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0602335.2 | 2006-02-07 | ||
GBGB0602335.2A GB0602335D0 (en) | 2006-02-07 | 2006-02-07 | Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/187,115 Continuation-In-Part | |||
US12/187,115 Continuation-In-Part US8541406B2 (en) | 2006-02-07 | 2008-08-06 | Thiadiazole derivatives for the treatment of neurodegenerative diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007090617A2 true WO2007090617A2 (en) | 2007-08-16 |
WO2007090617A3 WO2007090617A3 (en) | 2008-02-28 |
Family
ID=36101115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/001022 WO2007090617A2 (en) | 2006-02-07 | 2007-02-07 | Thiadiazole derivatives for the treatment of neuro degenerative diseases |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1981504B1 (en) |
JP (1) | JP5283511B2 (en) |
CN (1) | CN101378757B (en) |
AT (1) | ATE474579T1 (en) |
AU (1) | AU2007213954B2 (en) |
BR (1) | BRPI0707700B8 (en) |
CA (1) | CA2641453C (en) |
DE (1) | DE602007007890D1 (en) |
DK (1) | DK1981504T3 (en) |
EA (1) | EA018067B1 (en) |
ES (1) | ES2348999T3 (en) |
GB (1) | GB0602335D0 (en) |
HK (1) | HK1122989A1 (en) |
PL (1) | PL1981504T3 (en) |
PT (1) | PT1981504E (en) |
WO (1) | WO2007090617A2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009143404A1 (en) * | 2008-05-23 | 2009-11-26 | Wyeth | Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression |
WO2009156098A2 (en) * | 2008-06-27 | 2009-12-30 | Bayer Cropscience Ag | Thiadiazolyloxyphenylamidines and use thereof as fungicides |
AU2008225766B2 (en) * | 2007-03-15 | 2012-06-07 | Novartis Ag | Organic compounds and their uses |
WO2013004642A1 (en) | 2011-07-01 | 2013-01-10 | Remynd Nv | 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases |
WO2013024168A1 (en) | 2011-08-17 | 2013-02-21 | Remynd Nv | Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease |
US8906330B2 (en) | 2009-05-04 | 2014-12-09 | Basf Corporation | Lean HC conversion of TWC for lean burn gasoline engines |
US9018214B2 (en) | 2011-04-21 | 2015-04-28 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
WO2015140130A1 (en) * | 2014-03-17 | 2015-09-24 | Remynd Nv | Oxadiazole compounds |
US9617248B2 (en) | 2012-10-19 | 2017-04-11 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
US9617283B2 (en) | 2012-10-19 | 2017-04-11 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
US9663512B2 (en) | 2012-10-19 | 2017-05-30 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
US9783538B2 (en) | 2013-12-20 | 2017-10-10 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7178831B2 (en) | 2018-08-30 | 2022-11-28 | 日本特殊陶業株式会社 | Substrate holding member |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999051584A1 (en) | 1998-04-06 | 1999-10-14 | Apotex Inc. | Thiadiazole compounds useful as inhibitors of h+/k+ atpase |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002083863A2 (en) * | 2001-04-17 | 2002-10-24 | Sepracor, Inc. | Thiazole and other heterocyclic ligands and use thereof |
MXPA06001845A (en) * | 2003-08-21 | 2006-05-04 | Pfizer Prod Inc | Compounds for the treatment of neurodegenerative disorders. |
US7232820B2 (en) * | 2004-04-01 | 2007-06-19 | Pfizer Inc | Thiadiazole-amine compounds for the treatment of neurodegenerative disorders |
DE102004032567A1 (en) * | 2004-07-05 | 2006-03-02 | Grünenthal GmbH | Substituted 1-propiolyl-piperazines |
-
2006
- 2006-02-07 GB GBGB0602335.2A patent/GB0602335D0/en not_active Ceased
-
2007
- 2007-02-07 EA EA200870233A patent/EA018067B1/en not_active IP Right Cessation
- 2007-02-07 ES ES07711455T patent/ES2348999T3/en active Active
- 2007-02-07 PT PT07711455T patent/PT1981504E/en unknown
- 2007-02-07 AU AU2007213954A patent/AU2007213954B2/en not_active Ceased
- 2007-02-07 CN CN2007800045833A patent/CN101378757B/en not_active Expired - Fee Related
- 2007-02-07 CA CA2641453A patent/CA2641453C/en active Active
- 2007-02-07 JP JP2008553672A patent/JP5283511B2/en not_active Expired - Fee Related
- 2007-02-07 DK DK07711455.1T patent/DK1981504T3/en active
- 2007-02-07 EP EP07711455A patent/EP1981504B1/en active Active
- 2007-02-07 WO PCT/EP2007/001022 patent/WO2007090617A2/en active Application Filing
- 2007-02-07 AT AT07711455T patent/ATE474579T1/en active
- 2007-02-07 DE DE602007007890T patent/DE602007007890D1/en active Active
- 2007-02-07 PL PL07711455T patent/PL1981504T3/en unknown
- 2007-02-07 BR BRPI0707700A patent/BRPI0707700B8/en not_active IP Right Cessation
-
2009
- 2009-01-08 HK HK09100186.5A patent/HK1122989A1/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999051584A1 (en) | 1998-04-06 | 1999-10-14 | Apotex Inc. | Thiadiazole compounds useful as inhibitors of h+/k+ atpase |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008225766B2 (en) * | 2007-03-15 | 2012-06-07 | Novartis Ag | Organic compounds and their uses |
US8536168B2 (en) | 2007-03-15 | 2013-09-17 | Novartis Ag | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway |
WO2009143404A1 (en) * | 2008-05-23 | 2009-11-26 | Wyeth | Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression |
US8383139B2 (en) | 2008-06-27 | 2013-02-26 | Bayer Cropscience Ag | Thiadiazolyloxyphenylamidines and use thereof as fungicides |
EA020256B1 (en) * | 2008-06-27 | 2014-09-30 | Байер Кропсайенс Аг | Thiadiazolyloxyphenylamidines and use thereof as fungicides |
CN102066347A (en) * | 2008-06-27 | 2011-05-18 | 拜耳作物科学公司 | Thiadiazolyloxyphenylamidines and use thereof as fungicides |
EA020256B9 (en) * | 2008-06-27 | 2015-02-27 | Байер Кропсайенс Аг | Thiadiazolyloxyphenylamidines and use thereof as fungicides |
WO2009156098A3 (en) * | 2008-06-27 | 2010-04-01 | Bayer Cropscience Ag | Thiadiazolyloxyphenylamidines and use thereof as fungicides |
JP2011525509A (en) * | 2008-06-27 | 2011-09-22 | バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト | Thiadiazolyloxyphenylamidines and their use as fungicides |
WO2009156098A2 (en) * | 2008-06-27 | 2009-12-30 | Bayer Cropscience Ag | Thiadiazolyloxyphenylamidines and use thereof as fungicides |
US8906330B2 (en) | 2009-05-04 | 2014-12-09 | Basf Corporation | Lean HC conversion of TWC for lean burn gasoline engines |
US9018214B2 (en) | 2011-04-21 | 2015-04-28 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
US11866428B2 (en) | 2011-04-21 | 2024-01-09 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
US9676768B2 (en) | 2011-04-21 | 2017-06-13 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
AU2012280420B2 (en) * | 2011-07-01 | 2017-01-05 | Remynd Nv | 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases |
WO2013004642A1 (en) | 2011-07-01 | 2013-01-10 | Remynd Nv | 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases |
US9023852B2 (en) | 2011-07-01 | 2015-05-05 | Remynd Nv | 1, 2, 4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases |
WO2013024168A1 (en) | 2011-08-17 | 2013-02-21 | Remynd Nv | Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease |
US9187440B2 (en) | 2011-08-17 | 2015-11-17 | Remynd Nv | Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease |
US9808456B2 (en) | 2011-08-17 | 2017-11-07 | Remynd Nv | Piperazine thiazole derivatives useful in the treatment of tauopathies such as Alzheimer's disease |
AU2012296804B2 (en) * | 2011-08-17 | 2017-04-20 | Remynd Nv | Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease |
US9663512B2 (en) | 2012-10-19 | 2017-05-30 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
US9617248B2 (en) | 2012-10-19 | 2017-04-11 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
US9617283B2 (en) | 2012-10-19 | 2017-04-11 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
US9783538B2 (en) | 2013-12-20 | 2017-10-10 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
US10618895B2 (en) | 2013-12-20 | 2020-04-14 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
US11225476B2 (en) | 2013-12-20 | 2022-01-18 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
US11643410B2 (en) | 2013-12-20 | 2023-05-09 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
US10562869B2 (en) | 2014-03-17 | 2020-02-18 | Remynd Nv | Oxadiazole compounds |
WO2015140130A1 (en) * | 2014-03-17 | 2015-09-24 | Remynd Nv | Oxadiazole compounds |
Also Published As
Publication number | Publication date |
---|---|
BRPI0707700B8 (en) | 2022-12-20 |
WO2007090617A3 (en) | 2008-02-28 |
PL1981504T3 (en) | 2010-12-31 |
PT1981504E (en) | 2010-10-13 |
HK1122989A1 (en) | 2009-06-05 |
JP5283511B2 (en) | 2013-09-04 |
GB0602335D0 (en) | 2006-03-15 |
EA200870233A1 (en) | 2009-02-27 |
ES2348999T3 (en) | 2010-12-21 |
DE602007007890D1 (en) | 2010-09-02 |
AU2007213954A1 (en) | 2007-08-16 |
ATE474579T1 (en) | 2010-08-15 |
CA2641453C (en) | 2013-07-30 |
BRPI0707700B1 (en) | 2020-08-04 |
CN101378757A (en) | 2009-03-04 |
EP1981504A2 (en) | 2008-10-22 |
DK1981504T3 (en) | 2010-11-08 |
CA2641453A1 (en) | 2007-08-16 |
BRPI0707700A2 (en) | 2011-05-10 |
CN101378757B (en) | 2012-08-01 |
EP1981504B1 (en) | 2010-07-21 |
EA018067B1 (en) | 2013-05-30 |
AU2007213954B2 (en) | 2011-09-22 |
JP2009526000A (en) | 2009-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1981504B1 (en) | Thiadiazole derivatives for the treatment of neuro degenerative diseases | |
US7960556B2 (en) | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | |
US8541406B2 (en) | Thiadiazole derivatives for the treatment of neurodegenerative diseases | |
AU2011284688B2 (en) | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | |
EP2389362B1 (en) | Phenylcyclopropylamine derivatives and their medical use | |
TW200843770A (en) | RHO kinase inhibitors | |
JP2009543762A (en) | Benzazepinones as sodium channel blockers | |
JP2012516355A (en) | Substituted 1,1,3,3-tetraoxide benzo [d] [1,3,2] dithiazole as mGLuR4 allosteric enhancer, compositions, and methods of treating neurological dysfunction | |
JP2023540661A (en) | Methods and compositions for targeting Tregs using CCR8 inhibitors | |
JP2012509352A (en) | BACE1 Quinazoline Inhibitors and Methods of Use | |
CA2469801C (en) | Thiadiazoline derivative | |
JP2002053566A (en) | Thiazole compound and pharmaceutical use thereof | |
KR20220079546A (en) | How to treat epilepsy | |
EP2327702A1 (en) | Mitotic kinesin inhibitor | |
EP2188272B1 (en) | Phenyl- and benzylthiazolylpiperazine derivatives for the treatment of neurodegenerative diseases | |
WO2010065861A2 (en) | Inhibitors of bace 1 and methods for treating alzheimer's disease | |
AU2022246405A1 (en) | Novel inhibitors | |
CN114790177A (en) | Novel Hedgehog signaling pathway inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 6610/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2641453 Country of ref document: CA Ref document number: 2007711455 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780004583.3 Country of ref document: CN Ref document number: 2008553672 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007213954 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200870233 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2007213954 Country of ref document: AU Date of ref document: 20070207 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0707700 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080807 |